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Most human traits are influenced by a combination of genetic and environmental effects. 
Heritability expresses the proportion of trait variance that can be explained by genetic factors, 
and the 1980s heralded the beginning of studies that aimed to pinpoint genetic loci that 
contribute to trait variation, also known as quantitative trait loci (QTLs). Subsequently, the 
availability of cheap, high-resolution genotyping chips ushered in the era of genome-wide 
association studies (GWAS). These genetic studies have discovered many associations 
between single-nucleotide polymorphisms (SNPs) and complex traits, but these associations 
do not explain the genetic component of these traits entirely. This is known as the ‘missing 
heritability’ problem.  
Within this thesis, 40 medically-relevant human complex traits are studied in order to identify 
new QTLs. These traits include eye biometric traits, blood biochemical traits and 
anthropometric traits measured in approximately 28,000 individuals belonging to family-
based samples from the general Scottish population (the Generation Scotland study) or from 
population isolates from Croatian (Korčula, Vis) or Scottish (Shetland, Orkney) islands. These 
individuals had been genotyped using commercially-available arrays, and unobserved 
genotypes were imputed using the Haplotype Reference Consortium (HRC) dataset.  
In parallel to standard GWAS, these traits are analysed using two other statistical genetics 
approaches: variance component linkage analysis and regional heritability (RH) mapping. 
Each study is analysed separately, in order to detect study-specific genetic effects that may not 
generalise across populations. At the same time, because most traits are available in several 
studies, this also enables meta-analysis, which boosts the power of discovery and can reveal 
cross-study genetic effects.  
These methods are a priori complementary to each other, exploiting different aspects of human 
genetic variation, such as the segregation of variants within families (identity by descent, IBD), 
or the presence of the same variant throughout the general population (identity by state, IBS). 
The strengths and weaknesses of these methods are systematically assessed by applying them 






‘You have your mother’s eyes’ or ‘You are growing up to be just as tall as your father’ are 
phrases most of us hear while growing up. They are also testaments to the fact that our traits 
are heritable – that is, we inherit these (and many more) characteristics from our parents. 
Similarly, certain diseases, such as Huntington’s disease or some types of cancer are known 
to ‘run in the family’, where members of a family with a history of the disease are more likely 
to develop it during their lifetimes than the general population. 
This heritable information is encoded in our genes and it is passed down from parents to their 
offspring through DNA, a double helix-shaped molecule made up of the bases adenine, 
thymine, cytosine and guanine (A, T, C, G). Strikingly, while the human genome consists of 
3 billion base pairs, the genomes of any two people are 99.9% identical. The remaining 0.1% 
is responsible for most of the diversity we see in humans – this is because here, mutations have 
arisen, changing one base to a different one, like typos in a book. If they become widespread 
in a population, these mutations are called polymorphisms. Some mutations have no effect 
(that we currently know of), while others can either have a benign effect (influencing eye 
colour for example) or a serious health effect, either causing disease or increasing its likelihood 
of developing.  
Most human traits and diseases are complex, which means that they are influenced by many 
genes. Similarly, one gene can influence several traits – one example of this is the melanin 
gene, which partly determines your hair, eye and skin colour. If a gene acquires a mutation, 
this can alter its effect on a trait – for example, individuals who carry certain mutations in the 
FTO gene have higher rates of obesity than non-carriers. We have already discovered many 
associations between polymorphisms and traits, but they do not explain the full spectrum of 
human diversity, which is known as the ‘missing heritability problem’. The aim of this thesis 
is to uncover some of this missing heritability by applying different statistical tools to study a 
variety of medically-relevant traits within large family-based datasets. At the same time, this 
also enables the systematic evaluation of the relative strengths and weaknesses of these tools. 
By discovering new connections between our genome and our traits, we can improve the 
accuracy of trait prediction based on genetic information alone. This means that we may be 
able to diagnose a disease at a more early stage (possibly even before any visible symptoms 
have appeared), which can have direct consequences over disease management and 
prevention. Additionally, it can lead to the discovery of new drug targets, paving the way for 
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Chapter 1 Introduction 
1.1 Complex Traits 
Most of our traits, and our likelihood of developing certain diseases, are at least partially under 
genetic control. The proportion of trait variation that can be explained by genetic variation is 
called heritability. In this thesis, heritability refers to the narrow-sense heritability (h2), which 
is due to additive genetic effects – those transmitted from parents to offspring. Narrow-sense 
heritability is an important population parameter that informs on the limits of genetic 
prediction in humans and achievement of selection in animal breeding programmes. 
Few traits are monogenic, whereby the heritability of these traits can be explained by variation 
at one genetic locus. Often, these mutations affect a protein, destabilising it by altering its 
three-dimensional structure, rendering its active sites non-functional or truncating it 
prematurely. Such traits are also called Mendelian traits (or disorders, in the case of disease). 
For example, expansions of the CAG triplet repeat in the HTT gene gives rise to Huntington’s 
disease and homozygote carriers of certain mutations in the CFTR gene are highly likely to 
develop cystic fibrosis.  
In contrast, most common traits are polygenic, as they are influenced by tens, hundreds or even 
thousands of loci across the genome, with complex interplay with environmental factors. 
These loci may have one or more causal variants, and these variants vary in terms of allele 
frequency, effect size and penetrance. For example mutations in the ABO gene explain around 
30% of the heritability of the quantitative trait “von Willebrand factor levels” [1], but in most 
cases, a single quantitative trait locus (QTL) only explains a small proportion of trait 
heritability. Height is under strong genetic control, its heritability is estimated to be around 
80% and hundreds of loci have been reported to associate with this trait, but most height QTLs 
only alter stature individually by a fraction of a millimetre [2].  
At the completion of the Human Genome Project, before genetic mapping studies were in full 
swing, several models were proposed to explain the genetic basis of complex traits. Initially, 
the “common disease-common variant” and “common disease-rare variant” models were in 
competition [3–5], but today it is recognised that the variance of most complex traits arises 
through some combination of common and rare variants, with the latter often assumed to have 
a stronger effect.  
The “common disease-common variant” model [6] posits that the variants that influence 
common traits must themselves be common. Several factors back this theory, such as the rapid 
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expansion of modern humans from a founder population of relatively small size. The allelic 
diversity at neutral loci in such a population would be low. Additionally, variants that influence 
late-onset, common diseases such as type 2 diabetes or dementia do not have such a high 
impact on reproductive fitness, and therefore they are not under strong purifying selection so 
can drift to higher frequency. If a risk allele for a certain disease was at a high frequency in 
the past, because it conferred a selective advantage to an environmental factor that is no longer 
present, it would take a very long time before it is diluted out of a population by new alleles. 
For example, the ancestral E4 allele of the APOE gene is common in human populations today, 
and it is a risk factor for coronary artery disease and Alzheimer’s disease [7]. While this allele 
confers a selective advantage when food is scarce, as it leads to increased lipid absorption, the 
exposure to a ‘western’ diet that is rich in fats and carbohydrates but low in fibre, combined 
with a sedentary lifestyle, leads to carriers of the E4 allele having an increased risk of 
developing coronary artery disease and Alzheimer’s disease [8]. While many common variants 
have now been associated with quantitative traits and common diseases, with a few exceptions, 
most have a small effect on the trait.  
The competing “common disease, rare variant” model posits that causal variants are rare and 
have large effects in the people who carry them, but individually have a small effect on the 
population-wide trait variance due to their low allele frequency. Under this model, only a small 
number of individuals suffering from a common disease carry a specific risk allele, but there 
can be a high number of rare risk alleles segregating in the population, most of which are likely 
to have arisen within the last few generations [9]. For example, most breast cancer-causing 
mutations within the BRCA2 gene are rare, and only rare mutations of the LDLR (low-density 
lipoprotein receptor) gene have been found to affect premature coronary artery disease through 
familial hypercholesterolemia [4].  
Recently, an ‘omnigenic’ model was proposed by Boyle et al. [10] based on the suggestion 
that over 100000 variants could contribute independent effects to human height, but most of 
these would make only a one seventh of a millimetre difference. These variants are spread 
throughout the genome, possibly implicating every gene and pathway active in the tissues 
relevant to the trait. This is similar to the ‘infinitesimal model’ of Gibson [11], who postulated 
that “ultimately, every gene contributes to every trait, but with effect sizes so small that it 
would take samples greater than the population size of the species to detect them”.  
Today, we know that most common traits are highly polygenic and their variance is due to 
combinations of common and rare causal variants. The heritability of a trait depends primarily 
on additive variance, where the changes in the phenotype of an individual scale linearly with 
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the number of causal alleles they carry. In addition to additive variance, however, other types 
of genetic effects may also contribute to the architecture of complex traits, although their 
effects are often negligible compared to additive effects [12]. Dominance effects occur when 
one allele completely (or partially) masks the effect of the other allele, so that the phenotype 
of a heterozygote is not exactly at the midpoint between opposite homozygotes. Epistasis 
effects describe interactions between different loci that lead to phenotype values that are 
different to the sum of the effects at the two loci. 
1.2 Mapping Quantitative Trait Loci 
The aim of genetic mapping is to identify loci contributing to phenotypic variation, 
establishing new links between genetic variation and traits in order to gain a better 
understanding of the biological pathways that influence a trait. Genetic mapping can be done 
through several different statistical approaches that leverage the genetic similarities between 
individuals who are also similar at the phenotype level. The genetic architecture of a complex 
trait under study is a strong determinant of the success of different mapping strategies. The 
allele frequencies and effect sizes of the causal variants, as well as the presence (or absence) 
of composite large QTL effects from numerous clustered small effect variants all affect the 
power of a mapping strategy. 
Within this thesis, genome-wide association studies (GWAS), variance component linkage 
analyses and regional heritability (RH) mapping are performed using large, well-phenotyped 
family-based datasets in order to recover some of the missing heritability of medically-relevant 
complex traits. This also allows for the systematic comparison of these methods, evaluating 
their strengths and weaknesses in detecting variation contributing to complex traits.  
The availability of genotyping arrays ushered in the era of GWAS, first proposed in 1996 [13]. 
This method regresses the phenotype value onto the genotype of each genotyped (or imputed) 
single nucleotide polymorphism (SNP), while correcting for sources of potential confounding, 
for example covariates such as age and sex or excess genetic sharing due to relatedness [14], 
in order to identify genomic regions where SNP genotypes correlate with the phenotype. Even 
if the causal variant is not typed, it may be tagged by nearby variants that are in linkage 
disequilibrium (LD) with it [15], so the power to detect a QTL with this method depends on 
the allele frequency of the causal variant, as rarer variants will be in LD with fewer ‘tagging’ 
SNPs. GWAS utilise SNP identity-by-state (IBS). If two individuals carry the same allele at a 




Over 2500 GWAS have been published, identifying over 25000 SNP-trait associations [16]. 
While these associations have led to a greater understanding of the biological pathways that 
underlie complex traits, they fail to explain the full heritability of complex traits, leading to 
the ‘missing heritability’ problem [17].  
Several complementary hypotheses propose that the remaining heritability may be hidden in 
rare variants of large effect or in common variants of very small effect or low penetrance [11]. 
Studies have calculated the joint amount of heritability contributed by all genotyped, or 
imputed, SNPs, and they have shown that there is a sizeable contribution to heritability from 
genetic factors that GWAS are underpowered to detect because their effect sizes are too small 
[18, 19].  
GWAS are underpowered to study rare variants at the single-SNP level because by definition, 
these variants occur too infrequently to allow association tests of individual variants. Instead, 
rare variants may be studied with the help of burden or candidate gene set tests, by aggregating 
them into groups [20], but rare variants are often not included on genotyping chips and 
sequencing is required to detect them. Additionally, there is uncertainty about which variants 
to include in these groups, as well as the weights that should be assigned to different variants 
[21]. Genetic studies of complex diseases or traits that use whole-exome sequencing or exome 
“chips” designed to enrich for rare variants have largely been unsuccessful in identifying 
associations with novel genes however, generally due to lack of power, but also because many 
causal variants lie outside of gene coding regions [20]. 
Most GWAS are also underpowered to detect associations with common variants that have a 
small effect on the trait, as they require much larger sample sizes to be detected – in order to 
be well-powered to detect SNPs with such effect sizes, sample sizes larger than the current 
human population may be required. For example, height GWAS have been performed on 
increasingly larger sample sizes and these studies have identified an increasing number of 
associations. The largest height GWAS that had been performed at the commencement of this 
PhD used data from 250000 individuals, identifying 423 independent genome-wide significant 
loci that together only explained 16% of the heritability of height [22]. A follow-up study 
using 700000 individuals identified associations with an additional 83 uncommon and rare 
variants, 24 of which affect height by more than 1cm, effect sizes which are larger than those 
observed in associations with more common variants [23]. With these new findings, 27.4% of 
the heritability of height is accounted for, and studies on 2 million individuals are currently 




Gibson [11] proposed that hundreds of thousands of common and rare variants contribute to a 
complex trait and GWAS are detecting those with the largest effect sizes from among a range 
of normally distributed effects. With such a high number of small-effect variants, the utility of 
conducting GWAS on larger and larger scales can be called into question, as the variants 
identified with these are likely to act through complex regulatory networks rather than 
affecting the trait directly, and these variants would contribute little to understanding the 
underlying biology of complex traits and diseases [10, 24]. Corroborating this statement, many 
of the GWAS hits reported in this thesis as well as in the literature are in gene deserts or in or 
near genes that have no immediately obvious relevance to the trait they associate with. 
Some of the missing heritability may lie in structural variation [25], in the form of copy number 
variants (CNVs) [26], insertions or deletions (indels), inversions and translocations. Such 
variation cannot always be studied with the help of SNP arrays because SNP sites are not 
always altered directly, and it might be hard to pinpoint them through sequencing as repetitive 
regions, for example, are notoriously hard to sequence [27]. 
Allelic heterogeneity may also be a reason for the missing heritability – one SNP might 
(weakly) tag several independent variants but only a diluted effect may be observed through 
this tagging SNP, especially if the independent variants have opposite effects on the trait, or if 
their effects are very small to begin with [28]. GWAS are not well-powered to detect such loci, 
and while resequencing efforts targeting promising genes flagged with GWAS might uncover 
additional causal variants within the same gene [24, 29], other statistical methods may be better 
able to detect such effects without the need for additional sequencing. It is suggested that a 
combination of single-SNP and region-based analyses may provide more robust results than 
relying on either method in isolation [30]. For example, a linkage study of human longevity 
identified several broad linkage peaks that were then fine-mapped with the help of association 
studies, identifying the APOE locus to be a longevity gene [31]. 
Before SNP genotyping arrays became available, inheritance-informative microsatellite data 
were used to conduct classical linkage studies. Linkage analysis relies on establishing whether 
DNA segments between pairs of individuals are identical-by-descent (IBD, that is, alleles that 
are IBS but additionally also inherited from the same common ancestor), and uses this IBD 
sharing information to determine the location of QTLs. This is based on the principle that 
relatives who are phenotypically similar are more likely to have inherited a DNA segment 
harbouring a QTL from a common ancestor than relatives who are phenotypically dissimilar. 
Because genotypes are only available for 1-4 generations within a family, co-inherited DNA 
segments are large as the small number of meioses only allow for a few recombination events 
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to take place. A consequence of this is a lower mapping resolution, because regions flagged 
by linkage analysis are broad, often spanning several megabases (Mb) of a chromosome and 
encompassing tens or hundreds of genes. This makes it difficult to pinpoint not just the causal 
variant (or variants), but a causal gene as well.  
Linkage studies have been successful in locating highly penetrant variants that cause 
Mendelian disorders, for example linking the HTT gene to Huntington’s disease [32] and the 
CFTR gene to cystic fibrosis [33]. An early success story of complex trait linkage mapping 
was the identification of an obesity-related linkage peak on the short arm of chromosome 2, 
which was subsequently replicated in other populations [34]. The peak region contains 
multiple genes, two of which were good functional candidates, and resequencing efforts at the 
POMC (pro-opiomelanocortin) gene revealed rare (minor allele frequency < 0.01) coding 
variants [35]. These variants failed to explain the entire linkage signal, however, suggesting 
that there may be additional causal variants in the same, or another, gene that contribute to this 
signal – this is called allelic heterogeneity. Taking it one step further, functional follow-up of 
candidate variants may confirm that the candidate variants identified through statistical testing 
are indeed causal. An example of this is the identification of mutations within the F7 gene that 
affects the levels of Factor VII, a blood clotting protein. The locus containing the F7 gene was 
identified through a linkage study and, through resequencing, several variants within this gene 
were identified, cumulatively accounting for the entire QTL [36]. Functional follow-up 
studies, using in vitro expression assays, later demonstrated that these variants do indeed 
modulate Factor VII levels [37]. These examples are the exception, rather than the rule, in the 
field of complex trait linkage studies, as many linkage peaks do not replicate and they often 
do not contain genes that are obvious functional candidates. As a consequence, most of these 
linkage peaks are not followed up to the point of identifying the underlying causal variant, and 
even if one causal variant is identified, it often fails to explain the full QTL effect [38], as was 
the case with the obesity-linked locus described above. Linkage studies have more power to 
detect loci at which allelic heterogeneity is present, compared to GWAS, because they assess 
the proportion of variance explained by all causal variants in an analysed region – this means 
that if a QTL signal is due to the effects of several independent variants of small effect, these 
might be missed in an association study where the effect of each SNP is assessed individually 
[38]. It should be noted that these QTLs still need to explain a large amount of trait variance 
to be detected with linkage analysis, and many complex traits might not have such QTLs. 
The power to detect a QTL with linkage analysis can be boosted by using families consisting 
of many individuals and leveraging LD information between all genotyped SNPs in order to 
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construct haplotype patterns that can be used to accurately estimate IBD. Additionally, 
progress has been made with IBD inference methodologies that allow for the estimation of 
IBD sharing probabilities not just within families, but also between nominally unrelated 
individuals (those that are not connected in social pedigrees) who nonetheless shared a 
common ancestor and so may share some regions of their genome IBD [39]. This can also be 
an economical means of boosting the power of a linkage study by increasing the number of 
pairs that share a region IBD without the need to recruit additional family members. These 
IBD estimation methods rely on Hidden Markov Models (HMMs) and they can also be used 
to phase genotype data to facilitate parent-of-origin studies, or to impute missing genotypes 
based on a reference set [40]. IBD sharing estimation through HMMs was also applied to 
exome sequencing data in order to map recessive mutations leading to Mendelian diseases 
[41], which indicates that if IBD sharing can be inferred with high confidence, it could be used 
to flag regions carrying rare risk alleles of strong effect. In addition to applying IBD estimation 
methods to exome sequencing data, linkage analysis has recently also been re-emerging as a 
means to prioritise disease causing variants using whole-genome sequencing data, although 
such studies have mostly involved Mendelian diseases segregating in specific families [42–
44].  
Regional heritability (RH) mapping relies on estimating the heritability contributed by genetic 
regions consisting of groups of SNPs [45], drawing from the principles used by Yang et al. 
who demonstrate, by calculating the joint heritability explained by all genotyped SNPs, that 
the heritability is not ‘missing’, but merely ‘hidden’ in genotyped variants of small effect [18]. 
These regions can be defined in several ways. For example, one can use a sliding window 
consisting of an arbitrary number of SNPs, but these SNPs may be separated by recombination 
hotspots, so it might not make sense to analyse them together. Alternatively, genetic maps can 
be used to define recombination hotspots, and allocating SNPs this way leads to regions that 
are more biologically meaningful. Regions defined this way tag the effects of genotyped 
variants, so they are able to identify the same signals that are genome-wide significant in a 
GWAS, but they also capture the effect of ungenotyped and rare variants that might affect the 
trait but to an extent too small to be detected by single-SNP GWAS [46]. This has been 
demonstrated in a study that employed GWAS and RH mapping to evaluate the genetic 
architecture of nematode resistance in Scottish Blackface lambs, as well as in a study of blood 
lipid traits in isolated human populations. Both of these studies found that RH mapping 
identified additional suggestively significant loci compared to GWAS [47, 48], and the human 
study indicates that this method might be less likely to detect false positive associations. Lack 
of replication of hits identified with RH, but not GWAS, is generally due to a lack of a 
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widespread use of this method, and performing RH mapping of complex traits in several 
cohorts should provide a systematic assessment of this method. 
By substituting the sliding window approach with the haplotype-based approach of defining 
regions, some IBD sharing between pairs of individuals could be captured in addition to 
regions where causal variants are shared IBS. This has not been analysed previously, and by 
comparing the results of RH mapping to those generated by linkage analysis, it will be possible 
to assess how well the results obtained with these two methods match. The haplotype-based 
approach could also facilitate meta-analysis of RH results because the start and end positions 
of each region are constant between different studies, regardless of the number of SNPs used 
by that study, as long as the study participants belong to the same general ancestry group. 
It is important to note that, regardless of the mapping strategy used, if a QTL is identified, 
direct causal links cannot always be drawn between mutations, the genes they are found 
in/near, and the complex traits they associate with. This is because these mutations do not 
always alter protein structure or gene expression directly, or they are present within genes that 
encode transcription factors that may have an effect on many genes, rather than a gene that 
directly affects the studied trait. Reported associations are often found in intergenic regions or 
within gene introns, and while they might affect the trait indirectly (by altering transcription 
factor binding sites, modulating enhancer activity or affecting splicing, for example), these 
effects would need to be validated through functional follow-up studies. 
1.3 Family-based Studies and Population Isolates 
There are several advantages to using family-based datasets [30], and specifically population 
isolates [49], in genetic studies. For example, they help control for phenotypic and genetic 
heterogeneity, as well as population stratification, and they often have large, well-documented 
genealogies that are particularly useful for linkage analyses [50].  
Family-based studies have helped identify the causal genes that underlie monogenic disorders 
or contribute to the variance of complex traits [30], primarily through linkage analysis. In 
addition to being used to study the relationships between genotype and phenotype, datasets of 
related individuals continue to inform sequencing strategies, as sequencing a small number of 
unrelated individuals enables the imputation of rare variants into their genotyped or even 
ungenotyped relatives [51]. Haplotypes can be imputed thanks to the availability of long-range 
phasing methodologies. Once the haplotypes of genotyped relatives have been phased, the 
haplotypes of ungenotyped individuals can be imputed if the social pedigree (family tree, 
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genealogy) indicates that the haplotype must necessarily have passed through the ungenotyped 
relative. 
This is more cost-effective than sequencing several related individuals whose underlying 
haplotypes may not provide much additional information. Imputed genotypes have 
successfully been used in many large GWAS. For example, sequencing the genomes of 2636 
Icelandic individuals allowed the imputation of 20 million variants into 104220 genotyped 
individuals, down to a minor allele frequency (MAF) of 0.1%, and GWAS of this dataset 
revealed novel associations with causal variants affecting atrial fibrillation and gallstone 
disease [52]. Imputed genotypes are also useful in GWAS meta-analyses, as they ensure that 
the maximum number of genotypes is tested in every participating cohort, even if they were 
genotyped using different platforms. In addition to imputation, phased data can be used to 
study parent-of-origin effects, and such studies have identified genomic regions that are 
imprinted [53]. 
Population isolates derive from a limited number of founders so they have lower haplotype 
diversity and minimise the number of risk alleles entering the population. Population isolates 
may also harbour rare variants that are absent from the general population. A sequencing study 
of Icelandic individuals found that most variants that are common in this population (minor 
allele frequency > 2%) are also present in SNP databases, but this was true for only 20% of 
rare (minor allele frequency < 0.5%) Icelandic variants present in coding regions [54]. 
The higher prevalence of variants that are linked to recessive diseases or complex disorders 
causes a rise in the prevalence of these disorders in an isolate population. For example, the 
Greenlandic population has seen a marked increase in type 2 diabetes cases in the last few 
decades. Genetic studies in this population have revealed a variant within the TBC1D4 gene 
that causes carriers to have higher glucose levels and confers resistance to insulin-stimulated 
glucose uptake. This variant was present at a MAF of 17% in the Greenlandic population, 
while it was absent in most other populations, including Chinese, European and African 
populations, and only one heterozygote carrier was found in a Japanese individual in the 1000 
Genomes data [55]. In the Genome Aggregation Database (GnomAD, a follow-on from the 
Exome Aggregation Consortium ExAC [56]), in addition to this Japanese individual, only two 
non-Finnish Europeans are heterozygote carriers of this variant out of 123,000 sequenced 
individuals. 
In isolated populations, individuals tend to marry within their communities. This is also known 
as endogamy and it means that there is little genetic admixture from outside sources, which 
reduces genetic heterogeneity. In addition to reduced genetic complexity, population isolates 
25 
 
tend to be geographically isolated, share the same culture, are exposed to the same 
environmental effects and consume the same types of food and drink, which reduces 
phenotypic noise originating from environmental effects. It also implies that some genetic 
variants might be enriched in these populations if they improve adaptation to the local 
environment, and such variants could point to novel biological processes, such as the high-
altitude adaptation conferred to Tibetans by mutations in the EPAS1 gene, a transcription 
factor that modulates oxygen-regulated genes [57]. For example, a study of the Inuit isolate 
population in Greenland revealed novel genetic variants involved in fat metabolism that also 
had an influence on height and weight. [58]. A study of 6307 Sardinian individuals revealed 
mutations in two different genes, one of which is imprinted, that decreased height by 4.2cm 
and 1.83 cm (when maternally inherited) in heterozygote carriers. This could be a human 
example of the ‘island effect’ that selects for smaller size in mammals [59]. 
Taken together, these factors mean that population isolates have reduced genetic complexity 
and less phenotypic noise, so they are expected to lend themselves particularly well to genetic 
analyses, not just of Mendelian disorders but also complex traits [49]. Additionally, family-
based studies are enriched for genetic effects and so have higher power to detect causal loci 
than studies consisting of an equivalent number of unrelated individuals. Finally, family-based 
studies also allow for the identification and correction of genotyping errors. 
Genetic analysis in a family-based study presents a challenge in that the structure due to 
relatedness must be accounted for, as the genotypes of individuals are not completely 
independent of each other, and even within one individual, there could be some correlation 
between the alleles if inbreeding is present [50]. Failure to correct for this can lead to false 
positive associations due to an enrichment of the variant between, or within, individuals, rather 
than an actual link between the variant and the phenotype [60]. This means that often, 
statistical methods designed to be used in unrelated individuals are not appropriate for studying 
related individuals without some modification. For example, association analyses using related 
individuals can be done but this should be through a linear mixed model that includes a genetic 
relationship matrix as an additional random effect, and variance component based methods, 
such as the linkage analysis and RH mapping performed in this thesis, should include a genetic 
relationship matrix as an additional variance component in order to account for relatedness. 
Within this thesis, genotype and phenotype data from five studies were used, and the location 
of these studies is indicated in Figure 1. Four of these studies consist of populations living on 
Croatian and Scottish islands: genotype, phenotype and pedigree data were collected from 
individuals on the islands of Vis (data from 960 individuals) and Korčula (3000 individuals) 
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in Croatia, and the Orkney (2100 individuals) and Shetland (2100 individuals) archipelagos in 
the north of Scotland. 
The final dataset is from a large family-based study consisting of individuals from the general 
Scottish population, the Generation Scotland: Scottish Family Health Study (GS:SFHS) [61]. 
This study consists of genotype, phenotype and pedigree data on ~20000 healthy adult 
volunteers from the Scottish mainland [62], and most participants have additionally consented 
to linking their electronic health record (EHR) data, allowing the analysis of phenotypes that 
were not directly measured as part of the study [63]. Recruitment for this cohort was through 
primary care and participants were encouraged to recruit family members, so this is also a 
family-based cohort, but not a population isolate.  
1.4 Thesis Aims 
The aim of this thesis is to provide a better understanding of the variation that underlies 
complex traits. A particular focus was to provide a comprehensive assessment of the 
performance of different statistical methods (GWAS, linkage analysis and RH mapping) for 
the analysis of complex traits with varying degrees of heritability measured in studies where 
family structure is present. GWAS results were used as a baseline against which the results of 
Figure 1 - The location of the population isolates used in this thesis. 
The Scottish islands are indicated on the left, while the Croatian islands are indicated on the 
right. Additionally, Scotland, the location the individuals in the GS:SFHS cohort were 




linkage and RH analyses were compared, in order to assess the strengths and weaknesses of 
each method, in terms of their ability to detect signals. The five family-based studies used 
within this thesis varied in size and family structure, providing different genetic settings to 
carry out such analyses, but shared a subset of traits measured in a similar manner allowing 
comparisons of findings. The main aim is to investigate whether methods leveraging haplotype 
sharing, which should be increased in family-based samples, help pinpoint genetic loci 
influencing traits not revealed by standard single SNP GWAS. This would help showcase the 
advantages of using population isolates and justify the more widespread use of methods 
complementary to GWAS.  
The original contributions of this study to the field are that there are currently no studies that 
comprehensively compare the performance of these statistical methods on such a large scale. 
The large scale of this project is due to multiple factors. One of these factors is the use of 
datasets consisting of thousands or tens of thousands of related individuals and families of 
varying sizes and complexities. Another factor is the number of phenotypes analysed and the 
use of whole-genome genotyping and imputed data also contribute to the large scale of this 
project.  
Within this thesis, IBD sharing is computed between pairs of related individuals in these 
family-based population cohorts (as determined from social pedigrees) and this is then used to 
compute linkage to complex, medically-relevant traits. Additionally, a ‘pedigree-free’ linkage 
method is developed, which aims to leverage IBD sharing between pairs of distantly-related 
individuals who appear unrelated in the social pedigree, in order to boost the power of linkage, 
taking the process from the family to the population level, which has not been done to this 
extent in previous linkage studies. 
This study also refined the RH mapping methodology by using regions defined by 
recombination hotspots rather than windows consisting of an arbitrary number of SNPs. This 
leads to more biologically relevant regions, and also enables cross-study meta-analysis, as the 
window positions are independent of the number of genotyped SNPs available in a study. 
Meta-analysis was conducted on the results of GWAS using imputed genotypes, RH results as 
well as pedigree-based and pedigree-free variance component linkage results in order to 
identify variation that contributes to complex traits in multiple studies.  
Chapter 3, Chapter 4 and Chapter 5 describe the three statistical methodologies used and 
present the results obtained by applying these methods to each cohort individually as well as 
those obtained by meta-analysing the results. In Chapter 6, these methods are applied to 
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simulated phenotypes and the Orkney genetic data in order to obtain more easily-quantifiable 
metrics of their ability to detect a causal variant of small to large effect in the presence of 
varying degrees of environmental and genetic noise. In Chapter 7, the results obtained from 
real data are systematically compared in order to highlight the similarities and differences in 
the signals detected by these methods. Final conclusions are drawn in Chapter 8, where the 
implications of this study are also discussed.  
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Chapter 2 Materials and Methods 
2.1 Population Studies 
This thesis investigates five family-based European population cohorts from Scotland and 
Croatia. Recruitment, as well as phenotype collection and SNP genotyping was undertaken by 
colleagues and collaborators as described in the sections below. 
2.1.1 The Croatia Studies 
In the Adriatic Sea, along the Croatian Dalmatian coast, there are fifteen islands where the 
population exceeds 1000 individuals. Each island has its own specific history and founder 
population due to having been isolated from the population they derive from for several 
centuries, or, in some cases, millennia, and they have been studied for decades [64]. A pilot 
study was initiated in 2002 by collecting 100 individuals in each of ten villages on these islands 
to determine their suitability for recruitment into cohorts aimed at studying complex trait 
genetics. These villages differed in terms of population genetic and ethnic history, founding 
time, bottleneck events and admixture and showed high levels of genetic structure and 
differentiation, mostly due to their isolation and endogamy [65]. 
The islands of Vis (study referred to as Vis in this thesis) and Korčula (study referred to as 
Korčula in this thesis) were selected for further recruitment. 1008 participants were recruited 
from the villages of Komiza (546 participants) and Vis (414 participants) on the island of Vis 
between 2003 and 2004. Recruitment in Korčula occurred in three phases, with 968 
participants recruited between 2007 and 2008, 878 participants recruited in 2012 and 986 
participants recruited in 2014, for a total of 2832 individuals. Blood DNA, plasma and serum 
was collected from participants who also filled in questionnaires relating to general health, 
medical history, lifestyle and diet and were subjected to anthropometric and physical 
measurements. 
Ethical approval was given for recruitment of all Croatia study participants by ethics 
committees in Scotland and Croatia and participants gave informed consent prior to 
participation [66, 67]. 
2.1.2 The ORCADES Study 
The Orkney Complex Disease Study (ORCADES, referred to as ORCADES or Orkney in this 
thesis) is based on an isolated population from the 10 inhabited Orkney isles in the north of 
Scotland and was designed as a sister study to the Croatia studies. Compared to the Scottish 
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mainland, genetic diversity is reduced, due to isolation and endogamy [68], as was seen in the 
Croatia cohorts.  
Individuals were eligible to participate in this study if they had at least two grandparents born 
in the Northern Isles of Orkney and were residing in Orkney at the time of recruitment, which 
took place between 2005 and 2011. 2080 participants were recruited into this cohort, giving a 
fasting blood sample and attending a cardiovascular measurement clinic in addition to being 
subjected to anthropometric measurements, dual energy X-ray absorptiometry (DEXA) scans, 
cognitive tests and eye measurements.  
Ethical approval was given for recruitment of all ORCADES study participants by ethics 
committees in Scotland in 2004 and participants gave informed consent prior to participation 
[69]. 
2.1.3 The VHSS Study 
The Viking Health Study – Shetland (VHSS, referred to as Shetland in this thesis) is based on 
an isolated population from the Shetland isles in the north of Scotland. Study design was 
similar to that of the ORCADES study, with eligibility to participate based on volunteers 
having at least two grandparents originating from Shetland. Recruitment of 2105 study 
participants occurred between March 2013 and March 2015 at a dedicated research centre in 
Lerwick, where participants attended a measurement clinic and gave fasting blood samples.  
2.1.4 Generation Scotland 
The Generation Scotland: Scottish Family Health Study (GS:SFHS, referred to as Generation 
Scotland or GS in this thesis) is a family-based genetic epidemiology cohort with 24000 
participants recruited from the general Scottish population through referrals from general 
medical practitioners and individuals with at least one first-degree relative already in the study. 
Participants were recruited from the Glasgow and Tayside areas of Scotland between 2006 and 
2011, and participants from Ayrshire, Arran and Northeast Scotland were recruited during 
2011 [62, 70]. Participants provided blood and urine samples and attended a measurement 
clinic for anthropometric, respiratory function and cardiometabolic measurements. 
Participants were also assessed for psychiatric and emotional disorders using the structured 
clinical interview for DSM-IV and filled in questionnaires relating to medical history, general 
health, lifestyle and diet.  
Ethical approval for recruitment and Research Tissue Bank status was given by the NHS 
Tayside Committee on Medical Research Ethics (REC Reference Numbers 05/S1401/89 and 
31 
 
15/ES/0040, respectively), providing approval for a wide range of uses within medical 
research, including genetic analyses and linkage to electronic health records.  
2.2 Traits and Covariates 
Table 1 contains the list of traits that were analysed within this study, as well as their units, 
the covariates used and normalisations applied, if any. It also includes the number of 
individuals who possess each trait measure and all covariates used with that trait. For each 
trait, the covariates that are used match those previously used by research consortia in large 
meta-analyses. Some traits were only measured in a subset of a cohort, as indicated by the 
lower number of individuals with measurements for these traits.  
Some traits were transformed to meet the requirement of a close to normal distribution of the 
residuals in the linear models used for analysis. This was achieved either by simple 
arithmetical transformation (e.g. taking the natural log of the trait) or “forced normalisation”, 
using quantile normalisation [71] (in this thesis referred to as rank transformation), which was 
implemented using the rntransform() function in the GenABEL R package [72]. This method 
of trait normalisation is favoured by the GWAS community as it bypasses the sensitivity of 
models to outliers, kurtosis and skewness of analysed traits. Some trait measures displaying 




, where y is the trait value, and μ and σ are this trait’s mean and standard 
deviation, respectively. This operation is referred to as z-transformation within this thesis, and 





Table 1 - List of traits, covariates, units and normalisations used in this thesis 
This table lists the traits analysed within this thesis, as well as the number of individuals with measurements for each trait and all covariates used with 
that trait, within each cohort. NAs indicate that the trait was not analysed or available in a specific cohort. Rank and z-transformations were done by using 
the rntransform() and ztransform() functions, respectively, within the GenABEL R package, while ln indicates that the trait was log-transformed. 
YOB, year of birth. b – Systolic and diastolic blood pressure measures were increased by 15 and 10, respectively, in individuals on anti-hypertensive 
medications. a - Area is a binary covariate indicating whether individuals are from Glasgow (1) or not (0). d – Removed individuals reported as being 
diabetic, as well as individuals with fasting glucose values > 7mmol/L. s – ever_smoke is a binary covariate indicating whether an individual was never a 
smoker (0) or is a current or former smoker (1).  
Trait Vis Korčula Orkney Shetland GS Normalisation Covariates Units 
Anthropometric Traits 
Body Mass Index (BMI) 946 2611 1941 2093 19900 Rank Transform Sex+Age+Age*Age kg/m2 
Body Fat Percentage NA NA NA NA 19480 No Sex+Age % 
Height 946 2613 1941 2093 19965 No Sex+Age m 
Waist 946 2574 1938 2093 19664 Rank Transform Sex+Age+Age*Age+BMI cm 
Waist to Hip Ratio 945 2570 1936 2091 19645 Rank Transform Sex+Age+Age*Age+BMI NA 
Biochemistry Traits 
Albumin 946 2676 2007 2093 NA Rank Transform Sex+Age g/L 
Serum Calcium 948 NA 2007 2093 NA Rank Transform Sex+Age mmol/L 
Total Cholesterol 928 2676 2007 2093 19259 Rank Transform Sex+Age+Age*Age mg/dL 
Cortisol 922 NA 1999 NA NA Rank Transform Sex+Age μg/L 
Creatinine 927 2579 2007 2093 16347 Rank Transform Sex+Age mg/dL 
C-Reactive Protein (CRP) 900 NA 1991 2082 NA No Sex+Age mg/L 
D-Dimer 922 NA 1004 NA NA Rank Transform Sex+Age ng/dL 
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Trait Vis Korčula Orkney Shetland GS Normalisation Covariates Units 
Serum Insulin 815 NA 1927 2092 NA 
Rank 
Transform(ln) Sex+Age+Age*Age+BMI pmol/L 
Glucose 940 2595 1930 2093 16076 Rank Transform Sex+Age+Age*Age+BMI mmol/L 
Glucose (diabetics removed)d 818 2238 1845 2041 15141 Rank Transform Sex+Age+Age*Age+BMI mmol/L 
Fibrinogen 918 NA 1003 2089 NA Rank Transform Sex+Age g/L 
Gamma-Glutamyltransferase 
(GGT) 920 NA 985 2093 NA 
Rank 
Transform(ln) Sex+Age*Sex+BMI U/L 
Glutamate Pyruvate 
Transaminase (GPT) 920 NA 984 2090 NA Rank Transform Sex+Age*Sex+BMI U/L 
HbA1c (Glycated 
Haemoglobin)d 815 2164 1828 2088 NA Rank Transform Sex+Age+BMI 
% of total 
Haemoglobin 
HDL-Cholesterol 928 2673 2006 2093 19223 Rank Transform Sex+Age+Age*Age mg/dL 
LDL-Cholesterol 928 2640 2005 2093 NA Rank Transform Sex+Age+Age*Age mg/dL 
Serum Potassium NA NA NA NA 19020 Rank Transform Sex+Age mmol/L 
Serum Sodium NA NA NA NA 19277 Rank Transform Sex+Age+Areaa mmol/L 
Tissue Plasminogen Activator 
(tPA) 912 NA 1004 NA NA Rank Transform Sex+Age ng/mL 
Triglycerides 928 2674 2006 2093 NA ln Sex+Age+Age*Age mg/dL 
Urea 927 NA 1006 2093 19293 Rank Transform Sex+Age mg/dL 
Uric acid1 948 2674 2003 2093 NA Rank Transform Sex+Age mg/dL 
Uric acid2 940 2464 1715 2089 NA Rank Transform Sex+Age+BMI+Alc_gday mg/dL 
Von Willebrand Factor (vWF) 922 NA 1003 NA NA No Sex+Age IU/dL 
Cardiometabolic traits 
Diastolic Blood Pressureb 945 2551 1933 2093 19429 No Sex+Age+Age*Age+BMI mmHg 
Pulse Pressure 945 2551 1933 2091 19429 Rank Transform Sex+Age+Age*Age+BMI mmHg 
Systolic Blood Pressureb 945 2552 1935 2091 19430 Rank Transform Sex+Age+Age*Age+BMI mmHg 
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Trait Vis Korčula Orkney Shetland GS Normalisation Covariates Units 
Heart Rate NA 1498 NA 2090 19798 Rank Transform Sex+Age+Age*Age+BMI bpm 
Eye Traits 
Axial Length1 550 853 1194 1825 NA Rank Transform Sex+Age mm 
Axial Length2 548 841 1156 1816 NA Rank Transform Sex+Age+Height mm 
Central Corneal Thickness 561 858 1112 1888 NA Z-Transform Sex+Age μm 
Intra-ocular Pressure (IOP) NA NA 1111 1987 NA No Sex+Age mmHg 
Lens Thickness 533 853 NA NA NA Z-Transform Sex+Age mm 
Spherical Equivalent Refraction 527 835 1165 1927 NA Rank Transform Sex+Age diopter 
Pulmonary function traits 
Forced Expiratory Flow NA NA NA NA 15782 Rank Transform 
Sex+Age+Age*Age+Height+
ever_smokeds L/s 
Forced Expiratory Volume in 1 
second (FEV1) 925 2397 1828 1688 15847 Rank Transform 
Sex+Age+Age*Age+Height+
ever_smokeds L 
FEV1/FVC 925 2397 1828 1688 15847 Rank Transform 
Sex+Age+Age*Age+Height+
ever_smokeds NA 




Alcohol Consumption 946 2491 1720 2089 18213 Rank Transform Sex+Age+Age*Age+Weight g/day 
Educational Attainment 897 2632 1860 2081 18917 No Sex+YOB+YOB^2+YOB^3 NA 
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2.2.1 Significance Thresholds and Independent Traits 
The canonical genome-wide significance (GWS) p-value thresholds used in the literature are 
5×10-8 for GWAS [73] and 4.9×10-5 for linkage (equivalent to a decimal logarithm of the 
likelihood ratio, LOD score, of ∼3.3) [74]. For RH, a threshold of 4.13×10-6 is used 
(0.05/12101 regions). From simulation studies (discussed in Chapter 6), I obtained an 
empirical linkage significance threshold of LOD=3.41, which I will use in this thesis.  
As more than one phenotype was analysed within this thesis, these thresholds should be more 
stringent to account for additional multiple testing. The phenotypes used here are not all 
independent, so in order to determine the number of independent traits (and adjust significance 
thresholds accordingly), principal component analysis was carried out in each cohort, on all 
analysed phenotypes (pre-adjusted for covariates and kinship), using all phenotyped 
individuals, using the “prcomp” function in R. Table 2 shows the number of input phenotypes 
and the number of principal components (PCs) that cumulatively explain 99% of the variance.  
When reporting results in individual cohorts, the GWS threshold is adjusted for the number of 
PCs explaining 99% variance in that cohort. Table 2 shows the adjusted genome-wide 
significance thresholds for GWAS, linkage analysis and regional heritability. When reporting 
meta-analysis results, the genome-wide significance threshold is adjusted by 32, reflecting the 
largest number of PCs explaining 99% variance in any one cohort. Results that exceed the 
unadjusted GWS threshold of but do not reach the adjusted GWS threshold are considered 
strongly suggestive hits. 
Table 2 - Trait principal components and significance thresholds  
The genome-wide significance thresholds for GWAS, RH and linkage, adjusted for the number 



















Vis 39 32 8.80 6.89 5.93 4.84 
Korčula 31 24 8.68 6.76 5.81 4.73 
Orkney 39 32 8.80 6.89 5.93 4.84 
Shetland 36 29 8.76 6.85 5.89 4.80 
GS 23 19 8.58 6.66 5.71 4.63 
Meta - 32 8.80 6.89 5.93 4.84 
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2.3 Genetic Data 
DNA for genotyping was extracted by colleagues at the University of Edinburgh, the 
University of Zagreb and the University of Split Medical School, and subsequently genotyped 
as shown in Table 3. 
2.3.1 Genotyping and Quality Control  
Each cohort was genotyped on a commercially-available genotyping platform (Table 3) and 
genotypes were called using the BeadStudio software. I performed quality control checks in 
each cohort prior to downstream analysis, as detailed below. 
The final number of autosomal SNPs that were analysed in each cohort is reported in Table 3, 
as is the final number of individuals available after quality control. Quality control (QC) was 
carried out using PLINK [75, 76]. These SNPs were filtered using the following quality control 
procedures: 
 SNPs that were not in Hardy-Weinberg Equilibrium (HWE test P<10-6) were excluded 
 Mendelian errors (MEs) were detected and zeroed using the ‘--mendel --mendel-
duos --mendel-multigen --set-me-missing’ flags in PLINK, after merging 
the genotyped individuals with a file containing only ungenotyped individuals in order 
to preserve the full social pedigree for accurate ME detection 
 Monomorphic SNPs were removed 
 SNPs that did not lift over to Genome Reference Consortium build 37 were removed 
(the UCSC liftOver tool was used to perform the SNP position conversion) 
 SNPs with call rates lower than 98% were excluded 
 Individuals with call rates lower than 97% were excluded 
Within this thesis, only autosomal SNPs are analysed, but Y chromosome and mitochondrial 
DNA were used to assist with pedigree assembly (discussed in the next section). Additionally, 
X and Y chromosome marker counts were used to identify sex discrepancies that could 
indicate potential sample swaps. This check was performed in PLINK, using the ‘--check-
sex ycount’ option, which calculates F statistics (X chromosome homozygosity) and counts 
the number of Y chromosome markers in each individual. Individuals who are recorded as 
females in the input file but have F statistics higher than 0.8 and/or carry Y chromosome 
markers are flagged as male, while males that do not carry any Y chromosome markers are 
also flagged. If such inconsistencies could not be resolved, the individuals in question were 
removed from the data prior to downstream analysis.  
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In Orkney and Korčula, individuals were genotyped using one of several different genotyping 
platforms, and analyses within this thesis were performed on the overlapping markers from 
these platforms, hence the lower number of genotyped markers in these cohorts. The 
histograms in Figure 2 show the allele frequency distributions of the genotyped variants in 
each cohort and show that there is an enrichment of variants with allele frequencies below 5% 
in GS and Shetland, where denser genotyping chips were used. In contrast, most variants in 
the other cohorts have minor allele frequencies larger than 5%. There is a roughly even 
distribution of SNPs across the rest of the allele frequency spectrum in each cohort. 
Table 3 - Genotype Data Overview 
This table lists the genotyping platforms that were used to type individuals in each cohort. It 
also shows the number of genotyped SNPs that pass quality control, as well as the number of 
imputed SNPs that are not monomorphic and have imputation quality scores > 0.4.  









Vis Illumina HumanHap300v1 (Clinical 
Research Facility, University of  Edinburgh) 
273,645 12,468,939 960 
Korčula Illumina HumanHap370CNV DUO/QUAD 
Phase 1 (Helmholz Zentrum München, 
Germany) 
HumanOmniExpressExome8v1-2_A 
(Clinical Research Facility, University of  
Edinburgh) 
182,809 12,382,834 2701 
Orkney Illumina HumanHap 300v2 Phase 1 
(Helmholz Zentrum München, Germany) 
Illumina HumanHap370CNV DUO 
(Integragen, Paris, France) 
157,552 12,696,745 2027 
Shetland HumanOmniExpressExome8v1-2_A 
(Clinical Research Facility, University of  
Edinburgh) 
616,374 14,267,501 2182 
GS HumanOmniExpressExome8v1-2_A 
HumanOmniExpressExome8v1_A 
(Clinical Research Facility, University of  
Edinburgh) 







In order to enable meta-analysis of GWAS results, genotyped SNPs were imputed to the 
Haplotype Reference Consortium (HRC) panel v1.1 [77] using the Sanger Imputation Service. 
The same genotype quality control steps were used to prepare the files for imputation as those 
mentioned above, with the exception that where several genotyping platforms were used in a 
cohort (Orkney and Korčula), platform-specific call rate filters were used prior to merging in 
order to retain high quality variants even if they were only typed on one platform. 
Figure 2 - Histograms of allele frequency distributions of genotyped SNPs in each 
cohort 





Prior to imputation, autosomal SNPs were phased with Shapeit2 v2r837 [78, 79], using the 
‘duohmm option 11’ flag that takes advantage of the family-based nature of the data [80]. 
Imputed variants with low imputation quality scores (INFO < 0.4) were removed prior to 
downstream analysis, as were monomorphic variants. Table 3 presents the number of SNPs 
that were available for GWAS in each cohort. Genotype imputations were performed by Dr. 
Thibaud Boutin (MRC Human Genetics Unit). 
2.4 Pedigree Assembly, Correction and Summaries 
Linkage analysis traditionally requires social pedigrees alongside genetic data. Since all the 
studies used within this thesis are family-based, they provide the optimal setting for conducting 
linkage studies. Since the linkage analysis results depend on the accuracy and completeness 
of these social pedigrees, they were carefully checked and amended in order to remove 
incorrectly recorded relationships and, where possible, to add new connections. 
2.4.1 Vis 
The Vis social pedigree had been carefully sought out from church and census records dating 
back from the 1830s and had already been checked and corrected prior to the start of this study 
[81], so was used as-is in the linkage analyses. 
2.4.2 Korčula 
No social pedigree was available for Korčula, but since most linkage analyses require a 
pedigree, a pedigree was manually assembled based on the genetic kinship of the study 
participants. This was done by first calculating the pairwise genome-wide identity-by-descent 
(IBD) estimates for all pairs of individuals, using all autosomal SNPs with minor allele 
frequencies above 1%, using the program PLINK version 1.90b2c [75, 76]. This IBD matrix 
was passed onto the program PRIMUS [82] which creates networks of related individuals 
(families), where each person in a network has to be related to at least one other person in that 
network. The relatedness threshold was set to 0.1, or 10% of markers shared IBD, in the first 
instance. This grouped 1227 people into the same network, so PRIMUS was re-run in this 
network using a relatedness threshold of 0.15, in order to group these people into several 
smaller families where relationships could be reconstructed manually. 
Once these networks were created, PRIMUS attempts to reconstruct all possible pedigrees for 
each network, based on additional data such as age, sex and mitochondrial and Y chromosome 
matching information. This process works well with nuclear families, but often there can be 
more than one possible pedigree, so the decision of which pedigree is the most likely one lies 




Furthermore, PRIMUS was unable to reconstruct any pedigrees in many networks that 
contained more than 5 individuals, so pedigree reconstruction in these networks was done 
manually, making use of Y chromosome data to check paternal lineages and mitochondrial 
DNA data to check maternal lineages (Figure 4).  
In ambiguous cases where two individuals were equally likely to be related in several different 
ways, one was arbitrarily selected. This is not a problem for linkage analyses, as it only looks 
at the genetic sharing between relatives, but it might be an issue for other types of analyses, 
for example parent-of-origin studies.  
Figure 3 - Pedigrees reconstructed by PRIMUS. 
The coloured shapes correspond to two genotyped individuals assigned to the same 
network. They are estimated to share 25% of their alleles IBD, their mitochondria match, 
and their ages are shown. They are not related to any other genotyped individuals. Squares 
represent males; Circles represent females. PRIMUS reconstructs three equally-likely 
pedigrees (A, B, C) based on these data. Pedigree B looks less likely, due to the younger 
person being assigned to the older generation, but due to the 14-year age difference, it is 
not obvious whether the individuals belong to different generations (A) or the same 











2.4.3 Orkney and Shetland 
Both islands are part of Scotland and records of the births, deaths and marriages are all kept at 
the Edinburgh Register House. Emily Weiss, a PhD candidate in Prof. James F. Wilson’s group 
at the University of Edinburgh, used these records along with relationship information 
obtained from study participants and genealogies available online to assemble the social 
pedigree for Orkney and Shetland. This pedigree was corrected to reflect the genetic kinship 
between individuals, using the merged Orkney and Shetland genotype data. Y chromosome 
haplogroups (provided by Prof. James F. Wilson) were used to resolve some ambiguities.  
The joint Orkney-Shetland master pedigree file was then subdivided into Orkney-specific and 
Shetland-specific pedigrees. These pedigrees were pruned, keeping genotyped individuals and 
trimming uninformative individuals (defined as individuals with no genotype data in a cohort, 
who also do not link two individuals with genotype data), using the program PedStats [83] 
(Figure 5). 
Figure 4 - Y chromosome and Mitochondrial DNA sharing 
Males and females (black shapes) inherit autosomal DNA from both the maternal (pink) 
and paternal (blue) lines (left). Males inherit the Y chromosome along their paternal line, 
while females do not have a Y chromosome (centre). Males and females inherit 
mitochondrial DNA along their maternal line. Fathers do not pass their mitochondrial DNA 




The complete social pedigree dates back to ~900 A.D. and is very detailed, consisting of 42000 
individuals. After trimming, 22442 individuals were left in the combined Orkney – Shetland 
pedigree, 21599 of which belonged to one very large 36-generation family linking even very 
distant relatives. In the Orkney and Shetland-specific pedigrees, 14417 out of 14436 and 8899 
out of 9740 individuals, respectively, belonged to this large family. The IBD estimation 
software Loki [84] is not able to cope with such large family sizes, so the program PedCut 
[85] was used to generate families of bitsizes no larger than 50, where bitsize is defined as 
2 ∗ [𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑛𝑜𝑛𝑓𝑜𝑢𝑛𝑑𝑒𝑟𝑠] − [𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑓𝑜𝑢𝑛𝑑𝑒𝑟𝑠] 
Figure 5 - Pedigree subdivision and trimming 
This is a fictitious family tree that is used to illustrate the points of pedigree subdivision and 
trimming in Orkney and Shetland. The combined Orkney – Shetland family (top) is 
subdivided into Shetland-specific and Orkney-specific informative subfamilies (bottom left 
and right, respectively). Green shapes indicate individuals with genotype data in Shetland, 
blue shapes indicate individuals with genotype data in Orkney. Individuals outlined in red 
indicate entirely non-informative individuals that were removed from the sub-pedigrees and 
the trimmed Orkney – Shetland pedigree. Note that the genotyped Orkney male (blue square 
in the top panel) is still informative in the Shetland subfamily (because he links genotyped 





This was done to maximize the number of informative (genotyped/phenotyped) individuals in 
each family, and it resulted in some genotyped individuals getting dropped if they were 
unrelated to other individuals, and some individuals becoming duplicated as they were 
informative in several families. In order to avoid this affecting the phenotype distribution, 
phenotypes were first adjusted for covariates and transformed, where appropriate, without 
counting duplicated individuals twice, and the same residuals were assigned to each copy of a 
duplicated individual.  
2.4.4 Generation Scotland 
Social pedigrees were corrected as described in [62]. Briefly, pedigrees constructed from self-
reported data were checked using genetic relatedness (calculated as described for Korčula 
above, with the modification that only autosomal SNPs with minor allele frequencies above 
5% were used), breaking or modifying links to first and second-degree relatives where the 
expected and calculated IBD differed by more than 25%. The pedigree was updated to account 
for previously unrecorded first and second degree relationships (expected IBD = 0, calculated 
IBD ≥ 25%). After these corrections, the expected versus observed IBD sharing was plotted 
and the pairs were coloured by their pedigree kinship, which helped identify and correct further 
discrepancies (Figure 6). Mitochondrial and Y chromosome markers were used to resolve 
lineage-related ambiguities, where possible. Table 4 summarises the number and type of 
relationships that were changed as a consequence of these correction. 
Table 4 - Number and type of relationships that were changed following 
pedigree QC in Generation Scotland 
The first element of each pair reports the initial relationship between a pair of individuals, 
while the second element reports the corrected relationship, as ascertained from genetic data. 
FS, full sibling. PO, parent-offspring. OT – other related. UN – unrelated. HS – half sibling. 
2nd – second degree relative (can be either grandparent-grandchild, avuncular, or half-sibling). 
FS - 2nd 95 PO - FS 2 UN - PO 31 HS - FS 4 
FS - UN 13 PO - OT 5 UN - FS 8 HS - UN 3 





2.4.5 Pedigree Summaries 
The number of people in each pedigree, as well as information about family size and 
generation number are provided in Table 5. The number of genotyped people in each linkage 
study, as well as the number of different types of family relationships between genotyped 
individuals is presented in Table 6.
Figure 6 - Social pedigree vs Genotype Sharing 
This plot shows the average probability of two pairs of individuals sharing 0 alleles IBD (X 
axis) or 1 allele IBD (Y axis) across the genome, between every pair of individuals in 
Generation Scotland. Pairs are coloured based on their relationship in the social pedigree – 
red for parent-child pairs, green for full siblings, orange for half siblings, blue for other 
family relationships and black for unrelated pairs. The panel on the right represents the 
calculated genotype sharing coloured using the uncorrected pedigree while the panel on the 
left represents the same genotype sharing but coloured using the corrected pedigree. There 
is no unexpected clustering of different types of relationships, indicating that the pedigrees 




Table 5 - Pedigree summaries 




Family size (all) Family size (genotyped) Generations 
Average Maximum Average Maximum Average Maximum 
Croatia - Vis 1843 559 3 351 1.8 127 1.39 6 
Croatia - Korčula 4932 1226 4 184 2.2 83 1.62 6 
Orkney 14423 14 1030 14404 144.8 2012 3.57 35 
Orkney - bitsize 50 7296 170 43 74 11.6 32 6.35 9 
Shetland 9740 273 35 8899 7.9 1740 1.67 34 
Shetland - bitsize 50 5822 326 17 74 5.8 29 4.07 10 
Orkney + Shetland 22442 277 81 21599 15.2 3762 1.66 35 
Ork + Shet - bitsize 50 12642 479 26 74 8.1 33 4.74 9 









Table 6 - Summary of genotyped pairs used in linkage analysis 
The avuncular relationship type refers to aunt/uncle-niece/nephew relationships. Ork – Orkney, Shet – Shetland. 
Population 






sibs Cousins Avuncular 
Grandparent-
Grandchild 
Croatia - Vis 960 402 558 202 126 11 119 117 33 
Croatia - Korčula 2701 987 1714 772 480 55 615 607 124 
Orkney 2027 803 1224 796 719 51 1918 1082 132 
Orkney - bitsize 50 2081 (1968 unique) 818 1263 781 628 30 997 556 79 
Shetland 2182 864 1318 699 612 39 1952 1112 79 
Shetland - bitsize 50 1923 (1903 unique) 760 1143 692 512 33 1079 703 70 
Orkney + Shetland 4207 1665 2542 1541 1367 84 4010 2272 219 
Ork + Shet - bitsize 50 4015 1543 2343 1515 1151 58 2160 1325 159 






Chapter 3 Genome-Wide Association Studies 
3.1 Introduction 
Genome-wide association studies (GWAS) use statistical approaches to scan many genetic 
markers across the genome in order to identify genetic variation that is associated with a trait 
or disease (Figure 7). These studies leverage the presence of linkage disequilibrium (LD), that 
is the non-random association, of a genetic locus that exerts an effect on a trait (also referred 
to as a quantitative trait locus or QTL) and nearby genotyped variants that tag the effect of the 
QTL.  
Figure 7 - Outline of a GWAS 
A complex trait, here height, is measured in a population of individuals and the alleles carried 
by each individual at each SNP is ascertained through genotyping or sequencing. Then, trait 
values are regressed onto the genotypes in order to ascertain the strength of the association 
between the phenotype and each studied SNP. The more often a particular allele of a SNP is 
seen in individuals on one extreme of the trait distribution, the stronger the association signal 
between that SNP and the trait under study. For example, here, SNP 1 is monomorphic, which 
means that it is the same in all individuals regardless of their trait value, so it does not contribute 
to the variation of height in this population. The two alleles of SNP 2 seem to be present 
randomly in taller and shorter individuals, while the number of T alleles carried by each 
individual is correlated with their height, with this allele not appearing in the shortest people, 
so SNP 3 is said to associate with the trait. The results of this analysis on many SNPs across the 




GWAS have initially been conducted using datasets consisting of unrelated individuals, in 
order to avoid false positives that may arise if the genotypes of study participants are not 
independent of each other [50]. Additionally, false positives or false negatives may also occur 
if population stratification is present in the studied dataset, as then an association signal may 
simply be due to different SNP allele frequencies in different populations [86]. While there is 
no substantial population stratification within the cohorts used within this thesis, and quality 
control checks have been performed to exclude individuals who are ancestry outliers, there is 
a large amount of relatedness between individuals owing to the family-based nature of these 
cohorts. Historically, GWAS have excluded related individuals from the study sample prior to 
analysis, but excluding related individuals from the cohorts used in this thesis would lead to a 
huge loss in statistical power. Instead, linear mixed models (LMMs) can be used as these 
account for both population stratification and the presence of related individuals [87]. 
Over the past decade, GWAS have been the main tool for discovering loci contributing to 
complex trait variation [88]. GWAS associations reported in research papers are continuously 
being aggregated into the NHGRI GWAS Catalog [16], providing a simple means of checking 
whether variants discovered with a GWAS have previously been reported. It is also possible 
that a SNP reported in one study is not present on the genotyping panel used to conduct GWAS 
in a different study. In such cases, if a significant hit is detected at the same locus, LD between 
these two SNPs can be calculated in order to assess whether they are tagging the same signal 
or whether they are due to independent signals. Within this thesis, this LD lookup is performed 
with the help of HaploReg [89], which provides pre-calculated LD statistics between SNPs 
present in the 1000 Genomes data [90]. 
In this chapter, I present the statistical framework of conducting GWAS in datasets consisting 
of related individuals, and apply these to analyse complex human traits measured in five 
population cohorts of European ancestry. In addition to cohort-specific GWAS, I also perform 
a meta-analysis using the results of the GWAS that have been performed on the SNP 
genotyped imputed to the haplotype reference consortium (HRC) panel [77]. The results 
presented here are used a baseline against which the results obtained with linkage analysis and 
regional heritability are compared in later chapters. 
3.2 Methods 
3.2.1 Genetic Relationship Matrix 
In contrast to identity-by-descent matrices, presented later in section 4.2, “traditional” genetic 
relationship matrices (GRM) are calculated without making use of LD between SNPs and they 
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do not take SNP position into account. The matrix is symmetrical with elements corresponding 
to estimates of kinship coefficient between pairs of individuals that are calculated using the 
following formula, as implemented in the GenABEL, DISSECT and GCTA programs. 









where 𝑠𝑖𝑘 is the number of copies of the reference allele for SNP 𝑘 of individual 𝑖 and 𝑝𝑘 is 
the frequency of the reference allele for this SNP. N is the total number of SNPs used in the 
calculation [18]. Genome-wide GRMs were used to correct for relatedness in genome-wide 
association studies (GWAS) and regional heritability (RH) analyses within this thesis.  
For use in GWAS, the GRMs were calculated with the ‘ibs’ function of the GenABEL R 
package [72], which uses genotype data to estimate the realized kinship coefficient between 
all pairs of individuals. The weight=“freq” option was used, which weighs SNPs based on 
their minor allele frequency. No minor allele frequency cut-off was used when calculating 
these GRMs, and SNPs were not pruned for LD prior to GRM calculation. 
3.2.2 Linear mixed models 
Under a linear mixed model, a phenotype (y) can be expressed using the following equation:  
𝑦 = X𝛽 + Z𝑢 + 𝑒, 
where y is a vector of measured values, β is the vector of fixed effects with design matrix X 
(relating observations to fixed effects), u is the vector of random genetic effects with design 
matrix Z (relating observations to random effects), and e is the vector of residual error. Values 
of u and e follow normal distributions with means of 0 and variances var(u)=G𝜎𝑎
2 (where G is 
the relationship matrix and 𝜎𝑎
2 is the variance of additive genetic effects) and var(e)= 𝐼𝜎𝑒
2 
(where I is the identity matrix). A maximum likelihood method is used to estimate parameters 
(effect of fixed effects and the variance components), based on the multivariate normal feature 








GWAS were performed separately on genotyped SNPs and imputed data. In both cases, 
phenotypes were adjusted for covariates as well as for relatedness using a genome-wide 
kinship matrix, using the ‘polygenic’ function within GenABEL which implements the linear 
mixed model described above. While fitting one SNP as an additional fixed effect to test 
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association with a trait is possible, fitting each available marker across the whole genome this 
way would take too long computationally, so various solutions have been implemented to 
shorten the analysis time [91]. In GenABEL, GWAS is performed using a two-step process. 
First, the polygenic effects and the environmental residuals are estimated with the ‘polygenic’ 
function, and these estimates are then used to test association with every SNP in the analysis 
using the ‘mmscore’ function within the same package, which performs the GWAS under an 
additive model, using the score test devised by Chen and Abecasis [92]. The ‘polygenic’ 
function also produces residuals that are free of correlations (due to polygenic or 
environmental effects) that can be extracted and used as the phenotype inputs in external 
GWAS pipelines that do not account for relatedness. As such, the pgresidualY values were 
used to perform the imputed data GWAS, using the RegScan v0.2 software [93]. After this 
analysis was completed, the resulting p-values, effect sizes and effect size standard errors were 
corrected to account for relatedness using the GRAMMAR-Gamma correction factors 
provided by the ‘polygenic’ function [94].  
When using the imputed dataset, imputed SNP dosages, rather than hard-called genotype 
values, were used to perform the GWAS. Only SNPs with imputation quality scores greater 
than 0.4, and minor allele counts greater than 20 were used. Note that this minor allele count 
varies depending on phenotype, as it is calculated using only the individuals with non-missing 
phenotypes and covariates. Also, because the number of individuals varies between cohorts, 
the minor allele frequency that a minor allele count of 20 corresponds to will be different 
between cohorts, ranging from 1% in Vis to in 0.05% in GS. SNPs with Hardy-Weinberg 
equilibrium p-values < 10-6 were also removed. For a distribution of allele frequencies in each 
cohort, see Figure 2. 
When reporting the results of GWAS, if a region contained one or more SNPs that passed the 
genome-wide significance (GWS) threshold, the SNP with the lowest p-value in this region is 
reported as the lead SNP. The results also record the number of additional SNPs that pass the 
GWS threshold within a 500kb window up- and downstream of the lead SNP.  
Additionally, if the region within 100kb up- or downstream of a lead SNP contained an 
association reported in the NHGRI GWAS catalog [16], this is noted, regardless of the LD 
status between the two SNPs. To refine these results, the top SNPs reported here have also 
been analysed with the help of HaploReg v4.1 [89], which extracts all SNPs that are in strong 
LD with a query SNP (r2 >0.8) in the 1000 Genomes European dataset, and indicates whether 
any of these SNPs have been reported in any published GWAS.  
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In some cases, a SNP reported here is within 100kb of one or more SNPs reported in the 
GWAS catalog [16], but the two SNPs are not in strong LD according to HaploReg. This can 
occur due to four reasons. First, the two SNPs might really be independent variants. Second, 
one or both SNPs could be absent from the 1000 Genomes dataset. Third, novel associations 
have not yet been incorporated into HaploReg. Fourth, the two SNPs may have very different 
allele frequencies, which leads to a low r2 between them. Because HaploReg only filters based 
on r2, but not D’, two SNPs might appear not to be in LD if their allele frequencies are different. 
In order to discern whether the SNPs identified here flag QTLs independent to the ones already 
reported in the literature, or whether the two SNPs are in LD within the cohort where the signal 
was detected, cohort-specific LD calculations were carried out between these SNPs, using the 
--ld option in PLINK v1.9 [75], which reports both r2 and D’.  
3.2.4 Meta-Analysis 
Each cohort was processed using the same quality control protocols, phenotypes were in the 
same units and genotypes were imputed and analysed using the same imputation and GWAS 
pipelines. This means that the cohort-level GWAS results are particularly well-suited for meta-
analysis. In addition to providing additional evidence to the presence of a signal detected in 
one cohort, meta-analysis enables the detection of variants that have modest effect sizes in 
several cohorts, but do not exceed the genome-wide significance threshold in any one cohort. 
Meta-analyses of GWAS results were carried out using the METAL software [95], version 
2011-03-25. This software uses GWAS summary statistics to calculate an aggregate p-value 
for each SNP, and, if the phenotypes were in the same units across all analysed cohorts, 
calculates the meta-analysis level effect sizes and their standard errors as well.  
3.3 Results 
3.3.1 Cohort-Specific GWAS 
The GWAS results using imputed genotypes contain all of the hits identified with GWAS that 
only used genotyped SNPs, as well additional hits that are not present when only the genotyped 
SNPs are analysed. These additional associations are primarily with rarer SNPs that were not 
present on the genotyping chip. Table 7 reports the GWS loci identified in the GWAS of 
imputed data, and also indicates the position and test statistic of the genotyped SNP with the 
lowest p-value within 500kb of the reported SNP. Supplementary Table 1 reports all loci that 
exceeded the suggestive but not the genome-wide significance threshold (-log10(p-value)>7.3). 
In total, 8 new loci are identified, 4 in the smaller cohorts, and an additional 4 in GS. These 
hits are distinct and driven by low-frequency variants. There are no new loci identified in Vis, 
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where hits for von Willebrand factor, serum uric acid levels and CRP have already been 
described, respectively, at the well-documented ABO, SLC2A9 and CRP gene regions. All of 
the genome-wide associated SNPs are in high LD with SNPs previously associated with these 
traits. In Orkney, one new association is discovered with serum uric acid levels.  
Most of the other hits reported in Table 7 recapitulate loci that have been previously identified 
with other GWAS, as they either correspond to, or are in LD with, GWAS hits reported in the 
literature. In some cases however, the top SNP reported here is within 100kb of one or more 
reported associations, but HaploReg does not report that they are in LD. In such cases, the 
imputed data were used to calculate cohort-specific LD statistics between the SNP reported 
here and all SNPs within 100kb for which associations with the relevant trait have been 
reported in the literature. This was done to determine whether several independent QTLs 
segregate at a locus, or whether both GWAS have identified the same signal. These LD 
statistics are reported in Table 8 and show that, in most cases, the same signal is being detected 
by the GWAS presented here and the GWAS reported in the literature.  
In some cases, LD between such SNPs is stronger within a cohort than in the 1000 Genomes 
data. For example, cohort-specific LD calculation reveals that in Shetland, rs6540217 (the top 
SNP that associates with central corneal thickness (CCT) in this cohort) is in strong LD 
(r2=0.96, D’=0.98) with rs12447690, the top SNP reported by our group [96] in a CCT GWAS 
that included the Korčula, Vis and Orkney studies as well as a Croatian metropolitan 
population from the city of Split cohort. In the 1000 Genomes data, the r2 between these two 
SNPs is 0.73. Different allele frequencies can cause two SNPs to have low r2 values. For 
example, rs138326449, the top hit for HDL on chromosome 11 in GS, has a MAF of 0.32% 
in this cohort, while the SNPs reported in the literature have allele frequencies ranging from 8 
to 16%. R2 between the two SNPs is 0 in GS, but D’ is 1, which indicates that they are in LD. 
Sometimes, new hits reported in the GWAS catalog have not yet been imported to HaploReg. 
This is the case with 5 different associations in GS. For example, two different studies (in 
addition to our GS study) report associations between rs116843064 and HDL and triglycerides 
[97, 98], but HaploReg shows no GWAS catalog associations for this SNP. 
One exception is the chromosome 15 association with height in GS. The top SNP reported 
here (rs16942323) is within the ACAN gene, but it is not in LD with the two SNPs in this gene 
for which hits are reported in the literature (rs2238300 [22], rs4932217 [99]).
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Table 7 - GWAS genome-wide significant loci in each cohort following HRC imputation 
This table summarizes the hits that passed the GWS threshold in the GWAS using imputed genotypes, providing their -log10(p-value), effect size and its 
standard error (Beta and Beta_SE columns), the allele for which the effect size is reported (EA column) as well as the cohort and trait-specific frequency 
of this allele (EAF column). The nhits column indicates the number of SNPs within 500kb of the reported SNP that also exceeded the GWS threshold in 
the GWAS using imputed genotypes. Within this 1Mb interval, the position and -log10 (p-value) of the SNP with the most significant test statistic in the 
GWAS using genotyped SNPs is shown (Pos_G and logP_G columns). The name of, and distance to, the gene closest to the reported SNP is indicated – 
the distance is 0 if the SNP lies within the gene itself. The final column indicates whether other GWAS have identified this hit before. The first value 
indicates whether any SNPs in the 1000 Genomes data that are in strong LD with the reported SNP (R2 and D’ > 0.8) have been identified with other 
GWAS, while the second value looks at all SNPs within 100kb of the reported SNP, regardless of LD. 
Trait 
Chr Pos rsID logP Beta Beta_SE EA EAF nhits Pos_G logP_G Gene Dist GWAS 
Orkney 
HDL 16 56991363 rs183130 18.91 0.308 0.0339 T 0.3801 42 56993324 18.19 CETP 4470 1|1 
LDL 19 45412079 rs7412 19.55 -0.571 0.0619 T 0.0765 15 45395619 5.61 APOE 0 1|1 
Uric acid1 4 9993838 rs7663032 22.81 0.396 0.0396 T 0.7808 473 10001861 22.02 SLC2A9 0 1|1 
Uric acid1 11 46015152 rs149931947 9.66 -1.07 0.1686 C 0.0101 4 45975130 1.83 PHF21A 0 0|0 
Uric acid1 11 47995865 rs148724450 9.09 -1.027 0.1672 T 0.0104 4 48085189 3.02 PTPRJ 6243 0|0 
Uric acid1 11 50611953 rs182791637 9.38 -0.999 0.1600 C 0.0109 2 50114708 0.67 LOC646813 232150 0|0 
Uric acid1 11 51531051 rs145325964 9.67 -0.961 0.1514 G 0.0136 1 51440610 0.59 OR4C46 14839 0|0 
Uric acid1 11 54900697 rs571831626 9.77 -0.9 0.1410 A 0.0153 9 55091268 1.07 TRIM48 108961 0|0 
Uric acid1 11 63807869 rs183897166 10.86 -1.1 0.1627 A 0.0117 3 64150370 3.8 MACROD1 0 0|0 
Uric acid1 11 64773463 rs143417571 14.04 -1.164 0.1502 A 0.0127 19 65197393 3.32 
ARL2-
SNX15 8120 0|0 




Chr Pos rsID logP Beta Beta_SE EA EAF nhits Pos_G logP_G Gene Dist GWAS 
Uric acid1 11 71120029 rs117991852 9.06 -0.909 0.1483 T 0.0138 1 70919484 2.63 LOC339902 0 0|0 
Uric acid1 11 72900306 rs79750124 9.1 -0.873 0.1421 T 0.0158 2 73340690 2.49 P2RY2 29036 0|0 
Uric acid2 4 9951819 rs11723439 22.66 -0.461 0.0463 T 0.1825 521 10001861 20.54 SLC2A9 0 1|1 
Uric acid2 11 51531051 rs145325964 9.59 -1.055 0.1668 G 0.0128 1 51440610 0.42 OR4C46 14839 0|0 
Uric acid2 11 54900697 rs571831626 9.6 -0.999 0.1578 A 0.0141 8 55339652 1.22 TRIM48 108961 0|0 
Uric acid2 11 63807869 rs183897166 10.19 -1.113 0.1703 A 0.0121 1 63327186 3.12 MACROD1 0 0|0 
Uric acid2 11 64773463 rs143417571 12.8 -1.189 0.1612 A 0.0127 12 64305452 3.07 
ARL2-
SNX15 8120 0|0 
Uric acid2 11 66156532 rs193078128 11.52 -1.137 0.1630 C 0.0129 5 66058082 1.71 SLC29A2 17240 0|0 
Uric acid2 11 66944662 rs150613065 10.05 -0.816 0.1259 A 0.0226 1 67423892 2.35 KDM2A 0 0|0 
vWF 9 136142203 rs514659 35.19 22.477 1.7964 C 0.3423 193 136139265 25.07 ABO 0 1|1 
Vis 
CRP 1 159689388 rs2027471 9.16 -0.336 0.0544 A 0.3479 12 159302033 3.02 CRP 5008 1|1 
Uric acid1 4 9928017 rs13137069 9.64 0.326 0.0514 C 0.7097 94 9611013 9.55 SLC2A9 0 1|1 
Uric acid2 4 9928017 rs13137069 8.89 0.313 0.0516 C 0.7083 108 9611013 8.86 SLC2A9 0 1|1 
vWF 9 136137106 rs687289 22.38 18.768 1.8959 A 0.4143 95 136331174 2.14 ABO 0 1|1 
Shetland 
Central Corneal 
Thickness 16 88310910 rs6540217 14.44 0.28 0.0357 G 0.6677 58 88298124 12.73 ZNF469 182967 0|1 
Glucose 11 92708710 rs10830963 13.97 0.284 0.0368 G 0.26 18 92708710 13.68 MTNR1B 0 1|1 
Glucose_nodiab 11 92708710 rs10830963 16.34 0.311 0.0371 G 0.26 22 92708710 15.96 MTNR1B 0 1|1 
HDL 16 56997233 rs1864163 15.27 -0.308 0.0380 A 0.2395 36 56997233 15.1 CETP 0 1|1 
HDL 18 46578242 rs74489351 10.48 0.84 0.1266 A 0.0175 13 47017820 4.37 DYM 0 0|0 
LDL 19 45412079 rs7412 14.69 -0.532 0.0670 T 0.0575 16 45412079 12.29 APOE 0 1|1 
Total 




Chr Pos rsID logP Beta Beta_SE EA EAF nhits Pos_G logP_G Gene Dist GWAS 
Triglycerides 11 116559553 rs11824135 9.82 0.218 0.0341 T 0.0681 65 116648917 9.4 BUD13 59331 0|1 
Uric acid1 4 9997112 rs4529048 22.08 0.409 0.0416 A 0.8125 221 10001861 21.03 SLC2A9 0 1|1 
Uric acid2 4 9997112 rs4529048 21.56 0.403 0.0416 A 0.8121 297 9998493 20.82 SLC2A9 0 1|1 
Korčula 
fev1perfvc 4 72034716 rs62302428 8.93 1.041 0.1712 C 0.0123 1 71724706 1.97 SLC4A4 18285 0|0 
fev1perfvc 7 12963872 rs34079 8.92 0.3 0.0493 A 0.2046 1 12583080 3.56 ARL4A 233313 0|0 
HDL 8 19912370 rs115849089 10.22 0.292 0.0446 A 0.1216 56 19890612 3.03 LPL 87599 1|1 
HDL 16 56993324 rs3764261 14.03 0.233 0.0300 A 0.3099 28 56993324 13.95 CETP 2509 1|1 
LDL 19 45412079 rs7412 18.07 -0.545 0.0616 T 0.0577 14 45333834 2.32 APOE 0 1|1 
Total 
Cholesterol 19 45412079 rs7412 10.61 -0.409 0.0612 T 0.0579 2 45585167 2.34 APOE 0 1|1 
Triglycerides 11 116648917 rs964184 9.4 -0.107 0.0171 C 0.8079 29 116621963 7.33 ZNF259 357 1|1 
Uric acid1 4 9984541 rs9994216 20.97 0.314 0.0328 T 0.7759 218 10001861 18.78 SLC2A9 0 0|1 
Uric acid2 4 9984541 rs9994216 19.62 0.315 0.0341 T 0.7763 201 10001861 17.23 SLC2A9 0 0|1 
GS 
Alcohol 
consumption 4 100239319 rs1229984 9.21 0.282 0.0456 C 0.9826 1 100256984 2.8 ADH1B 0 1|1 
BMI 2 630075 rs73139123 8.87 0.088 0.0145 T 0.817 183 653195 8.47 TMEM18 37896 1|1 
BMI 16 53809123 rs55872725 20.24 0.104 0.0111 T 0.3952 102 53800954 19.63 FTO 0 1|1 
Body fat 16 53809123 rs55872725 15.26 0.643 0.0794 T 0.3949 100 53800954 14.52 FTO 0 1|1 
Creatinine 5 176813404 rs3812036 9.95 0.093 0.0144 T 0.2304 17 176801131 9.59 SLC34A1 0 0|1 
Educational 
Attainment 5 44719845 rs150675176 9.35 1.68 0.2694 T 0.0056 1 44646453 3.36 MRPS30 89180 0|0 
Forced 
Expiratory 




Chr Pos rsID logP Beta Beta_SE EA EAF nhits Pos_G logP_G Gene Dist GWAS 
fev1perfvc 15 93685164 rs72749974 9.37 -0.118 0.0189 G 0.1223 2 93681470 4.11 RGMA 52720 0|0 
Forced Vital 
Capacity 6 7807702 rs1225986 8.66 0.098 0.0165 T 0.8306 17 7789943 7.52 BMP6 0 0|1 
Glucose 2 169763148 rs560887 67.22 0.224 0.0129 C 0.7085 152 169763148 66.42 G6PC2 0 1|1 
Glucose 3 170733076 rs9873618 11.01 -0.089 0.0131 A 0.2869 23 170715830 10.73 SLC2A2 0 0|1 
Glucose 7 44245853 rs917793 23.6 0.156 0.0153 T 0.1829 35 44240407 23.03 YKT6 0 1|1 
Glucose 8 118184783 rs13266634 10.44 -0.083 0.0126 T 0.316 7 118184783 10.32 SLC30A8 0 1|1 
Glucose_nodiab 2 169763148 rs560887 74.68 0.244 0.0133 C 0.7087 163 169763148 73.61 G6PC2 0 1|1 
Glucose_nodiab 3 170724883 rs8192675 10.08 -0.087 0.0134 C 0.284 18 170715830 9.71 SLC2A2 0 0|1 
Glucose_nodiab 7 44245853 rs917793 27.84 0.175 0.0158 T 0.182 37 44240407 27.08 YKT6 0 1|1 
Glucose_nodiab 8 118185733 rs11558471 12.33 -0.093 0.0129 G 0.3235 8 118185733 12.28 SLC30A8 0 1|1 
Glucose_nodiab 13 28499962 rs7981781 9.3 0.089 0.0143 A 0.2342 31 28491198 8.91 PDX1 0 1|1 
HDL 8 19824667 rs15285 17.94 0.109 0.0124 T 0.2671 264 19824492 17.55 LPL 0 1|1 
HDL 11 116701354 rs138326449 19.54 0.981 0.1064 A 0.0032 7 116660686 6.95 APOC3 0 0|1 
HDL 15 58678720 rs261290 24.56 -0.122 0.0117 C 0.6556 124 58679668 23.39 LIPC 45453 1|1 
HDL 16 56993324 rs3764261 112.85 0.266 0.0117 A 0.3263 165 56993324 111.02 CETP 2509 1|1 
HDL 17 41926126 rs72836561 10.81 -0.236 0.0351 T 0.0297 2 41978756 2.31 CD300LG 0 0|1 
HDL 19 8429323 rs116843064 9.25 0.248 0.0399 A 0.0231 1 8458960 4.7 ANGPTL4 0 0|1 
HDL 19 45412079 rs7412 13.23 0.156 0.0208 T 0.0777 12 45410002 9.83 APOE 0 1|1 
Heart Rate 14 23861811 rs365990 9.39 0.784 0.1254 G 0.3635 6 23861811 9.33 MYH6 0 1|1 
Height 3 141133450 rs1991431 12.28 0.005 0.0007 A 0.4337 47 141102833 12.04 ZBTB38 0 1|1 
Height 6 26184102 rs7766641 12.48 -0.006 0.0008 A 0.255 13 26233387 11.61 HIST1H2BE 0 1|1 
Height 6 34219698 rs57026767 10.35 -0.006 0.0009 T 0.8448 36 34194866 10.09 C6orf1 2793 1|1 
Height 6 126851160 rs1490384 9.15 0.004 0.0007 T 0.4851 153 126744087 8.97 CENPW 181405 1|1 




Chr Pos rsID logP Beta Beta_SE EA EAF nhits Pos_G logP_G Gene Dist GWAS 
Height 10 130682872 rs144225905 8.67 -0.092 0.0154 T 0.001 1 130588415 3.2 MGMT 582580 0|0 
Height 11 67024534 rs7952436 11.72 -0.009 0.0012 T 0.0896 5 67472145 3.75 KDM2A 0 0|0 
Height 15 89383764 rs16942323 10.96 -0.013 0.0019 C 0.0345 12 89408081 6.34 ACAN 0 0|1 
Height 18 20713215 rs8096254 11.36 0.005 0.0008 A 0.7404 21 20716805 11.16 CABLES1 1311 0|1 
Height 20 34005240 rs6060402 12.55 -0.005 0.0007 C 0.6415 136 34001250 11.79 UQCC 5294 1|1 
Total 
Cholesterol 1 55505647 rs11591147 16.74 -0.361 0.0424 T 0.0168 1 55505647 16.68 PCSK9 0 1|1 
Total 
Cholesterol 1 62957030 rs10889333 9.67 -0.072 0.0113 A 0.3599 218 62905893 9.53 DOCK7 0 1|1 
Total 
Cholesterol 1 109817590 rs12740374 21.09 -0.124 0.0129 T 0.2294 20 109817192 21.44 CELSR2 0 1|1 
Total 
Cholesterol 2 21319016 rs672889 15.42 0.13 0.0159 G 0.8644 289 21288321 15.07 APOB 52070 1|1 
Total 
Cholesterol 2 44069772 rs75331444 10.73 -0.142 0.0211 A 0.0723 22 44065090 10.16 ABCG8 0 0|1 
Total 
Cholesterol 5 74656539 rs12916 10.2 0.073 0.0112 C 0.3973 51 74656539 10.31 HMGCR 0 1|1 
Total 
Cholesterol 8 9183664 rs4841133 8.6 0.112 0.0187 G 0.9074 7 9177732 6.42 LOC157273 0 1|1 
Total 
Cholesterol 19 11193949 rs10412048 24.3 -0.181 0.0175 G 0.1084 69 11202306 23.64 LDLR 6087 1|1 
Total 
Cholesterol 19 45412079 rs7412 93.28 -0.42 0.0204 T 0.0776 155 45415640 51.48 APOE 0 1|1 
Urea 3 187687840 rs16862780 9.52 -0.093 0.0147 A 0.1572 23 187687890 9.5 LOC339929 181152 0|1 
Waist 6 127454893 rs72959041 9.99 0.161 0.0249 A 0.0567 3 127519234 2.02 RSPO3 0 0|1 
Waist Hip Ratio 6 127454893 rs72959041 13.59 0.188 0.0246 A 0.0567 4 127481154 5.04 RSPO3 0 0|1 
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Cohort Trait Chr SNP GWC SNP R
2
 D' 
Shetland Central Corneal 
Thickness 
16 rs6540217 rs12447690 0.96 0.98 
rs9938149 0.88 0.98 
Shetland Triglycerides 11 rs11824135 rs12272004 0.5 0.72 
rs1558861 0.008 0.09 
rs28927680 0.47 0.73 
rs12286037 0.45 0.72 
rs964184 0.31 0.8 
rs603446 0.06 0.91 
rs7350481 0.01 0.13 
rs4938303 0.18 0.94 
rs2160669 0.008 0.09 
rs6589566 0.008 0.09 
Korčula Uric Acid 4 rs9994216 rs12498742 0.65 0.92 
rs734553 0.55 0.78 
rs16890979 0.61 0.87 
rs7442295 0.71 1 
rs3775948 0.82 0.91 
rs11722228 0.2 1 
rs13129697 0.83 0.98 
rs6855911 0.58 0.81 
rs6449213 0.66 0.99 
rs737267 0.58 0.81 
rs6832439 0.61 0.87 
GS Creatinine 5 rs3812036 rs3812036 1 1 
GS Forced Expiratory 
Flow 4 rs34712979 rs34712979 1 1 
GS Forced Vital 
Capacity 6 rs1225986 rs6923462 0.74 0.88 
GS Glucose 3 rs9873618 rs11920090 0.32 1 
GS Glucose_nodiab 3 rs8192675 rs11920090 0.32 1 
GS HDL 11 rs138326449 rs662799 0.0001 1 
rs964184 0.0003 0.96 
rs651821 0.0001 1 
rs11216126 0.0004 1 
GS HDL 17 rs72836561 rs77697917 0.72 0.95 
GS HDL 19 rs116843064 rs116843064 1 1 
GS Height 15 rs16942323 rs2238300 0.0001 0.06 
rs4932217 0.001 0.19 
rs2351491 0.04 0.82 
rs16942341 0.69 0.84 




Cohort Trait Chr SNP GWC SNP R
2
 D' 
rs2280470 NA NA 
rs3817428 0.03 0.6 
rs8041863 0.007 0.5 
rs8042988 0.05 0.88 
GS Height 18 rs8096254 rs4800148 0.71 0.95 
rs4369779 0.73 0.97 
rs4800452 0.72 0.95 
rs8098316 0.05 0.37 
rs11082304 0.35 0.95 
GS Total Cholesterol 2 rs75331444 rs6756629 0.93 0.98 
rs4299376 0.04 0.99 
rs76866386 0.99 1 
GS Urea 3 rs16862780 rs10937329 0.34 0.93 
GS Waist 6 rs72959041 rs72959041 1 1 
GS Waist Hip Ratio 6 rs72959041 rs72959041 1 1 
 
3.3.2 GWAS Meta-analysis 
The loci that exceeded the GWS threshold in the meta-analysis of GWAS using the HRC 
imputed genotypes are summarised graphically in Figure 8, and described in detail in Table 9. 
Supplementary Table 2 lists all loci that exceeded the suggestive but not the genome-wide 
significance threshold (-log10(p-value)>7.3). 
The meta-analysis identifies 109 GWS loci, 37 of which were not GWS in any cohort-specific 
GWAS. There are 7 novel loci where no GWAS hits are reported in the literature within 100kb 
of the lead SNP, and 5 of these had no GWS association in any cohort-specific GWAS. Forest 
plots showing the per-cohort and meta-analysis effect size and direction for the 5 novel loci 




Figure 8 - GWAS meta-analysis results overview 
This figure shows a plot of the -log10(p-value) of every hit that passed the GWS threshold in the GWAS meta-analysis, plotted by chromosome position and 
coloured by trait. In the legend on the right, the highest -log10(p-value) was taken from each trait, and was used to rank the traits in decreasing order – this rank 
number precedes each trait name. Each trait is allocated a colour that is used to represent all points associated with that trait. In order to help distinguish colours 




Table 9 - Genome-wide significant hits in the GWAS meta-analysis 
This table summarizes the hits that passed the GWS threshold in the GWAS meta-analysis, providing their -log10(p-value), effect size (Beta) of the effect 
allele (EA) and its standard error (Beta_SE) as well as the direction of the effect in each cohort (O=Orkney, V=Vis, K=Korčula, S=Shetland, G=GS; - or 
+ values indicate effect size direction, ? indicates that this SNP was not available in the cohort, x indicates that the trait was not analysed in the cohort). 
The nhits column indicates the number of SNPs within 500kb of the reported SNP that also exceeded the GWS threshold in the meta-analysis. The name 
of, and distance to, the gene closest to the reported SNP is indicated – the distance is 0 if the SNP lies within the gene itself. The final column indicates 
whether other GWAS have identified this hit before. The first column indicates whether any SNPs in the 1000 Genomes data that are in strong LD with 
the reported SNP (R2 and D’ > 0.8) have been identified with other GWAS, while the second value looks at all SNPs within 100kb of the reported SNP, 
regardless of LD. 
Trait Chr Pos rsID MAF logP EA Beta BetaSE nhits n O V K S G Gene Dist GWAS 
BMI 16 53809123 rs55872725 0.4019 23.32 T 0.0974 0.0096 113 27488 + + + + + FTO 0 1|1 
Calcium 3 122013465 rs73186030 0.1476 11.46 T 0.2009 0.0289 5 5045 + + x + x CASR 8120 1|1 
Central Corneal 
Thickness 9 137437183 rs943423 0.3341 11.58 A 0.1691 0.0242 19 4416 + + + + x COL5A1 96467 0|1 
Central Corneal 
Thickness 9 139862633 rs57024841 0.4074 9.46 A -0.1467 0.0234 15 4416 - - - - x PTGDS 9321 0|1 
Central Corneal 
Thickness 16 88314452 rs11117401 0.3485 25.14 A 0.2434 0.0231 113 4416 + + + + x ZNF469 179425 1|1 
Creatinine 4 77358987 rs10023335 0.4111 10.72 T -0.0679 0.0101 56 23950 - - - - - SHROOM3 0 1|1 
Creatinine 5 176801131 rs10866705 0.2522 11.73 A -0.0815 0.0116 13 23950 - - - - - RGS14 1531 0|1 
CRP 1 159668984 rs11265257 0.3866 17.16 T -0.2142 0.0249 49 4970 - - x - x CRP 13093 1|1 
CRP 12 121420260 rs7979473 0.3858 8.92 A -0.1522 0.025 26 4970 - - x - x HNF1A 0 1|1 
CRP 19 45411941 rs429358 0.1562 10.55 T 0.2361 0.0355 24 4970 + + x + x PVRL2 0 0|1 
D Dimer 1 95052032 rs2022030 0.3127 9.12 A -0.2188 0.0356 19 1926 - - x x x F3 44618 1|1 
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Trait Chr Pos rsID MAF logP EA Beta BetaSE nhits n O V K S G Gene Dist GWAS 
GGT 22 24996582 rs2330795 0.345 14.88 A 0.2259 0.0283 34 3075 + x x + x GGT1 0 1|1 
Glucose 2 169763148 rs560887 0.2892 66.07 T -0.1847 0.0107 144 23631 - - - - - G6PC2 0 1|1 
Glucose 3 170709193 rs1604038 0.2903 15.3 T -0.0869 0.0107 35 23631 - - - - - SLC2A2 4942 0|1 
Glucose 7 44243438 rs2971668 0.1877 31.66 C 0.1498 0.0126 46 23631 + + + + + YKT6 0 1|1 
Glucose 8 118191475 rs35859536 0.3197 13.56 T -0.0797 0.0105 8 23631 - + - - - SLC30A8 2521 1|1 
Glucose 10 114758349 rs7903146 0.2791 11.14 T 0.0752 0.011 26 23631 + + + + + TCF7L2 0 1|1 
Glucose 11 92708710 rs10830963 0.2709 20.77 C -0.1049 0.011 45 23631 - - - - - MTNR1B 0 1|1 
Glucose 13 28498265 rs60353775 0.2332 10.59 C -0.0772 0.0116 32 23631 - - - - - PDX1 0 1|1 
Glucose_nodiab 2 169763148 rs560887 0.2891 82.82 T -0.2138 0.011 169 22080 - - - - - G6PC2 0 1|1 
Glucose_nodiab 3 170709193 rs1604038 0.291 12.93 T -0.0822 0.0111 26 22080 - - - - - SLC2A2 4942 0|1 
Glucose_nodiab 7 44248828 rs2908282 0.1873 39.61 A 0.1737 0.0131 51 22080 + + + + + YKT6 0 1|1 
Glucose_nodiab 8 118185733 rs11558471 0.3216 16.56 A 0.0909 0.0107 8 22080 + - + + + SLC30A8 0 1|1 
Glucose_nodiab 11 92708710 rs10830963 0.2688 21.22 C -0.11 0.0114 42 22080 - - - - - MTNR1B 0 1|1 
Glucose_nodiab 13 28498265 rs60353775 0.2329 11.53 C -0.0835 0.012 32 22080 - - - - - PDX1 0 1|1 
HbA1c 10 71094504 rs17476364 0.1117 10.34 T 0.1972 0.0299 7 6892 + + + + x HK1 0 0|1 
HDL 8 9183596 rs4841132 0.0904 10.6 A -0.1109 0.0166 12 26920 - - - - - LOC157273 0 1|1 
HDL 8 19824667 rs15285 0.2762 26.91 T 0.1152 0.0106 384 26920 + + + + + LPL 0 1|1 
HDL 9 107661742 rs2740488 0.2738 15.21 A 0.0866 0.0107 43 26920 + + + + + ABCA1 0 1|1 
HDL 11 116701354 rs138326449 0.0038 23.52 A 0.9351 0.092 29 23902 + ? + ? + APOC3 0 0|1 
HDL 15 58680178 rs261291 0.3423 34.42 T -0.1248 0.0101 128 26920 - - - - - LIPC 43995 1|1 
HDL 16 56993324 rs3764261 0.3336 148.14 A 0.26 0.01 228 26920 + + + + + CETP 2509 1|1 
HDL 16 67327250 rs530515679 0.0032 10.36 A -0.9837 0.1493 75 21229 - ? ? ? - LRRC29 0 0|1 
HDL 17 41926126 rs72836561 0.0372 13.13 T -0.2084 0.0279 3 26920 - - - - - CD300LG 0 0|0 
HDL 18 47106028 rs149615216 0.0124 16.34 T 0.3808 0.0453 40 25992 + ? + + + LIPG 0 0|1 
HDL 19 8429323 rs116843064 0.0236 12.03 A 0.2451 0.0343 1 26920 + + + + + ANGPTL4 0 0|1 
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HDL 19 45412079 rs7412 0.0751 15.63 T 0.1506 0.0184 14 26920 + + + + + APOE 0 1|1 
HDL 19 54837635 rs17634081 0.3224 10.22 T 0.0744 0.0114 49 26920 + + + + + LILRA4 7055 0|0 
HDL 20 44547970 rs2868346 0.2318 9.67 T 0.0714 0.0112 4 26920 + + + + + PLTP 6966 1|1 
Heart Rate 5 102601697 . 0.0049 10.48 T 
-
15.7929 2.3818 1 2087 x x ? - ? C5orf30 0 0|0 
Heart Rate 14 23861811 rs365990 0.3614 12.46 A -0.8306 0.1142 24 23383 x x - - - MYH6 0 1|1 
Heart Rate 20 36841914 rs3746471 0.4574 8.93 A -0.6672 0.1097 25 23383 x x - - - KIAA1755 0 1|1 
Height 3 141133450 rs1991431 0.4217 14.9 A 0.0047 0.0006 67 27555 + + + + + ZBTB38 0 1|1 
Height 4 145566848 rs13125694 0.4247 9.71 T 0.0038 0.0006 34 27555 + + + + + LOC646576 42363 0|1 
Height 5 32773275 rs72742734 0.0527 9.43 A -0.0082 0.0013 10 27555 - - - - - NPR3 0 0|1 
Height 6 26186200 rs9379832 0.2763 11.33 A 0.0046 0.0007 21 27555 + + + + + HIST1H2BE 1741 0|1 
Height 6 34219698 rs57026767 0.1557 11.78 T -0.0057 0.0008 35 27555 - + - - - C6orf1 2793 1|1 
Height 6 142745883 rs7753012 0.3092 9.14 T 0.0039 0.0006 52 27555 + + - + + GPR126 0 1|1 
Height 7 2836848 rs2533884 0.2892 10.75 T 0.0044 0.0006 108 27555 + + + + + GNA12 0 1|1 
Height 7 28185091 rs849141 0.2908 9.6 A 0.0041 0.0006 14 27555 + + + + + JAZF1 0 1|1 
Height 11 67024534 rs7952436 0.0881 9.88 T -0.0072 0.0011 5 27555 - + - - - KDM2A 0 0|0 
Height 12 4384844 rs76895963 0.0336 9.15 T -0.0116 0.0019 1 27555 - - - - - CCND2 0 0|0 
Height 12 66376091 rs7306710 0.4818 9.8 T 0.0038 0.0006 12 27555 + + + + + HMGA2 16019 1|1 
Height 15 89383764 rs16942323 0.0316 9.41 T 0.0111 0.0018 12 27555 + - + + + ACAN 0 0|1 
Height 18 20724328 rs4800148 0.2163 13.78 A 0.0055 0.0007 30 27555 + + + + + CABLES1 0 1|1 
Height 20 34025756 rs143384 0.405 16.81 A -0.0052 0.0006 139 27555 - - - - - GDF5 0 1|1 
LDL 19 11190534 rs142158911 0.0935 12.05 A -0.2101 0.0294 36 7663 - - - - x LDLR 9502 1|1 
LDL 19 45412079 rs7412 0.0688 57.47 T -0.5432 0.0338 54 7663 - - - - x APOE 0 1|1 
Total 
Cholesterol 1 55505647 rs11591147 0.0182 20.07 T -0.3373 0.0361 2 26960 - - - - - PCSK9 0 1|1 
64 
 
Trait Chr Pos rsID MAF logP EA Beta BetaSE nhits n O V K S G Gene Dist GWAS 
Total 
Cholesterol 1 62940097 rs1979722 0.3427 10.24 A -0.064 0.0098 218 26960 - + - - - DOCK7 0 1|1 
Total 
Cholesterol 1 109817590 rs12740374 0.2288 24.24 T -0.1132 0.011 24 26960 - - - - - CELSR2 0 1|1 
Total 
Cholesterol 2 21271323 rs1713222 0.1513 16.18 A -0.1088 0.013 293 26960 - - - - - APOB 4377 0|1 
Total 
Cholesterol 2 44069772 rs75331444 0.0699 13.46 A -0.1387 0.0183 28 26960 - - - - - ABCG8 0 1|1 
Total 
Cholesterol 5 74656539 rs12916 0.396 15.71 T -0.0779 0.0095 249 26960 - - - - - HMGCR 0 1|1 
Total 
Cholesterol 6 160997118 rs74617384 0.0802 9.02 A -0.1117 0.0183 5 26960 - - + - - LPA 0 0|1 
Total 
Cholesterol 8 9183664 rs4841133 0.0909 11.81 A -0.1141 0.0161 20 26960 - - - - - LOC157273 0 1|1 
Total 
Cholesterol 8 126506694 rs112875651 0.4082 10.99 A -0.0654 0.0096 21 26960 - - - - - TRIB1 56049 0|1 
Total 
Cholesterol 9 107661742 rs2740488 0.2739 10.96 A 0.0707 0.0104 21 26960 + + + + + ABCA1 0 1|1 
Total 
Cholesterol 11 116651115 rs11604424 0.2113 8.82 T -0.0695 0.0115 3 26960 - - - - - ZNF259 0 1|1 
Total 
Cholesterol 15 58723426 rs1077835 0.225 9.42 A -0.0703 0.0112 12 26960 - - - - - LIPC 747 1|1 
Total 
Cholesterol 19 11193949 rs10412048 0.1049 32.65 A 0.1827 0.0152 105 26960 + + + + + LDLR 6087 1|1 
Total 
Cholesterol 19 19379549 rs58542926 0.0637 8.91 T -0.1152 0.019 4 26960 - - - - - TM6SF2 0 1|1 
Total 
Cholesterol 19 45412079 rs7412 0.0752 120.07 T -0.4146 0.0177 176 26960 - - - - - APOE 0 1|1 
Triglycerides 7 73001021 rs35173225 0.1383 8.82 T -0.074 0.0122 38 7698 - - - - x MLXIPL 6501 0|1 
Triglycerides 8 19933089 rs79445051 0.0826 13.23 C 0.1173 0.0156 172 7698 + + + + x SLC18A1 69275 0|1 
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Triglycerides 8 126495818 rs10808546 0.4511 9.17 T -0.0528 0.0086 8 7698 - - - - x TRIB1 45173 1|1 
Triglycerides 11 116648917 rs964184 0.165 26.82 C -0.1261 0.0116 107 7698 - - - - x ZNF259 357 1|1 
Urea 1 155178782 rs760077 0.4201 10.75 A 0.0682 0.0101 5 23316 + + x + + MTX1 0 0|1 
Urea 3 187719348 rs9880162 0.3183 11.06 A 0.0727 0.0106 25 23316 + + x + + LOC339929 149644 1|1 
Urea 5 40635920 rs112647987 0.07 9.58 T -0.1239 0.0196 24 23316 - - x - - PTGER4 44110 0|0 
Urea 7 151413194 rs10224210 0.2806 9.36 T -0.0718 0.0115 15 23316 - - x - - PRKAG2 0 1|1 
Urea 18 43252053 rs12963357 0.0268 10.07 T 0.2194 0.0338 2 23316 + + x + + SLC14A2 0 0|1 
Uric acid1 4 9995240 rs3775947 0.2297 68.07 T 0.3476 0.0198 1132 7715 + + + + x SLC2A9 0 1|1 
Uric acid1 11 44713083 rs536771513 0.01 9.33 C -1.132 0.1817 2 2003 - ? ? ? x TSPAN18 34932 0|0 
Uric acid1 11 46015152 rs149931947 0.0101 9.66 T 1.0701 0.1686 2 2003 + ? ? ? x PHF21A 0 0|0 
Uric acid1 11 47081384 rs757626652 0.0087 9.12 A -1.1432 0.1858 1 2003 - ? ? ? x C11orf49 0 0|0 
Uric acid1 11 49008491 rs534640316 0.0091 9.74 T -1.1318 0.1775 10 2003 - ? ? ? x TRIM51CP 41245 0|0 
Uric acid1 11 50740928 rs117993891 0.0081 8.83 A -1.1264 0.1862 3 2003 - ? ? ? x LOC646813 361125 0|0 
Uric acid1 11 50751235 . 0.0081 8.83 A -1.1264 0.1862 3 2003 - ? ? ? x OR4A5 660143 0|0 
Uric acid1 11 51531051 rs145325964 0.0136 9.67 A 0.9614 0.1514 2 2003 + ? ? ? x OR4C46 14839 0|0 
Uric acid1 11 55186768 rs142280180 0.0138 9.07 A 0.9075 0.1479 4 2003 + ? ? ? x OR4A15 50373 0|0 
Uric acid1 11 57113738 . 0.0088 9.43 A -1.1348 0.1811 3 2003 - ? ? ? x P2RX3 0 0|0 
Uric acid1 11 65943116 rs185509475 0.0086 15.65 T -1.4796 0.1802 23 2003 - ? ? ? x PACS1 0 0|0 
Uric acid1 11 67726024 rs193229075 0.008 15.54 A -1.5199 0.1859 8 2003 - ? ? ? x UNC93B1 32549 0|0 
Uric acid1 11 70619477 rs182623072 0.0065 10.32 T -1.3599 0.2067 2 2003 - ? ? ? x SHANK2 0 0|0 
Uric acid1 11 72769082 rs544872267 0.0078 10.29 A -1.3182 0.2007 15 2003 - ? ? ? x FCHSD2 0 0|0 
Uric acid2 4 9993838 rs7663032 0.2301 64.22 T 0.3472 0.0204 1122 7205 + + + + x SLC2A9 0 1|1 
Uric acid2 4 89039082 rs1481012 0.0934 9.05 A -0.1843 0.0301 9 7205 - - - - x ABCG2 0 1|1 
Uric acid2 11 46015152 rs149931947 0.0096 9.36 T 1.156 0.1853 3 1715 + ? ? ? x PHF21A 0 0|0 
Uric acid2 11 48999881 rs141399760 0.0081 9.2 T 1.2284 0.1987 10 1715 + ? ? ? x LOC120824 0 0|0 
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Uric acid2 11 51531051 rs145325964 0.0128 9.58 A 1.0548 0.1669 2 1715 + ? ? ? x OR4C46 14839 0|0 
Uric acid2 11 55186768 rs142280180 0.0126 9.07 A 1.0166 0.1657 4 1715 + ? ? ? x OR4A15 50373 0|0 
Uric acid2 11 66208468 rs553549722 0.0092 14.34 C 1.4905 0.1902 20 1715 + ? ? ? x MRPL11 0 0|0 
Uric acid2 11 67846680 rs370311822 0.0082 14.49 T -1.5557 0.1974 8 1715 - ? ? ? x CHKA 0 0|0 
Uric acid2 11 70619477 rs182623072 0.0067 8.94 T -1.3306 0.2186 2 1715 - ? ? ? x SHANK2 0 0|0 
Uric acid2 11 72769082 rs544872267 0.0082 10.23 A -1.3834 0.2114 6 1715 - ? ? ? x FCHSD2 0 0|0 
vWF 9 136137106 rs687289 0.3765 56.06 A 20.7077 1.304 245 1925 + + x x x ABO 0 1|1 
Waist 6 127454893 rs72959041 0.0563 10.69 A 0.1454 0.0217 4 27212 + - - + + RSPO3 0 0|1 





Most GWAS hits identified in cohort-specific GWAS, as well as the GWAS meta-analysis, 
replicate previously-identified GWAS loci, by either corresponding to, or being in LD with, 
SNPs reported in the literature. Yet, a few additional loci were found, and most of these have 
evidence of consistency of effect across populations, which provides a promising source of 
preliminary replication.  
Figure 9 - Forest plots of novel GWAS meta-analysis hits 
The trait name and top SNP position are shown in the plot titles. The rows of the plot show the effect 
size and direction of this top SNP (bars represent the standard error). The first row (“All”) in each plot 
shows the meta-analysis results, and indicates the aggregate minor allele frequency as well as the number 
of individuals that were included in the meta-analysis. Subsequent rows show the results in each analysed 




Within this thesis, the function of genes nearest the GWS hits is discussed, but it is 
acknowledged that the target gene of an association signal is not necessarily the closest gene. 
For example, intronic variants within the FTO gene consistently associate with obesity 
phenotypes but no functional connection between this gene and obesity has been established. 
Instead, it was found that this locus directly interacts with the promoter of the IRX3 gene 500kb 
downstream of FTO, and irx3-deficient mice were shown to have markedly reduced body 
weight as a consequence of increased metabolic rate and loss of fat mass [100]. Nonetheless, 
the relevance of the known function of the closest gene to the associated phenotype is always 
checked as potentially revealing. 
In Shetland, there is one novel association with HDL cholesterol, on chromosome 18. The top 
SNP has a 1.5% MAF and lies within DYM, a gene implicated in skeletal development and 
brain function [101, 102]. There is no known link between this gene and cholesterol regulation, 
however. This SNP is 3Mb upstream of the LIPG (Lipase G) gene, located at 49Mb, which 
has reported associations with HDL, but it is not in LD with any of the reported associated 
SNPs. 
In Korčula, two novel associations are detected with a lung function trait – fev1/fvc, or the 
ratio of forced expiratory volume in 1 second (fev1) and forced vital capacity (fvc).  
One association is on chromosome 4 and the top SNP has a 1.2% MAF and lies upstream of 
the SLC4A4 gene, which encodes a sodium bicarbonate transporter. The lungs are the primary 
site of the bicarbonate-carbonic acid buffer system, and the rate of breathing can change to 
compensate for changes in the blood concentration of CO2 [103], so altering bicarbonate 
transport can have an effect on lung function in this way. 
The second association is on chromosome 7 and the top SNP is common, with a 20% MAF in 
Orkney. The lead SNP, rs34079, is 230kb downstream of the nearest gene, ARL4A, which 
encodes a GTP-binding protein. This SNP is also within the RBMX2P4 pseudogene, which 
encodes a long non-coding RNA. 
The novel hits identified with imputed data in GS have been reported in [62], with the 
exception of those for lung function traits and educational attainment, which are reported here. 
The educational attainment hit, flagged by a low MAF SNP on chromosome 5, is near the 
MRPS30 gene, and while no SNPs within 100kb of the SNP reported here are in the NHGRI 
GWAS catalog, common SNPs within the MRPS30 gene associated with educational 
attainment and have been reported in a large GWAS meta-analysis [104]. The novel lung 
function hit for fev1/fvc ratio, is driven by a common SNP in an intergenic region, 52kb away 
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from the RGMA gene, which is primarily expressed in neurons and encodes an axon guidance 
protein.  
In Orkney, results of the GWAS of serum uric acid levels shows many GWS SNPs along a 
~30 Mb stretch of the centromeric region of chromosome 11. When the trait is only adjusted 
for age and sex (referred to as ‘Uric acid 1’), there are 60 GWS SNPs in the 46-73Mb region, 
all with MAFs lower than 2%. When the trait is additionally adjusted for BMI and grams of 
alcohol consumed per day, there are 28 GWS SNPs in this region (Figure 11). The SNPs in 
this region that are reported in Table 7 are not in LD with each other in the 1000 Genomes 
European set of individuals, but they are in LD with each other within Orkney. Re-running the 
GWAS after conditioning on the SNP with the lowest p-value in this region causes the signals 
of all other SNPs to disappear, indicating that these markers are all flagging the same QTL. 
This region contains the SLC22A11 and SLC22A12 genes at the 64.3-64.5 position, and these 
genes code for known urate transporters [105, 106] that have been flagged in a large uric acid 
meta-analysis conducted by the Global Urate Genetics Consortium (GUGC) [107]. 
Interestingly, the 64-68 Mb interval harbouring these genes has the smallest p-values in the 
Orkney GWAS, but the GUGC meta-analysis does not have GWS signals in the broader region 
flagged in the Orkney GWAS (Figure 10). 
Figure 10 - Orkney and GUGC uric acid GWAS results 
This figure shows a plot of the –log10(p-value) of every SNP on chromosome 11 in the GUGC 
uric acid meta-analysis in black, and the Orkney uric acid GWAS using imputed data in red. The 
blue arrow indicates the position of the top GUGC hit that is within the SLC22A11 gene, and 




Look-up of the effect of these associated variants across the different studies should reveal 
whether these signals are study specific or show some replication. This was examined as part 
of a general meta-analysis of the datasets, and some of the meta-analysis results are discussed 
below. 
As was seen in the results of GWAS of serum uric acid levels in Orkney, several SNPs along 
chromosome 11 also appear in the GWAS meta-analysis of this trait. The meta-analysis signal 
originates from Orkney only, as these SNPs were filtered out in the other cohorts due to low 
allele frequency, while the haplotype carrying them drifted to a higher frequency in Orkney.  
Figure 11 - Manhattan plot of chromosome 11 results for uric acid GWAS 
These Manhattan plots depict every imputed SNP with minor allele count > 20 and imputation 
quality score > 0.4 on chromosome 11 in Orkney. Uric acid 1 was adjusted for age and sex, 
while Uric acid 2 was additionally also adjusted for BMI and grams of alcohol consumed per 




SNPs in, and near, CD300LG and LILRA4, associate with HDL cholesterol levels, and the top 
SNPs show a consistent direction of effect in all 5 cohorts. Both genes encode 
immunoglobulin-like cell surface glycoproteins and are implicated in immune system 
pathways. High levels of cholesterol lead to cholesterol accumulation in immune cells, leading 
to increased inflammation through Toll-like receptor signalling. This, in turn, leads to 
decreased cholesterol efflux from these cells, amplifying the inflammatory response [108], so 
it is feasible that there could be an interaction between inflammation genes and cholesterol 
levels.  
Meta-analysis of urea levels yields an association with a locus that is 44kb upstream of the 
PTGER4 gene, which encodes a prostaglandin E2 receptor. This trait was not measured in 
Korčula, and the other 4 cohorts show a consistent direction of effect at the top SNP. 
Prostaglandin E2 has been shown to act as a second messenger that inhibits the effects of 
arginine vasopressin on water permeability and water, sodium and urea transport in the kidney 
inner medullary collecting duct [109]. Mutations that may affect the expression of its receptor 
can therefore have an indirect effect on urea levels by modulating prostaglandin activity. 
In general, the direction of the effect at the lead SNP is consistent across every analysed cohort. 
Exceptions to this may occur when one cohort does not contribute to the signal. An example 
is the fasting glucose hit on chromosome 8, where the lead SNP in Vis has an opposite 
direction of effect compared to other 4 cohorts (rs35859536 has a 0.37 p-value in Vis). Vis 
also has this inconsistency at three loci that show associations with height (p=0.68 at 
rs7952436, p=0.61 at rs57026767 and p=0.26 at rs16942323) and one of the chromosome 1 
associations with total cholesterol (p=0.93 at rs1979722). The lack of association signals at 
this SNP in Vis leads to effect sizes that are close to 0 and happen to have an opposite sign in 
Vis compared to the other cohorts. 
The top association with waist circumference and waist to hip ratio, on chromosome 6 at 
rs72959041, shows a negative direction of effect in both Vis and Korčula but a positive 
direction of effect in the three Scottish cohorts. The association signals originate from the 
Scottish cohorts only (p-values are 0.84 in Vis, 0.79 in Korčula, 4.3×10-3 in Orkney, 2.8×10-5 
in Shetland and 2.8×10-14 in GS), and the effect sizes in the Croatian cohorts are again close 
to 0 (beta values are -0.02 in Vis, -0.01 in Korčula, 0.21 in Orkney, 0.30 in Shetland and 0.18 
in GS). 
These results also highlight the value of using the genotypes imputed to the HRC reference 
panel [77] as this permits access to many low and rare frequency variants (0.5-5% MAF) that 
are often not present on genotyping arrays and imputed poorly with previous reference panels 
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[110]. The datasets used within this thesis have been also been imputed to the 1000 Genomes 
reference panel version 3 [90], which yielded approximately 9.5 million SNPs with high 
imputation quality in each cohort. In comparison, the HRC imputation panel, which consists 
of sequence data from 38000 individuals including the 1000 Genomes samples, yielded 12.3-
24.1 million high imputation quality SNPs in these cohorts. 
Rare variants can be imputed with high accuracy especially when the genotyped samples 
originate from the same population as some of the individuals sequenced as part of the 
reference panel. In fact, the HRC reference panel contains 400 low-depth (4x) whole genome 
sequences of individuals from the ORCADES study, so it should be particularly valuable for 
the imputation into the remaining individuals within this cohort. 
Indeed, the unusual GWAS signals originating from the serum uric acid GWAS in Orkney are 
due to associations with rare variants with high imputation qualities that were excluded from 
analysis in the other cohorts because they did not have a minor allele count of at least 20. This 
indicates that these variants drifted to a slightly higher frequency in Orkney. Interestingly, the 
pedigree-free linkage, which is discussed in Chapter 4, also flags a 2.5 cM interval within this 
region (at 58-61Mb) where IBD sharing explains some of the serum uric acid trait variance in 
Orkney and this region is 3Mb away from the urate transporter genes mentioned above.  
One possible explanation for this signal is that a small number of (distantly) related carriers of 
the rare variants share a large haplotype IBD which has not recombined due to chance 
recombination events. Due to the association pattern spanning the centromere, it is possible 
that this shared haplotype is tagging a pericentric inversion in some individuals within Orkney. 
Such an inversion has previously been documented on this chromosome [111], and pericentric 
inversions on other human chromosomes are not uncommon in the general population [112, 
113]. Because the centromere regions are usually comprised of heterochromatin, these types 
of balanced inversions do not generally affect phenotypes noticeably.  
To confirm the presence of such an inversion, experimental validation would be required, as 
SNP genotype data are not sufficient for determining the presence of a balanced inversion. 
Experimental validation could be done using cytogenetic methods or targeted long-read 
sequencing, as genotyping data or short sequencing reads that do not span the entire inversion 
site are not able to detect large balanced inversions. 
This locus also harbours two urate transporter genes, and associations with common variants 
have been reported at this locus [114]. The fact that no signal is detected in any of the other 
cohorts hint at the presence of a signal that is distinct from the one tagged by common variants 
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at this locus. It is known that both common and rare variants within a gene can have an effect 
on a phenotype, and one of the best-known examples of this is the PCSK9 gene where it has 
been shown that coding and non-coding variants across the whole spectrum of allele 
frequencies (0.2-34%) modulate the levels of LDL cholesterol [115]. The rare variant 
associations within this gene have been replicated in other cohorts, indicating that it is likely 
to be a true positive signal. 
The association with the rare variants described above could be a testament to the value of 
imputation by using sequences from the same cohort as a reference, as it could help detect 
haplotypes carrying these rare variants. However, one cannot exclude the possibility that, due 
to the low number of carriers, this association is detected by chance as all the carriers just 
happen to have similar phenotype values, or that these genotypes were incorrectly imputed. 
The latter could be checked by sequencing the candidate locus in order to assess the presence 
of the variants obtained from imputation. In Generation Scotland, exome sequence data were 
available for 864 individuals, but these were not used in the imputation, so they can provide 
an important source of imputed variant validation. 20 of the GWS SNPs reported in [62] were 
available in the exome sequencing data, 2 of which were rare (rs142101835 (in IRS1) and 
rs138326449 (in APOC3)), and each of which had at least a 97% concordance with the imputed 
genotypes. 
The findings reported here serve as the baseline results against which the results of variance 
component linkage analysis and regional heritability mapping are compared in the following 




Chapter 4 Identity by Descent and Linkage Analysis 
4.1 Introduction 
Before the advent of dense genotype data and computational methods capable of analysing 
these data, linkage analysis was the predominant genetic mapping approach. This approach 
relies on the fact that loci that are physically close to each other along a chromosome are linked 
– that is, the closer they are, the less likely it is that they will be broken up by recombination 
during meiosis. The long-term consequence of recombination occurring in past generations 
can be observed through the presence of linkage disequilibrium (LD) – that is, the non-random 
occurrence of specific alleles at different loci [116]. Linkage should not be confused with 
linkage disequilibrium - two loci that are in LD will also generally be linked, but the reverse 
it not true – genetic linkage can extend beyond the range of LD [117]. By tracking the 
recombination rate between marker loci along a genome, a genetic map can be created. It 
should be noted that recombination rates are not even along the genome, as there are ‘hotspots’ 
where recombination happens more often than expected by chance [118].  
In classical linkage analysis, microsatellite markers were typed and used to track segregating 
haplotypes within families in order to identify markers inherited by affected, but not by 
unaffected, individuals. That is, attempts were made to map major disease loci based on the 
fact that the inheritance pattern of a marker physically close to a disease-causing variant tracks 
the inheritance pattern of a disease, and recombination narrows down the potential location of 
this variant (Figure 12) [116]. When a pair of people share copies of a chromosomal segment 
inherited from a common ancestor without any recombination, this locus is said to be identical 
by descent (IBD), and it is the increased sharing of these IBD segments amongst individuals 
with similar phenotypes, compared to what is expected under random allocation of inherited 
material, that is the focal point of linkage analysis.  
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The first step to performing a linkage analysis is therefore to identify the presence of segments 
that are IBD between pairs of individuals in a family. When both the number of individuals as 
well as the number of marker loci are small, an exact algorithm can be used to calculate IBD 
coefficients at each locus [119], which enumerates all possible inheritance patterns for each 
pair of individuals. As the complexity of the data increases, applying these methods becomes 
unfeasible, so approximate algorithms relying on Markov Chain Monte Carlo methods (as 
implemented in e.g. Loki [84]) or Hidden Markov Models (as implemented in e.g. IBDLD 
[120]) are used, which calculate the most likely IBD sharing coefficient for each pair of 
individuals by sampling different realisations of possible inheritance patterns, and yielding 
IBD sharing posterior probabilities. 
Figure 12 - Classical linkage analysis 
This figure is a schematic representation of a family segregating a disease-affecting locus. 
Four founders exist within this family and their two haplotypes are indicated by light and dark 
shades of blue, pink, orange or green. The two haplotypes segregating within each individual 
are shown, with colour-coding corresponding to haplotype segments inherited by each 
individual. The haplotype segments inherited only by affected descendants of the blue 
founder are circled. The more individuals in a family, the higher the number of observed 
meioses, which allows researchers to narrow down the position of the disease-linked locus 




As linkage analysis relies on using genetic data from related individuals belonging to a small 
number of generations, this also means that there will be a limited number of observable 
meioses. A consequence of this is that regions identified by linkage analysis are broad, 
encompassing many genes, and often, secondary analyses are required to fine-map the region 
and pinpoint the causal variant(s). A classic example of this is the CFTR gene locus, 
responsible for cystic fibrosis. In the steps taken to identify this locus, first a large region on 
the long arm of chromosome 7 was identified through linkage analysis [33], but this region 
had to be fine-mapped with molecular genetic approaches such as chromosome walking and 
positional cloning [121] in order to home in on the causal gene. 
While linkage analyses have been successful in identifying loci underlying Mendelian diseases 
of simple genetic architecture, they have had less success with mapping complex trait loci, 
because the effect of any one locus influencing a complex trait is often too small to be detected 
unless data with very large sample sizes are available [116]. Yet if some rare variants of strong 
effect contribute to the genetic architecture of complex traits, those would cluster amongst 
related individuals and linkage analysis methods would be suited to flag regions harbouring 
those co-segregating with high or low trait values. Within this chapter, I study complex traits 
in large populations of related individuals, including population isolates, and explore an 
analytical framework for pedigree-free linkage analysis, which aims to maximise the number 
of informative individual pairs that share regions that are IBD by including relationships that 
are not indicated in a social pedigree. 
4.1.1 Pedigree-free Linkage Analysis 
Linkage analysis, by definition, requires the use of individuals who shared a recent common 
ancestor and it cannot be performed on individuals who are completely unrelated. Linkage 
studies traditionally use social pedigrees to track this relatedness between individuals. While 
the cohorts studied within this thesis consist of related individuals, detailed genealogy 
information was not always available. Social pedigrees can be stitched together with the help 
of genetic data, as is discussed in section 2.4, but this is very time-consuming and it also 
becomes difficult to ascertain the correct way in which distantly related individuals are 
connected.  
Another drawback of using known pedigrees to perform linkage analysis is the loss in power 
due to the inability to use more distant relatives who are not connected in the social pedigree, 
but still share some DNA segments IBD. These individuals might not be linked in the pedigree 
simply because of insufficient genealogical information or the need to “clip” large pedigrees 
to a manageable size so that each family falls under a certain bit-size threshold to accommodate 
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the computational requirements of software used in traditional linkage analysis (e.g. Loki). 
This problem is illustrated in Figure 13. With the availability of novel IBD coefficient 
estimation algorithms, there is no longer a need to clip pedigrees and, in theory, social 
pedigrees do not need to be used at all. Nonetheless, limitations remain in the accuracy of the 
IBD coefficient estimations and some DNA segments that are IBD between (distant) relatives 
are likely to go undetected. 
Within this chapter, I also discuss the framework for a pedigree-free linkage analysis 
methodology that aims to circumvent the need for a social pedigree, by relying entirely on 
genotype-derived kinship. 
4.2 Methods 
The basic principle of linkage analysis is that within a genetic region harbouring a QTL that 
affects a trait, relatives who have similar trait values will share more alleles IBD within this 
region compared to relatives with dissimilar trait values. 
Figure 13 - Gain in sample size from pedigree-free linkage analysis 
This is a schematic representation of pedigrees. Genotyped individuals are represented by 
coloured shapes, and the thick lines represent relationships as they exist in the pedigree files. 
White symbols represent individuals who are not genotyped, and thin lines represent genealogical 
connections that are not represented in the pedigree, either because they are unknown or because 
pedigrees had to be clipped. The circle schematic on the left represents the pairs that are 
considered in traditional linkage analysis, while the circle schematic on the right represents the 




In this section, the statistical basis of variance component linkage analysis in complex traits is 
introduced, describing its implementation in the program SOLAR [122]. Also described are 
the statistical methods used to estimate IBD coefficients using genetic data and, optionally, 
social pedigrees, as implemented in different software packages. Finally, the linkage meta-
analysis methodology is described. 
4.2.1 IBD Coefficient Calculations with Loki 
The datasets used within this thesis consist of thousands of people and hundreds of thousands 
of marker loci, and some large pedigrees have been reconstituted. As such, it is impossible to 
calculate IBD coefficients between individuals in these pedigrees using exact enumerations of 
all inheritance vectors as implemented in algorithms such as the Elston-Stewart or Lander-
Green algorithms. In contrast, approximate methods using Markov Chain Monte Carlo 
(MCMC) algorithms can handle large pedigrees, multiple families (note that complex families 
may still be a limiting factor, as noted above) and a larger number of markers because they 
consider underlying segregation patterns in relation to their likelihood of occurring. The 
program Loki [84] version 2.4.5 was used to estimate IBD coefficients within 2.5 cM intervals 
along each chromosome, between pairs of related individuals, resulting in 1462 regions across 
the whole genome. Using the social pedigree, Loki uses an MCMC algorithm to estimate IBD 
coefficients between related individuals by drawing segregation patterns over 10000 sampling 
iterations and calculating the identity coefficients associated with the segregation pattern 
drawn. Each iteration tries to update every parameter in the segregation model. For the 
purposes of IBD coefficient estimation, these parameters consist of ordered genotypes and 
allele frequencies.  
Loki does not take LD between markers into account, and because the inheritance probability 
of one marker is conditional on the inheritance probability of a neighbouring marker, this could 
result in distorted inheritance probabilities if markers are in LD. To avoid this problem, Loki 
needs to be supplied with a pruned genotype set to avoid incorrect estimation of IBD 
coefficients. Pairwise pruning was done using PLINK’s --indep-pairwise command, 
using windows of 100 SNPs, shifting the window by 25 SNPs at each step and using an r2 
threshold of 0.2 to remove one of a pair of SNPs when their LD is greater than this value. This 
left the following number of SNPs in each cohort: 127770 (Generation Scotland), 71881 
(Korčula), 81041 (Vis), 134099 (Shetland), 66818 (Orkney).  
The input marker files were updated to include positions in cM (using Kosambi’s map function 
[123]), using the map positions calculated from the 1000 Genomes Phase 3 dataset (available 
for download from http://mathgen.stats.ox.ac.uk/impute/1000GP_Phase3/, using the files 
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called genetic_map_chr*_combined_b37.txt). For SNPs that were not in this database, cM 
position was calculated from surrounding SNPs, using the following formula: 
𝑐𝑀𝑛 =
(𝑐𝑀𝑛+1 − 𝑐𝑀𝑛−1) ∗ (𝑏𝑝𝑛+1 − 𝑏𝑝𝑛)
𝑏𝑝𝑛+1 − 𝑏𝑝𝑛−1
 
Where 𝑐𝑀𝑛  is the cM position of SNP n and 𝑏𝑝𝑛  is the basepair position of SNP n. Care was 
taken to assign a unique cM position to each SNP, as Loki is unable to deal with duplicated 
cM positions at multiple SNPs. 
Loki can output results that can be used directly by the variance component linkage analysis 
software SOLAR, recoding IDs into SOLAR’s internal IDs (IBDIDs), if the pedindex.out and 
pedindex.cde files (obtained by loading the social pedigree into SOLAR) are provided prior to 
performing the IBD coefficient estimation. These output files consist of pairs of individuals, 
twice their kinship coefficient at the given position (phi2, calculated using the following 
formula: 2𝛷 = 2 ∗ (Δ1 +
1
2
∗ (Δ3 + Δ5 + Δ7) +
1
4
∗ (Δ8) , where Δn corresponds to the 
Jacquard’s condensed identity state probabilities [124]), and their inbreeding coefficient 
(delta7), equivalent to Jacquard’s Δ7 + Δ1 (the sum of the probabilities of both alleles between, 
and within individuals are shared IBD). Note that SOLAR ignores the inbreeding coefficient 
when performing linkage analyses without a dominance model. 
4.2.2 IBD Coefficient Calculations with IBDLD 
The program IBDLD [120] v3.32 was used to estimate IBD coefficients between pairs of 
people at SNPs along each chromosome, as well as to estimate whole-genome kinship. Given 
unphased genotype data, this program uses Hidden Markov Models (HMMs) to estimate 
multipoint IBD coefficients at each locus, taking into account the genotypes of all markers on 
the chromosome, and can also utilise the LD between SNPs to accurately infer haplotypes, so 
genotypes do not need to be LD pruned. It has options to estimate IBD coefficients with (LD-
RR method) or without (GIBDLD method) social pedigree information. 
IBDLD is robust to missing genotypes, accurately inferring the presence of IBD segments 
even when 20% per-individual, or 5% per-SNP missingness is present [39]. As the genotype 
data used in this thesis have been through stringent quality control, there will be, at most, 3% 
per-individual and 2% per-SNP missingness. Finally, IBDLD is robust to pedigree errors (in 
the LD-RR method, where pedigrees are used), as it can correctly infer IBD coefficients even 
when relationships are grossly misspecified – this again should not be the case in the data that 
were used in this thesis, as the pedigrees have been screened prior to analysis and gross 
pedigree errors (that did not match the genetic kinship) were fixed. While the GIBDLD method 
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(that estimates IBD coefficients without using a social pedigree) was not part of the initial 
release of IBDLD, this robustness to pedigree errors is the reason it was developed and 
implemented into later version of the program. 
IBDLD estimates IBD coefficients through two separate computational steps. In step 1, the 
background LD parameters are estimated, while step 2 estimates the IBD coefficients at each 
SNP, between pairs of individuals.  
Within this thesis, the LD-RR and GIBDLD methods were used. Both methods calculate LD 
between markers prior to inferring IBD coefficients, but GIBDLD does not require social 
pedigree information and was used to set up the pedigree-free linkage analysis methodology 
introduced in section 4.1.1 and described in more detail in section 4.2.5 below. Both methods 
use ridge regression to calculate LD patterns, jointly conditioning on the genotypes of two sets 
of markers: the genotypes of n previous SNPs (here set to 10, the default option) as well as the 
genotypes of all previous SNPs within k cM (here set to 2.5 cM to align with the input 
parameters used with Loki).  
cM positions were assigned to each SNP as described in section 4.2.1 above and, while all 
SNPs along the chromosome are used to infer IBD at each SNP, output was only requested at 
0.1 cM intervals prior to performing pedigree-based linkage analysis, resulting in IBD 
coefficients at ~33,000 SNPs. This was done to reduce the computational time of the linkage 
analysis that was performed with SOLAR, and because, due to the LD pattern between SNPs, 
linkage peaks tend to be broad, encompassing several cM, and denser sampling does not 
narrow the width of the associated “peak” region (although can more accurately pinpoint the 
position of the apex), as shown in Figure 15, where pedigree-based linkage analysis results 
using IBD coefficients calculated by Loki and the two IBDLD methods are plotted together. 
IBDLD can output probabilities for the 9 Jacquard’s condensed identity coefficients [124] at 
each locus as well as for each chromosome (by averaging the identity coefficients from all 
markers on the chromosome). It also outputs the IBD sharing (the kinship coefficient) at each 
locus and each chromosome (calculated by averaging the kinship coefficients from all markers 
on the chromosome), as well as the genome-wide kinship coefficient. The genome-wide 
kinship coefficient is calculated using the following formula:  











Where 𝑊ℎ is the number of SNPs on each chromosome and ?̂?ℎ  is the ℎth chromosome’s 
chromosome-wide kinship coefficient between individuals i and j. 𝑛𝐶ℎ𝑟 is the total number of 
chromosomes (22 in humans). 
As IBDLD does not automatically output SOLAR-formatted files, I have written R scripts that 
convert IBDLD output files into the SOLAR input files, creating IBD files in the same format 
as described in section 4.2.1 above, by adding Δ7 + Δ1 to obtain the “delta7” value used by 
SOLAR, and multiplying the kinship coefficient by 2 to obtain 2Φ. 
When pedigree data were used (LD-RR method), per-SNP IBD output was requested for every 
genotyped pair within each family. In Orkney and Vis, where the pedigree-free IBD estimation 
(using IBDLD’s GIBDLD method) and linkage analysis was trialled, output was requested for 
all genotyped ID pairs in the dataset (rather than only pairs of individuals within families), at 
each genotyped SNP. Analysing a region in SOLAR with pedigree-free linkage analysis takes 
approximately 8 minutes in Orkney, so instead of analysing SNPs at 0.1 cM intervals as 
described above, in order to reduce the analysis time, the genome was split into 2.5 cM regions 
and the kinship coefficients of all SNPs within each region were averaged to obtain a regional 
kinship coefficient. This resulted in 1446 non-empty regions (that is, regions that contain at 
least one SNP). The median number of SNPs in each region was 107 SNPs in Orkney (180 
SNPs in Vis), and the interquartile range was 47 SNPs in Orkney (93 SNPs in Vis). Figure 14 
shows the distribution of the number of SNPs allocated to each region, within each cohort. 
Figure 14 - Distribution of SNPs into 2.5 cM regions in Orkney and Vis 
The X axis shows the number of SNPs in each 2.5 cM region across the autosomal genome, 






4.2.3 Variance Component Linkage Analysis in Complex Traits 
In variance component linkage analysis, phenotypic variance is partitioned into components 
derived from fixed effects and random effects consisting of additive polygenic variance, 
additive QTL variance and residual variance. The polygenic term 𝑍𝑢 described in section 
3.2.2 is therefore split into two components, hence there is an additional variance 
Figure 15 - Results of linkage analysis using SOLAR, with IBD coefficients 
calculated by Loki, LD-RR or GIBDLD. 
This figure shows the educational attainment linkage analysis results on chromosome 12 in 
Orkney. The SOLAR analysis is identical in all three cases (it uses the same social pedigree to 
estimate genome-wide kinship), only the regional IBD estimations differ. In red, IBD coefficients 
calculated at 2.5 cM intervals (for a total of 64 regions on this chromosome) by Loki, using pruned 
SNP data. In dark blue, IBD coefficients calculated using the LD-RR method in IBDLD (uses 
pedigree information). In light blue, IBDs calculated using the GIBDLD method in IBDLD (does 
not use pedigree information). IBD coefficients at 1540 SNPs along chromosome 12 were obtained 
from both IBDLD methods. Note that while GIBDLD does not use pedigree information to 
calculate IBD coefficients, SOLAR was still provided with a pedigree to estimate linkage (in order 
to make the results comparable), so this figure does not show results obtained with the pedigree-




component, 𝑊𝑣, that needs to be estimated. In variance component linkage analysis, the trait 
y can therefore be expressed as 
𝑦 = 𝑋𝛽 + 𝑍𝑢 + 𝑊𝑣 + 𝑒 
where Z and W are the design matrices for random effects, u is the whole-genome additive 
effect with variance 𝑣𝑎𝑟(𝑢) = ɸ𝜎𝑢
2, v is the regional additive effect with variance 𝑣𝑎𝑟(𝑣) =
?̂?𝜎𝑣
2, e is the residual effect with variance 𝑣𝑎𝑟(𝑒) = 𝐼𝜎𝑒
2. Matrices ɸ, ?̂? and I are the whole-
genome kinship coefficient, regional IBD coefficient and the identity matrix. 
This generalises to pedigrees of arbitrary complexity, such as those used within this thesis, and 




𝑖=1  where 
?̂?𝑖 is a matrix with elements 𝜋𝑖𝑘𝑗  that provide the proportion of alleles that are IBD between 
individuals k and j at the ith QTL, ɸ is the matrix of kinship coefficients and 𝛪 is the identity 
matrix. 
Note that the kinship coefficient can be derived in two ways. It can be estimated from a social 
pedigree, in which case the pairwise kinship coefficients are calculated based on the average 
expected amount of genetic sharing given the number of meioses separating the two 
individuals through their most recent common ancestor or ancestors (where common ancestor 
is defined as an individual whose descendants are not also a common ancestor of the two 




𝑥=1  , where 𝛷𝑗𝑘 is the kinship 
coefficient between individuals j and k, 𝐹𝑥  is the inbreeding coefficient of their most recent 
common ancestor x, and 𝑀𝑥  is the number of meioses separating them through ancestor x. The 
pedigree-based kinship is always the same fixed value for pairs with the same degree of 
relatedness. For example, in the absence of inbreeding, a parent-child pair or a pair of full 
siblings will always have an estimated kinship coefficient of 0.25 (2Φ =0.5). While a child 
inherits exactly half of a parent’s genome, realised kinship for full siblings can vary greatly 
around this average value due to the randomness of inherited chromosomes at each meiosis. 
Whole-genome kinship coefficients and regional IBD coefficients can also be derived solely 
from genetic data, as described in the sections above, and these values reflect the true amount 
of genetic sharing between a pair of individuals.  
Linkage analysis was performed using the program SOLAR [122], which carries out linkage 
analyses using variance component methods, considering the likelihood of the entire pedigree 
(which may consist of multiple, complex families) jointly. SOLAR can calculate multipoint 
IBD coefficients internally but also accepts externally-computed IBD coefficients as long as 
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the files containing these are provided in the appropriate format. Note that while SOLAR 
allows for the estimation of dominance and epistasis effects, within this thesis, only additive 
effects are assessed. 
SOLAR uses maximum likelihood functions to test for the presence of a QTL in a given region 
by comparing the full model (QTL effect + polygenic effect) with a null model that does not 
include the QTL effect. The null hypothesis is (H0) is the absence of regional contribution to 
the variance, while the presence of regional contribution constitutes the alternative hypothesis 
(H1). Within each region, these hypotheses will have likelihoods L0 and L1, respectively and a 
likelihood ratio test (LRT) statistic can be calculated from these with LRT=-2ln(L0/L1). The 
LRT follows a distribution that is a 50:50 mixture of a point mass at 0 and a χ2 distribution 
with 1 degree of freedom [74]. To correctly account for the fact that this is a one-sided test, 
the p-value for the LRT needs to be divided by 2. SOLAR expresses the test statistic as a log 
of odds (LOD) score, to be in line with previous linkage studies, which is calculated by 
dividing the LRT by 2ln(10). 
Within this thesis, the “multipoint” command of SOLAR was used to run linkage analyses 
using IBD coefficients estimated at 2.5 cM intervals along each chromosome by the program 
Loki. In contrast, the IBD coefficients calculated by IBDLD were analysed using the 
“twopoint” command in SOLAR, which calculates linkage at each input SNP. Note that while 
this is called a twopoint analysis in SOLAR (as the input to SOLAR is one SNP at a time), in 
reality, this is also a multipoint analysis, as the IBD status at each SNP was calculated using 
other markers on the chromosome. 
4.2.4 Converting LOD Scores to P-values 
As stated above, linkage (and also RH) analyses use likelihood ratio tests (LRTs) to test for 
the presence of a QTL in a given locus. The RH analysis software reports associated p-values, 
while the linkage analysis software converts them to LOD scores, to be in line with the 
conventional measure of confidence used in linkage studies performed on traits with 
Mendelian inheritance (parametric linkage analysis). While both LOD scores and p-values are 
used in this thesis, some comparisons are facilitated by all results being reported using the 
same metric (p-values).  
In order to convert LOD scores into p-values, the method described by Nyholt [74] is used. 
LOD scores are first converted to LRT statistics with the formula LRT=LOD×2×ln(10), since 
LODθ = log10(Λθ) and LRTθ=2×ln(Λθ), where θ is the parameter estimated by the maximum 
likelihood method and Λ is the likelihood function. The distribution of these LRTs is a 50:50 
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mixture of a chi-square distribution with 1 degree of freedom and a point mass centred at 0 
and is converted to a p-value using the pchisq() function in R followed by dividing these p-
values by 2 to reflect the properties of its distribution, using this function: 
p(LOD)=0.5×pchisq(LOD×2×ln(10), df=1, lower.tail=FALSE).  
4.2.5 Pedigree-free Linkage Analysis 
Pedigree-free linkage analysis attempts to bypass the need for a social pedigree altogether, 
using the “GIBDLD” method within the IBDLD3 program [120], as described above. 
GIBDLD can estimate IBD sharing at given SNPs even in the absence of a social pedigree, 
which was not possible using the Loki software [84].  
As described above, IBD sharing was estimated at each genotyped SNP, between all pairs of 
individuals in the cohort, the genome was split into 2.5 cM regions and regional IBDs were 
obtained by averaging the IBDs of all SNPs within each region. This larger interval was used 
with pedigree-free linkage in order to reduce the analysis time, as analysing each region with 
pedigree-free linkage analysis takes approximately 8 minutes in Orkney, so analysing SNPs 
spaced at 0.1 cM intervals would have been unfeasible. Following the IBD estimation step, 
linkage analysis was carried out in SOLAR as described previously, with the following 
differences: 
1. The true social pedigree was not used by SOLAR. However, SOLAR needs to load a 
pedigree prior to any analysis. For this purpose, the “pedigree” file containing a list of 
the genotyped individuals only, without any parental information, is provided. 
2. By default, this “pedigree” is used by SOLAR to estimate the genome-wide kinship 
coefficient (which is going to be 0 between all pairs as no actual relatedness 
information was recorded in this pedigree). This matrix is overridden by the genome-
wide kinship matrix estimated by GIBDLD. 
3. By default, SOLAR only calculates linkage using pairs whose kinship coefficient is 
not 0, as calculated from the social pedigree. To force SOLAR to use all pairs of 
individuals in the data, the ‘option MergeAllPeds 1’ command was used, which uses 
the IBD sharing estimates between all pairs of individuals, regardless of their 
relatedness according to the social pedigree. 
Where a regional LOD score exceeded the multiple testing-corrected GWS threshold, linkage 
analysis was additionally run on every SNP in the region separately, by using the IBD 
coefficients estimated at each SNP within that region.  
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4.2.6 Linkage Analysis Power Calculations in SOLAR 
The methods described in this section are used to assess the performance of each cohort for 
linkage studies. They highlight the importance of large families over a simple increase in 
sample size in order to increase power to detect a QTL using linkage analysis. The social 
pedigrees derived in each of the cohorts (see section 2.4) were used in this section. 
The power to detect a linkage signal with a LOD score of 2 or 3 was assessed in each 
population. This was done using the ‘power’ command in SOLAR. These calculations were 
done by simulating traits with total heritability ranging from 25% to 80% (increasing in 
increments of 5%), with one QTL explaining 0 to 100% of the total heritability (increasing in 
increments of 1%). QTLs with allele frequencies of 2, 10, 25 and 50% were used to assess the 
power to detect linkage. 
SOLAR uses the social pedigree to assign reference or alternate causal alleles to individuals, 
using a drop-down method. This means that it first randomly assigns alleles to a number of 
founders based on the minor allele frequency, and then propagates these alleles through the 
families using chromosomal segregation.  
4.2.7 Meta-analysis 
Linkage analysis was performed using the same pipeline, and phenotypes quality controlled 
in the same way, in 5 different cohorts. Meta-analysing the results may reveal common 
patterns emerging in several cohorts that may not have been obvious when each cohort was 
analysed on its own. 
As described in section 4.2.2, pedigree-based linkage analysis was performed at every 0.1 cM 
along the chromosome in each cohort, which partitions the genome into 36269 regions. With 
pedigree-free linkage analysis, linkage analysis was performed at 2.5 cM intervals along each 
chromosome, which results in 1464 regions across the genome. Some of these regions may 
contain no genotyped SNPs in some cohorts – in such cases, the LOD score of the nearest non-
empty region was used. The LOD scores within the corresponding region in each cohort were 
meta-analysed using Fisher’s combined test, described below. 
In 1952, Ronald Fisher described a statistical method that allows the combining of p-values 
into a joint test to determine whether the global null hypothesis can be rejected [125]. To use 
this method, LOD scores are first converted into p-values. This is done by calculating 𝐿𝑂𝐷 ∗
(2 ∗ 𝑙𝑛10), which yields an LRT test statistic with a distribution that is a 50:50 mixture of a 
point mass at 0 and a χ2 distribution with 1 degree of freedom [74], from which the p-value 
can be determined using the upper tail of a χ2 test, using the pchisq() function in R. To account 
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for the 50:50 mixture of function distributions, the p-values are divided by 2. Then, the statistic 
−2 ∑ ln (𝑝), is calculated at each locus, which, following Fisher’s combined test, has a χ2 
distribution under the null. The global p-value, Pmeta, for each locus is obtained by taking the 
upper tail of a χ2 test with degrees of freedom equal to 2 times the number of studies used. 
Regions with -log10(Pmeta) > 4.43 (corresponding to LOD = 3.41) are considered suggestively 
significant, while regions with -log10(Pmeta) > 5.93 (corresponding to LOD = 4.84) are 
considered genome-wide significant, taking into account the number of traits analysed. 
If the linkage signals are generated by rare variants or rare combinations of variants in one 
population, replication in another population depends on whether these alleles are also 
segregating within the target populations. Therefore, it could be the case that a QTL 
segregating in Scotland is not segregating in Croatia (or vice-versa), and therefore cannot be 
detected in that population. This could dilute the signal of the meta-analysis, so in addition to 
analysing all the cohorts together (which could reveal common linkage regions across 
European populations), the cohorts were also subdivided into the following groups: Croatia 
(Vis and Korčula), Scotland (GS, Shetland, Orkney) and Scottish Islands (Orkney and 




4.3.1 Identity by Descent Estimations 
4.3.1.1 Genome-wide Kinship 
Figure 16 shows a comparison between the genome-wide pairwise relationship coefficient 
(twice the kinship coefficient=2Φ) in Orkney, as calculated by SOLAR using the clipped social 
pedigree and calculated by IBDLD’s GIBDLD (pedigree-free) method, which uses solely the 
genotype data.  
Figure 16 - Pedigree-based and SNP-based whole genome kinship 
The SNP-based kinship, as calculated by IBDLD’s GIBDLD (pedigree-free) method is plotted 
on the X axis. The Y axis shows the kinship estimated from the clipped social pedigree by 
SOLAR. All pairs (including self-pairs, in the top right corner) in Orkney are depicted. Pairs 
in the blue rectangle are pairs who are unrelated in the social pedigree but have non-0 kinship 
according to IBDLD. Note that here, 2Φ is used (that is, twice the kinship coefficient, which 




The genome-wide kinship, as calculated by GIBDLD, is nearly identical to the genetic 
relationship matrix calculated using the IBS-based relatedness formula described in section 
3.2.1 (for a comparison of the relationship-values calculated by these two methods, see section 
7.1.1), but shows marked differences compared to the pedigree-based kinship. For example, 
126731 pairs of individuals are unrelated according to the clipped social pedigree but have 2Φ 
> 0.03. 2091 of these are seemingly compatible third degree relatives or closer relatedness (2Φ 
> 0.125). Other than these pairs of relatives who appear unrelated in the social pedigree, there 
appear to be no gross misspecifications of relationships in the social pedigree (gross 
misspecification being defined as a difference of more than 0.25 between the pedigree-based 
kinship and the genetic relatedness), which is expected, given that such misspecifications were 
addressed prior to downstream analysis, as described in section 2.4.  
4.3.1.2 Regional Kinship 
When two individuals are distantly related, their probability of sharing IBD segments 
decreases exponentially with each meiosis that separates them, but should they share an IBD 
segment, the length of it decreases only linearly with each meiosis [126]. The estimation of 
pairwise kinship coefficients based on the genotype data indicates that many pairs of 
individuals in Orkney are distantly related, therefore there is a lot of potential in using these 
pairs in linkage analysis. Additionally, the rationale behind the pedigree-free linkage analysis 
also makes use of the fact that regions where DNA segments are shared IBD come in large 
blocks and therefore may be easier to ascertain. 
Figure 17 illustrates the difference between the genome-wide kinship coefficient and the 
regional kinship coefficient, where the latter was obtained by averaging the GIBDLD-IBD 
estimates output at 28 SNPs in a 0.3 cM region around the SLC2A9 gene. 48131 pairs who are 
unrelated in the clipped social pedigree have a kinship-value that indicates the sharing of at 
least 1 allele IBD throughout this region, and 45866 of these pairs are less than 4th degree 
relatives (2Φ < 0.0625). Additionally, 34 pairs appear to be homozygous by descent (HBD) in 





4.3.1.3 Pedigree-free IBD coefficient Estimation Accuracy 
The benefit of pedigree-free IBD estimation is that it enables the use of regions that are shared 
IBD by distantly-related individuals, increasing the power to detect a QTL with linkage 
analysis. This way, untyped rare variants may be detected as long as they segregate on a clear 
haplotype. However, the power gained will critically depend on the accuracy of the IBD 
coefficients.  
In order to evaluate the IBD coefficients estimated by GIBDLD, I chose a relatively rare 
variant (rs16865292, 2.5% C allele frequency) and explored its segregation within a family in 
Orkney, as well as in the whole Orkney cohort. Shared haplotypes in the vicinity of this variant, 
inferred through the IBD coefficients estimated by GIBDLD, were compared to haplotypes 
Figure 17 - Whole genome versus regional kinship at the SLC2A9 locus 
The SNP-based whole genome relationship coefficient (2Φ) between all pairs of individuals 
(including self-pairs) is plotted on the X axis. The regional average relationship coefficient 
(2Φ) obtained from the 28 SNPs in the 0.3 cM region around the SLC2A9 gene is plotted on 
the Y axis. The possible configurations of alleles shared IBD corresponding to regional 
relationship-values of 0, 1, 2 and 4 are plotted on the right hand side on their respective rows 
– here, the unordered alleles of two individuals are shown as nodes and the lines connecting 




obtained from genotype data that had been phased using the SHAPEIT program version 
2.r644, with the duoHMM option that made us of pedigree information (run previously by Dr 
Peter Joshi for imputation purposes). Because the SHAPEIT output matches well with 
expected Mendelian inheritance in the families recorded, it is considered as the “true” 
haplotype. In the phased data, the haplotype region was defined as the region consisting of 
rs16865292 and 25 flanking SNPs on either side. 
Figure 18 shows this family’s pedigree, and indicates the rs16865292 alleles carried by 
specific individuals. Within this family, there is one “major” (more common) haplotype, 
originating from one of the founders, that carries the C allele. There are three other distinct 
haplotypes, originating from married-in individuals, which also carry this allele. Table 10 
illustrates the four different haplotypes on which the C allele appears in this family. 
Using the genotypes of the whole Orkney dataset, GIBDLD accurately detected sharing of 
rs16865292 C-carrying haplotypes, and correctly distinguished between them in all but one 
pair within this family. While ORCA1193 and ORCA1607 (outlined in red in Figure 18) carry 
two different C haplotypes, as well as two different T haplotypes, GIBDLD estimated that they 
share one allele IBD. GIBDLD correctly distinguished the different haplotypes that carry the 
T allele, indicating that, for example, ORCA1202 and her sister, ORCA1345, do not share this 
region IBD, while ORCA1345 and her aunt, ORCA3951, share one of the T haplotypes. 
Next, I broadened this comparison to include all pairs of individuals in the cohort. I extracted 
pairs of individuals where both members of the pair carry at least one C allele at this SNP. 
There were 5151 such pairs. I then looked at whether they share the haplotype of the C allele 
(and the T allele, when both carried this allele), as ascertained by the phased data, to evaluate 
the consistency between the IBD coefficients output by GIBDLD and haplotype sharing. 549 
pairs shared at least one C haplotype, and all were reported to share at least one allele by IBD 
GIBDLD. 170 of these pairs consisted of an individual from the family shown in Figure 18 
and an individual who is unrelated to them according to the social pedigree. The median 
genome-wide kinship between these 549 pairs was 0.017. Three individuals carried 
homozygous C haplotypes, which was also predicted by GIBDLD.  
Conversely, there were 394 pairs who shared no C or T haplotypes, but GIBDLD reported that 
they share at least one allele. I investigated whether some of these “false positives” could be 
explained by the way in which GIBDLD constructs the LD patterns – as mentioned in the 
Methods section of this chapter, at each SNP, IBDLD conditions jointly on the genotypes of 
the 10 previous SNPs, as well as the genotypes of all previous SNPs within 2.5 cM. Where 
both the 10 previous SNPs, as well as SNPs within 2.5 cM match between two individuals, 
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GIBDLD accurately detects IBD sharing (which is the case for all 170 distantly related pairs 
that share C haplotypes). However, if the 10 previous SNPs match but there is some mismatch 
in the SNPs within 2.5 cM, IBD sharing accuracy seems to decrease, as detailed below: 
There were 30 different haplotypes carrying the C allele in Orkney, based on the phased output. 
Figure 19 illustrates these haplotypes by showing the 25 SNPs up- and downstream of 
rs16865292. Looking only at the 10 SNPs upstream of rs16865292, however, these 30 
haplotypes can be condensed into 8 different ones (coloured rectangles in Figure 19). Three 
quarters, or 295 out of the 394, “false positive” pairs (who are reported to share at least 1 allele 
by GIBDLD but do not share haplotypes according to the phased data) share these reduced 
haplotypes (and a further 33 share haplotypes on the T allele), but not the 2.5 cM region, which 
could explain why GIBDLD is not able to accurately distinguish IBD sharing here.  
The reason GIBDLD looks at IBD sharing at the previous 10 SNPs as well as all SNPs within 
2.5 cM becomes apparent when we look at the pairs that share the smaller, but not the larger 
region –1075 pairs share these reduced haplotypes (but not the bigger haplotypes), and 
GIBDLD detects that they do not share rs16865292 IBD – eliminating a lot of potential false 
positives. It is not clear why GIBDLD determines that 295 pairs share this region IBD despite 
this not appearing to be the case according to the phased data. 
One possible explanation for the remaining 66 pairs that do not share this smaller region’s 
haplotypes but have IBD values that suggest they do could be the fact that GIBDLD was 
unable to correctly determine the haplotypes segregating in these people (the input to GIBDLD 
consists of genotype data that have not been phased, and no pedigree information was 
provided). Alternatively, GIBDLD did accurately estimate sharing and the phasing could be 






Figure 18 - Tracking rs16865292 in an Orkney family. 
This is a schematic representation of the Orkney family. Pink rectangles indicate females, blue rectangles indicate males. The _0, _1, _2 or _NA following each ID indicates the number 
of C alleles (the minor allele) each individual has at this SNP, as ascertained from the genotype data. I indicate the 4 different haplotypes that carry the C allele with different colours 
and subscripts, and the “major” haplotype carrying the C allele is shown in red. The polymorphism is C/T and subscripts of the T allele show the haplotypes that carry this allele. These 
haplotypes were inferred from phased data and are shown in Table 10. The two individuals highlighted by the red rectangles are reported to have 1 allele IBD by IBDLD, even though 
they have no matching haplotypes in the region. The individuals in green were not part of the clipped social pedigree (they were part of the full pedigree), but IBDLD detected the 
shared haplotype between them and their parents. 
Table 10 - Four distinct haplotypes carrying the C allele of rs16865292 in an Orkney family.  
rs16865292 is positioned in the column with thick borders, and the alternate alleles (0) at each SNP have a green background, while the reference alleles (1) 
have a yellow background. 
C 1 1 1 0 0 1 1 1 0 1 1 1 1 1 0 1 0 1 0 1 0 0 1 1 1 1 0 1 1 1 1 1 1 1 0 1 0 0 
C2 1 1 1 0 1 1 1 1 0 0 0 1 1 1 1 1 1 0 1 1 1 0 1 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 
C3 0 1 1 0 1 1 0 1 0 1 1 1 0 1 0 0 1 1 0 1 1 0 1 1 1 1 1 0 1 0 0 1 1 1 0 1 0 0 




4.3.1.4 Regions under Selective Pressure 
As IBDLD allows for the estimation of IBD sharing between all pairs of people in study 
samples of arbitrary size, it becomes possible to calculate the average IBD sharing at each 
genotyped SNP, as well as the average genome-wide IBD. This gives an overview of the 
population-wide IBD in a cohort, at each SNP, and can help detect regions where the amount 
of IBD sharing is higher (or lower) than the average IBD sharing. 
The average kinship coefficient across the genome is 0.00995 in Orkney and 0.013 in Vis, 
corresponding to 6th and 5th degrees of relatedness, respectively. These are higher than the 
sharing observed in datasets of unrelated European individuals, which is around 0.0022 [127]. 
As both Orkney and Vis are population isolates consisting of many related individuals, this 
higher average sharing is not unexpected. Previous analyses of the Orkney and the Croatian 
cohorts show similarly increased levels of IBD sharing [128]. 
Figure 19 - 30 different haplotypes carrying the C allele at rs16865292. 
The genotypes of rs16865292 (at point 0 on the Y axis) and the genotypes of the 25 flanking SNPs are 
pictured, for each haplotype. Each column represents a haplotype, named along the top and bottom x 
axes. Each haplotype is distinct when all 51 SNPs are considered, while each differently-coloured box 




Figure 20 shows the average kinship coefficient at each SNP in Orkney and Vis. One feature 
that can be observed from these plots is that the average chromosome-wide IBD sharing 
correlates with chromosome length (correlation coefficient 0.91 in Vis, 0.8 in Orkney), ranging 
from 0.007 to 0.018 in Vis and 0.006 to 0.015 in Orkney. This is a consequence of crossing 
over (recombination) during meiosis: homologous chromosomes align during meiosis and 
chromatids from different chromosomes come into contact at one or more points along their 
length, resulting in a crossover. To ensure accurate chromosome cohesion and segregation, at 
least one recombination needs to occur on each chromosome. The recombination rate is higher 
in shorter chromosomes, so IBD along shorter chromosomes breaks down faster [129]. One 
crossover inhibits the formation of additional crossovers nearby, in a process known as 
crossover interference. Crossover interference is higher on shorter chromosomes, which 
decreases the probability of double crossovers occurring [130]. However, it appears that the 
reduced rate of double crossovers on shorter chromosomes is not enough to compensate for 
the higher number of recombination events. 
Figure 20 - Average kinship at each SNP across the genome in Orkney and Vis. 
The X axis marks the position of SNPs along the genome. The Y axes show the average kinship coefficient 




There are also several peaks and trends that can be observed in Figure 20 and these agree with 
previous reports of genomic features. The peak on chromosome 6 represents the human 
leukocyte antigen (HLA) region that is well-documented as being under a strong selective 
pressure, leading to lower haplotype diversity as it contributes to immune function [127, 131]. 
The telomeric regions show increased IBD sharing followed by a region of decreased IBD 
sharing. One study ([132]) reported that this is due to a telomere-mediated suppression of 
recombination at the chromosome extremes, followed by a region of high recombination. This 
leads to telomeric haplotypes that are unaffected by natural selection and recombination and 
this can be used for lineage tracing over large time scales. Other studies have found similarly 
increased sharing at telomeres [133, 134] but others also report reduced sharing [135] at this 
region. Centromeric regions also show increased sharing, which is likely due to the 
suppression of recombination here [136]. A region around the centromere of chromosome 11 
shows increased sharing, especially in Vis. This region contains clusters of olfactory receptor 
genes, and other studies have also reported excess sharing across populations in this region 
[134]. The region of increased sharing between 9 and 11Mb on chromosome 8 has also been 
previously documented by several studies [134, 137] including the Generation Scotland study 
[138]. This region is near a cluster of defensin genes, and one study has found that it is also 
the site of a large polymorphic inversion [139]. The region of increased sharing on 
chromosome 2 (2q21.3-2q22.1) has also been previously documented [39], and contains 45 
genes including the lactase gene, which has strong evidence for being under selective pressure 
[140].  
4.3.2 Power Calculations 
Power calculations done using SOLAR underestimate the power to detect linkage, as they only 
consider individuals within families. However, we know that there is substantial relatedness 
between individuals in different families, especially in the Orkney and Shetland populations, 
where pedigrees had to be clipped in order to accommodate the linkage analysis software. 
Because of this, individuals who share segments of their genome that are IBD have been 
assigned into different families and this sharing will not be accounted for in the power 
calculations, where the simulated alleles are assigned in each family independently. 
With this limitation in mind, comparisons of the relative power of linkage analysis in the 
different cohorts can still be made. As Figure 21 shows, the cohort of Vis is the poorest 
performer, because in this cohort, a QTL can only be detected if it explains nearly all of the 
trait heritability. This is not surprising, as Vis has the lowest number of individuals and both 
it and Korčula have the lowest number of individuals per family – a metric that is very 
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important in linkage studies [141]. The second important metric in linkage studies is the total 
number of individuals in a study – this is why Shetland appears to perform worse than Korčula 
despite having more people per family. Korčula has nearly 1000 more individuals than 
Shetland, and this 50% larger sample size contributes strongly to the increased power to detect 
linkage. Yet, the importance of large families over a simple increase in the number of 
individuals, can be seen when comparing Orkney with Korčula and Generation Scotland. 
Orkney, like Shetland, has 2000 individuals but outperforms Korčula and performs nearly as 
well as GS despite GS having a 10-fold higher sample size. Indeed, Table 5 shows that Orkney 
has the highest number of genotyped individuals per family. 
Interestingly, the combined Orkney + Shetland dataset performs more poorly than Orkney 
alone (but better than Shetland alone), despite the doubling in sample size (Figure 19). Again, 
this can be explained by a drop in the number of genotyped people per family once the 
combined pedigrees are clipped to bitsize 50, compared to Orkney. Also, due to the drop-down 
QTL simulations, stronger linkage signals are created in deeper families, which are more 
frequent in Orkney. The families where the simulated QTL does not segregate dilute the signal, 
which is exactly what is seen when the (smaller) Shetland families are added. 
Figure 21 - Power to detect linkage in a trait with 0.8 heritability, using a QTL with 
2% MAF across a range of heritabilities 
The X axis shows increasing QTL heritability (up to the value of the total trait heritability). The 




A final validation of the importance of sample size and family size comes from power 
calculations done on pedigrees where a random subset of genotyped individuals were masked 
(Figure 23). Reducing the number of individuals in Generation Scotland to 2100 in order to 
match the number of individuals in Orkney led to a big drop in power as these individuals 
were spread over 450 families, rather than the 170 families in Orkney. Once the family size in 
GS was reduced to 170, an even bigger drop in power could be observed, as only 827 
individuals were retained. This sample size is comparable to Vis (960 individuals) which still 
performs worse due to the sparse family structure in this cohort. As families become sparser, 
power drops significantly and family structure becomes less important compared to sample 
size. When the sample size in Orkney is halved, its performance matches that of the 827-
individual GS sample. 
It should, however, be noted that to have an 80% power to detect a QTL with pedigree-based 
linkage analysis, its effect size needs to be quite large, as it has to explain about 8% of the trait 
heritability in the cohorts that have the highest power to detect linkage. 
Figure 22 - Power to detect linkage in a trait with 0.5 heritability, using a QTL 
with 2% MAF 
This figure shows the power to detect linkage in Orkney, Shetland and the combined Orkney 




4.3.3 Linkage Analysis Results 
Here, I present the results of linkage analyses performed in individual cohorts, as well as the 
results of meta-analysis. Estimation of segments shared IBD is an important step in linkage 
analysis, and since IBD coefficients were calculated using different methods (Loki, IBDLD-
LD-RR (pedigree) and IBDLD-GIBDLD (no pedigree)), three different sets of results will be 
presented. Since regions of IBD sharing can extend over large distances, linkage analysis 
cannot pinpoint the precise location of a QTL causing a linkage signal, and this is why the 
interval that is within a 2-LOD drop of the peak is also provided. The suggestive and genome-
wide significance thresholds are described in section 2.2.1. 
4.3.3.1 Linkage Results Obtained with IBD Coefficients Calculated by Loki 
Table 11 presents the pedigree-based linkage analysis results that pass the suggestive 
significance threshold, and which were obtained by using regional IBD coefficients calculated 
by Loki. In total, 16 loci pass the suggestive significance threshold. The only locus with a 
Figure 23 - Power to detect linkage in a trait with 0.8 heritability, using a QTL 
with 1% MAF 
Genotyped individuals from Orkney and Generation Scotland were randomly masked from 
SOLAR when estimating power in order to assess the effect of reducing sample and family 




LOD score exceeding the genome-wide significance threshold is the chromosome 4 hit for 
fasting plasma glucose levels in Orkney, which is why the suggestive and genome-wide 
significant results are not presented in separate tables. This locus has a lower, but suggestively 
significant LOD score (3.44) with the pedigree-based linkage analysis conducted on IBD 
coefficients calculated by IBDLD. 
Table 11 - Linkage analysis loci that reached the uncorrected GWS threshold, 
using IBD coefficients calculated by Loki 
Loki outputs IBD coefficients at every 2.5 cM along the genome. The peak where the highest 
LOD score is reached is shown, as is the interval where LOD scores that are within a 2-LOD 
drop of the top hit. The total trait heritability (h2) and heritability explained by the hit (h2QTL), 
as output by SOLAR, are shown, and the chromosome band containing each locus is indicated. 
The last column shows if the locus has been associated with the relevant trait in the literature. 
Trait 











BMI 16 80 3.5043 0.42 0.28 60-100 q12.1-q23.2 Yes 
FEV1 12 130 3.9894 0.41 0.37 110-135 q22-q24.21 Yes 





GGT 10 35 3.6281 0.58 0.58 20-50 p14-p12.1 Yes 





Creatinine 9 35 4.032 0.41 0.3 30-45 p23-p21.3 No 
Diastolic BP 1 110 3.5 0.34 0.34 105-120 p31.1-p22.2 Yes 
HbA1c 8 105 4.5454 0.45 0.37 100-110 q21.11-q21.3 No 
Spherical 
Equivalent 






Thickness 13 50 3.7958 0.75 0.7 40-60 q13.3-q21.2 
No 
Glucose_nodiab 10 65 3.6544 0.35 0.35 55-90 p12.1-q21.3 No 
GS  
Alcohol 
consumption 7 60 3.4515 0.29 0.1 50-70 p14.3-p13 
Yes 
Forced Vital 
Capacity 9 105 3.5034 0.42 0.13 80-110 q13-q22.2 
No 
Forced Vital 
Capacity 21 10 4.0323 0.41 0.13 0-20 p11.2-q21.2 
No 
Height 7 75 4.1948 0.92 0.08 70-85 p13-q11.22 Yes 
Height 17 85 3.8357 0.92 0.08 75-90 q21.33-q24.1 Yes 
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4.3.3.2 Linkage Results Obtained with IBD Coefficients Calculated by the Pedigree-based 
method of IBDLD (LD-RR) 
In this section, I present the regions that passed the genome-wide LOD significance threshold 
adjusted for the number of traits analysed, within each cohort (Table 12). For suggestively 
significant results that exceeded the unadjusted LOD threshold (LOD>3.41) but not the GWS 
threshold, see Supplementary Table 3.  
These results were obtained using regional IBD coefficients calculated by the pedigree-based 
method of IBDLD (LD-RR), and kinship coefficients were calculated by SOLAR using the 
social pedigree. Note that the pairs used in this linkage analysis are restricted to those that are 
connected in the social pedigree rather than all pairs of individuals in the data.  
In total, 158 regions pass the suggestive significance threshold (LOD>3.41), and 26 of these 
regions pass the GWS threshold. Every locus that was suggestively significant in the linkage 
analysis using the IBD coefficients calculated by Loki also exceeds the suggestive significance 
threshold in this analysis, with the exception of 4 loci that do not reach this threshold when 





Table 12 - Loci that reached the GWS threshold with pedigree-based linkage analysis, using IBD coefficients calculated by 
IBDLD 
The rsID of the SNP at which the highest LOD score was obtained is shown, as is the chromosome (Chr column) and position (Pos column) where this 
SNP is located. The start and end positions of the interval where LOD scores that are within a 2-LOD drop of the top hit are shown, in Megabases (2-
LOD drop column). The total trait heritability (h2) and heritability explained by the hit (h2QTL), as output by SOLAR, are shown. The ‘Gene’ and 
‘Gene_Dist’ columns indicate the gene nearest the top hit, as well as the distance to this gene from the top hit (this distance is 0 when the top hit is within 
the gene itself). The last column shows if the locus has been associated with the relevant trait in the literature. 




QTL 2-LOD drop Band Gene Gene_Dist Known? 
Orkney 
Diastolic BP 2 rs6432025 9758621 6.2592 0.32 0.28 8.63-11.16 p25.1 YWHAQ 0 Yes 
Vis  
Central Corneal 
Thickness 1 rs240099 176547669 5.0805 0.84 0.58 175.89-177.02 q25.1-q25.2 PAPPA2 0 
No 
Central Corneal 
Thickness 12 rs901232 128073805 7.7858 0.79 0.64 127.88-128.15 q24.32 FLJ37505 292355 
No 
Forced Vital Capacity 1 rs1251531 76469334 6.0745 0.31 0.26 75.94-76.57 p31.1 ST6GALNAC3 71053 Yes 
GGT 1 rs2053675 188967356 6.3055 0.43 0.36 188.62-189.72 q31.1 FAM5C 1099439 No 
GGT 19 rs217541 54443866 8.4062 0.63 0.36 54.27-54.76 q13.42 CACNG7 0 No 
Lens Thickness 7 rs4724195 43326197 7.1727 0.47 0.46 43.28-43.57 p14.1-p13 HECW1 0 No 
Urea 9 rs12001341 86203246 8.0489 0.42 0.35 86.18-86.76 q21.32 C9orf103 34785 No 
Urea 9 rs12554805 87092773 7.7952 0.43 0.34 86.96-87.41 q21.33 SLC28A3 109359 No 
Urea 9 rs1885493 38335475 6.931 0.52 0.25 37.73-38.56 p13.2-p13.1 ALDH1B1 57225 No 
Shetland  








QTL 2-LOD drop Band Gene Gene_Dist Known? 
BMI 11 rs7932734 11201684 5.7443 0.55 0.1 11.11-11.3 p15.3 GALNTL4 90735 No 
Educational Attainment 6 rs2523949 29917591 5.6092 0.49 0.09 29.34-30.77 p22.1-p21.33 HLA-A 3929 No 
Educational Attainment 9 rs7850169 24152518 6.1377 0.5 0.15 23.52-25.26 p21.3 ELAVL2 326454 Yes 
Educational Attainment 9 rs10967133 25942793 5.1814 0.5 0.14 25.56-27.34 p21.3-p21.2 LOC100506422 123878 Yes 
Educational Attainment 9 rs527427 22748466 4.7856 0.5 0.13 20.61-27.34 p21.3-p21.2 FLJ35282 0 Yes 
Educational Attainment 12 rs987019 63311148 5.539 0.51 0.14 63.16-64.19 q14.2 PPM1H 0 No 
Educational Attainment 12 rs11175348 64740578 5.028 0.51 0.13 63.05-66.42 q14.1-q14.3 C12orf56 0 No 
Height 2 rs1371040 148165153 5.145 0.92 0.09 143.93-149.93 q22.2-q23.2 ACVR2A 437415 No 
Height 7 rs2240090 51096974 5.3466 0.92 0.09 46.71-52.72 p12.3-p12.1 COBL 0 Yes 
Height 10 rs7089663 71652580 5.0763 0.92 0.09 71.39-73.24 q22.1 COL13A1 0 No 
Height 11 rs921443 57902114 4.645 0.92 0.07 56.91-59.81 q12.1 OR9Q1 0 No 
Height 15 rs2439359 66887723 5.2906 0.92 0.09 65.21-67.68 q22.31-q23 LCTL 29887 No 
Height 15 rs1994534 63226015 5.2442 0.92 0.09 62.86-68.07 q22.2-q23 TLN2 89185 No 
Sodium 11 rs4936111 130573050 5.187 0.26 0.12 130.22-130.65 q24.3 SNX19 172714 No 




4.3.3.3 Linkage Results Obtained with IBD Coefficients Calculated by the Pedigree-free 
Method of IBDLD (GIBDLD) 
 In this section, I present the regions that passed the suggestive LOD significance threshold 
(unadjusted for the number of traits analysed) within Orkney and Vis. There are 8 loci that 
reach the suggestive significance threshold in Orkney and 4 in Vis, and there is some overlap 
with GWAS and RH results. Only one hit has a LOD score that passes the GWS threshold, so 
all hits that exceed the suggestive LOD significance threshold are shown in Table 13. 
The pedigree-free linkage analysis was performed using IBD coefficients calculated by the 
pedigree-free method of IBDLD (GIBDLD), between all genotyped pairs at all SNPs. For each 
pair, IBD coefficients were calculated at every genotyped SNP, and within every 2.5 cM 
interval across the genome, these IBD coefficients were averaged across all SNPs falling into 
that region. Whole-genome IBD coefficients between every genotyped pair were also 
calculated by GIBDLD. These regional and whole-genome IBD matrices were then used by 
SOLAR to perform linkage analysis. 
If a region’s LOD score exceeded the suggestive genome-wide significance threshold, linkage 
analysis was re-run separately using each SNP within that region (that is, without averaging 
IBD coefficients over SNPs in the 2.5 cM region).  
The top hits identified in the pedigree-free linkage analysis do not appear in the pedigree-based 
linkage analysis results, but some of the peaks identified here overlap with loci flagged by 
GWAS, indicating that this method may be capturing some population-level IBD sharing. I 
briefly discuss some of the hits identified with pedigree-free linkage analysis in section 4.4.4 





Table 13 - Loci that reached the uncorrected GWS threshold with pedigree-free linkage analysis, using IBD coefficients 
calculated by IBDLD 
The regions with the highest LOD scores are shown, with the start and end positions (in bp) of these regions indicated. The total trait heritability (h2) and 
heritability explained by the region (h2Reg), as output by SOLAR, are shown. Within each region, the SNP that had the highest LOD score in individual 
SNP analysis is shown. 2.5 cM regions were numbered sequentially from the start of each chromosome, and the chromosome and region number are 
shown in the “Region” column. The last column shows if the locus has been associated with the relevant trait in the literature. 




Reg Band rsID Pos SNP_LOD Known? 
Orkney 
Axial 
length1 8 8_33 57560788 59785090 3.5578 0.64 0.07 q12.1 rs2939966 59066247 3.5353 
No 
Fibrinogen 11 11_8 7909715 10372041 3.579 0.28 0.09 p15.4 rs3751050 9091244 3.3997 No 
HDL 16 16_29 55535678 56696613 4.5121 0.49 0.05 q12.2 rs7189840 56683626 5.2585 No 
Height 3 3_68 153057662 155051740 3.6363 0.7 0.04 q25.2-q25.31 rs1025192 154827787 4.4078 No 
Systolic BP 19 19_42 56767367 57747455 3.7334 0.22 0.05 q13.43 rs1860565 57335022 4.0186 No 
Uric acid1 4 4_10 8384752 11408142 4.2712 0.4 0.04 p16.1-p15.33 rs7685513 9728599 5.1457 Yes 
Uric acid2 4 4_10 8384752 11408142 4.6392 0.41 0.04 p16.1-p15.33 rs7685513 9728599 5.0944 Yes 
Uric acid2 11 11_28 57901987 60858840 3.4616 0.41 0.05 q12.1-q12.2 rs7925914 59708244 3.7537 No 
vWF 9 9_67 135670467 136511711 10.4832 0.55 0.11 q34.13-q34.2 rs574347 136135659 11.0415 Yes 
Vis  
Axial 
length1 1 1_67 149401422 153179458 4.7575 0.36 0.15 q21.2-q21.3 rs1332506 152724053 5.1656 
No 
Axial 
length2 1 1_67 149401422 153179458 4.7332 0.33 0.15 q21.2-q21.3 rs873775 152692472 4.506 
No 
Pulse 
Pressure 14 14_34 88727479 90015642 3.4585 0.33 0.09 q31.3-q32.11 rs17714667 89550378 3.62 
No 
Calcium 14 14_11 32847232 33600856 3.5881 0.13 0.1 q12-q13.1 rs2103781 33258553 3.5635 No 
Height 15 15_24 37968377 39155424 3.7772 0.76 0.1 q14 rs11629949 38717660 3.9326 No 
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4.3.4 Meta-analysis Results 
The meta-analysis results for pedigree-based linkage analysis are presented in Table 14, 
while Table 15 shows the results obtained when grouping cohorts based on geographical 
location. Only results exceeding the GWS threshold (LOD>4.84 or logP>5.93) are listed in 
these tables, while Supplementary Table 4 and Supplementary Table 5 list the results that 
exceed the suggestive but not the genome-wide significance threshold in the joint and 
geographical location-based meta analyses. Table 16 shows all the pedigree-free linkage 
meta-analysis results that pass the suggestive significance threshold. 
When all cohorts are included in the meta-analysis, 15 regions yield meta-analysis test 
statistics that exceed the genome-wide significance threshold. While most of these are due to 
strong signals in one cohort, 4 regions resulted in per-cohort LOD scores of at least 1 in at 
least 2 different cohorts. Of note, sometimes the position of the point with the highest LOD 
score in a cohort-level analysis is not the same as the position of the peak in the meta-analysis, 
and this is discussed in more detail at the end of section 4.4.5. 
Meta-analysis restricted to the Croatian or Scottish island populations identifies no loci that 
contain a signal in both cohorts, as the meta-analysis signals that pass the GWS threshold 
originate from strong signals in one cohort only. The Scottish cohorts meta-analysis reveals 4 
height-linked loci that segregate in GS and one (but not both) Scottish island populations. 
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Table 14 - Meta-analysis results that exceed the genome-wide significance threshold in pedigree-based linkage analysis 
The meta-analysis -log10(p-value) is indicated (logP column) for each peak. These peaks represent a 0.1 cM interval that starts at the cM position indicated 
(cM column). The start and end positions of the region surrounding these peaks where the meta-analysis test statistic continuously exceeded the suggestive 
significance threshold (logP>4.43) is indicated in cM (Reg_cM) and Mbp (Reg_Mbp), as is the chromosome band where these regions can be found. The 
per-cohort LOD scores in the 0.1 cM peak region are indicated in the last columns (O = Orkney, S=Shetland, G=Generation Scotland, V=Vis, K=Korčula), 
and the intensity of the green shading corresponds to the magnitude of the LOD score (darker green = higher LOD score). The last column shows if the 
locus has been associated with the relevant trait in the literature. 
Trait 
Chr cM logP Band Reg_cM Reg_Mbp O S G V K Known? 
Central Corneal Thickness 12 157.6 7.19 q24.32 157.5-157.7 128.06-128.11 0 0.4 NA 7.79 0 No 
Educational Attainment 6 50.8 6.63 p22.1-p21.33 50-51.3 29.34-31.34 1.32 0 3.85 0.12 1.99 No 
Forced Vital Capacity 1 105.1 7.03 p31.1 105-105.2 76.1-76.57 0.14 0.6 1.08 6.07 0 Yes 
GGT 19 94.3 8.88 q13.42 94.2-94.4 54.41-54.45 0.68 0.02 NA 8.41 NA No 
GGT 19 95 7.31 q13.42 94.9-95.1 54.58-54.68 0.62 0.06 NA 6.73 NA No 
Glucose 4 185 6.06 q34.1 182.1-185.7 173.01-175.79 1.06 4.36 0 0.04 1.34 No 
HbA1c 8 103.8 7.03 q21.12-q21.13 102.2-105.2 79.83-83.18 0.3 7.19 NA 0.2 0.01 No 
HDL 18 87.5 6.07 q21.33 86.5-87.9 60.82-61.34 0.38 3.47 2.99 0.03 0 Yes 
Height 15 89.8 6.03 q22.31 88.4-90.3 65.37-67.04 0.17 0.04 5.29 0.2 1.04 No 
Lens Thickness 7 68.7 7.32 p14.1-p13 68.6-68.8 43.28-43.43 NA NA NA 7.17 0 No 
Lens Thickness 7 69.1 7.20 p13 69-69.2 43.48-43.56 NA NA NA 7.05 0 No 
Total Cholesterol 6 81.1 6.12 p11.2-q12 80.5-81.3 57.27-64.61 0.39 0 5.7 0.25 0.59 No 
Urea 9 101.6 7.55 q21.32-q21.33 101.3-101.7 86.87-87.23 0.5 0 0.08 7.8 NA No 
Urea 9 100.6 7.02 q21.32 100.5-100.7 86.18-86.34 0.05 0 0.01 8.05 NA No 
Urea 9 63.9 6.43 p13.2 63.8-64.2 38.3-38.4 0.07 0 0.23 6.93 NA No 
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Table 15 - Meta-analysis results that exceed the genome-wide significance threshold in pedigree-based linkage analysis, with 
cohorts grouped by geographical location 
The meta-analysis -log10(p-value) is indicated (logP column) for each peak. These peaks represent a 0.1 cM interval that starts at the cM position indicated 
(cM column). The start and end positions of the region surrounding these peaks where the meta-analysis test statistic continuously exceeded the suggestive 
significance threshold (logP>4.43) is indicated in cM (Reg_cM) and Mbp (Reg_Mbp), as is the chromosome band where these regions can be found. The 
per-cohort LOD scores in the 0.1 cM peak region are indicated in the last columns (O = Orkney, S=Shetland, G=Generation Scotland, V=Vis, K=Korčula), 
and the intensity of the green shading corresponds to the magnitude of the LOD score (darker green = higher LOD score). The last column shows if the 
locus has been associated with the relevant trait in the literature. 
Trait - Croatia Chr cM logP Band Reg_cM Reg_Mbp V K Known?  
Central Corneal Thickness 12 157.6 7.93 q24.32 157.5-157.7 128.06-128.11 7.79 0 No  
Forced Vital Capacity 1 105.1 6.25 p31.1 105-105.2 76.1-76.57 6.07 0 Yes  
Lens Thickness 7 68.7 7.32 p14.1-p13 68.6-68.8 43.28-43.43 7.17 0 No  
Lens Thickness 7 69.1 7.20 p13 69-69.2 43.48-43.56 7.05 0 No  
Trait - Scotland Chr cM logP Band Reg_cM Reg_Mbp O S G Known? 
Educational Attainment 6 50.4 6.21 p22.1 49.8-50.6 28.26-30.37 0.6 0.05 5.61 No 
Forced Vital Capacity 9 101.9 6.16 q21.33 101.6-103.3 87.09-88.1 0.51 0.89 4.54 No 
HbA1c 8 104 7.96 q21.12-q21.2 102.2-106.7 79.83-85.64 0.31 7.21 NA No 
HDL 18 87.5 7.09 q21.33 86.4-87.9 60.78-61.34 0.38 3.47 2.99 Yes 
Height 2 167.8 6.27 q22.3-q23.2 166.4-169.1 145.3-149.93 1.23 0 5.14 No 
Height 5 61.2 6.42 p13.1 60.9-61.5 40.29-41.3 0.28 2.26 3.64 No 
Height 15 75.8 6.23 q21.3 75.5-77.5 56.32-58.1 0 2.8 3.41 No 
Height 17 86 6.46 q22-q23.2 84.2-88.1 55.85-60.54 1.9 0.01 4.54 No 
           






Trait - Scottish Isles Chr cM logP Band Reg_cM Reg_Mbp O S 
Known?  
Diastolic BP 2 22.7 6.48 p25.1 19.2-25.8 8.64-11.23 6.23 0.01 No  
Glucose 4 185 6.05 q34.1 182.1-185.7 173.01-175.79 1.06 4.36 No  
Glucose_nodiab 4 185.3 6.25 q34.1-q34.2 182.1-186.6 173.01-176.57 1.2 4.41 No  
HbA1c 8 104 7.96 q21.12-q21.2 102.2-106.7 79.83-85.64 0.31 7.21 No  
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Table 16 - Meta-analysis results of pedigree-free linkage analysis 
The meta-analysis -log10(p-value) is indicated (logP column) for each peak. These peaks represent a 2.5 cM interval whose start and end positions are 
indicated in Mbp (Mbp column), and which start at the cM position indicated (cM column). The start and end positions of the region surrounding these 
peaks where the meta-analysis test statistic continuously exceeded the suggestive significance threshold (logP>4.43) is indicated in cM (Reg_cM) and 
Mbp (Reg_Mbp), as is the chromosome band where these regions can be found. The per-cohort LOD scores in the 0.1 cM peak region are indicated in 
the last columns (O = Orkney, V=Vis), and the intensity of the green shading corresponds to the magnitude of the LOD score (darker green = higher LOD 
score). The last column shows if the locus has been associated with the relevant trait in the literature. 
Trait Chr cM Mbp logP Band Reg_cM Reg_bp O V Known? 
Axial length1 1 165 149.4-153.18 5.26 q21.2-q21.3 162.5-167.5 147.64-153.18 0.1 4.76 No 
Axial length2 1 165 149.4-153.18 4.99 q21.2-q21.3 162.5-167.5 147.64-153.18 0 4.73 No 
Pulse Pressure 14 82.5 88.73-90.02 4.46 q31.3-q32.11 80-85 85.93-90.02 0.45 3.46 No 
GGT 22 22.5 24.41-25.93 5.87 q11.22-q12.1 20-25 23.4-25.93 2.21 2.97 Yes 
HDL 16 70 55.54-56.7 4.73 q12.2 67.5-72.5 54.53-56.7 4.51 0 No 
LDL 19 67.5 43.87-45.23 4.49 q13.2-q13.32 65-70 41.17-45.23 3.26 0.64 Yes 
Uric acid1 4 22.5 8.38-11.41 7.11 p16.1-p15.33 20-25 7.67-11.41 4.27 2.15 Yes 
Uric acid1 11 77.5 69.79-71.31 4.45 q13.2-q13.4 75-80 68.16-71.31 3.33 0.54 No 
Uric acid2 4 22.5 8.38-11.41 7.15 p16.1-p15.33 20-25 7.67-11.41 4.64 1.84 Yes 




4.4.1 IBD Estimation 
Genome-wide kinship is more accurately estimated with the help of genetic data and IBD 
sharing matrices estimated this way give a more accurate representation of genetic kinship 
compared to pedigree-based genome-wide kinship estimates, as shown in Figure 16. This is 
because pedigree-based kinship estimates will always assume the same fixed kinship-value for 
a specific relative pair type, e.g. full siblings will always have 2Φ =0.5 (assuming no 
inbreeding) according to a social pedigree, but the true amount of genetic sharing can vary 
widely – between 0.36 and 0.63 in Orkney, which is in line with the sib pair empirical genome-
wide IBD coefficient that ranged between 0.374 and 0.617 according to one study of 4401 
siblings [142]. 
IBDLD offers many benefits for IBD coefficient estimation compared to Loki. The fact that 
IBDLD can use compressed PLINK files, as opposed to a highly specific format and 
uncompressed files, reduces the space needed to store the files, as well as the time required to 
pre-process them. Its LD-RR method can handle large and complex pedigrees without the need 
to clip these to a certain bit-size, which offers a substantial increase in power, especially in 
Orkney and Shetland, which have very detailed pedigrees spanning 35 generations. Because 
it explicitly models LD, genotype data do not need to be pruned and, in fact, denser marker 
data allow for IBD coefficients to be estimated more accurately, picking up IBD segments that 
might otherwise have been missed [39]. Since IBD coefficients can be output at any or all 
genotyped SNPs, this also offers an increase in resolution for linkage analysis, with the caveat 
that IBD segments shorter than 3 cM cannot reliably be detected.  
One slight drawback is that IBDLD does not offer the option to output files directly into 
SOLAR format, so some additional downstream processing is required. However, this offers 
more flexibility in manipulating the IBD files for other purposes. Also, newer versions of 
SOLAR accepts as input file formats where individual IDs do not need to be coded using 
SOLAR’s internal system, which greatly facilitates file manipulation and accessibility. 
One issue with using regional IBD coefficients that only include pairs of individuals that are 
related according to the social pedigree is that while two individuals may share only a very 
small proportion of their genome overall, they might still share loci that were inherited from 
the same common ancestor, as shown in Figure 17. The IBD coefficients calculated by Loki 
therefore incorrectly indicate pairwise IBD sharing between such pairs is 0 at every locus, 
which may dilute the linkage signal. IBDLD’s GIBDLD (pedigree-free) method is attractive 
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in principle to circumvent this problem by estimating IBD sharing probabilities along the 
genome without the need for a social pedigree.  
The fact that GIBDLD accurately detects shared haplotypes between distantly related 
individuals is encouraging and adds to the power to detect a QTL with the help of pedigree-
free linkage analysis – these examples of IBD sharing would go unnoticed if pedigree-based 
linkage analysis was used. However, it could be seen that sometimes, GIBDLD yields IBD 
coefficients that are incorrect when compared to the phased data. The parameters that 
GIBDLD uses to estimate LD (instructing it to utilise SNPs in the previous 2.5 cM as well as 
the previous 10 SNPs) were kept constant within my analyses, but by systematically modifying 
these parameters, better insight could be gained about the performance of GIBDLD. 
While IBDLD circumvents the software limitation for IBD estimation and allows for IBD 
estimation between all pairs of individuals in the data, the linkage analysis process still 
experiences a bottleneck with SOLAR. In Orkney, SOLAR takes 8 minutes to calculate 
linkage statistics in each region, because each region contains IBD coefficients for 2055378 
pairs of individuals. This means that calculating linkage statistics at each individual SNP 
across the entire genome is currently unfeasible. Additionally, SOLAR fails to estimate the 
reference polygenic model when presented with the Korčula whole-genome kinship matrix 
(3649051 pairs) and a phenotype that is present in all 2701 individuals, and this is the upstream 
step that needs to be performed prior to linkage analysis.  
This is one of the reasons for using regional, rather than per-SNP, IBDs to test pedigree-free 
linkage analysis in Orkney and Vis. Regional IBD sharing is calculated by averaging the IBD 
sharing at all SNPs within each 2.5 cM region, for every pair of genotyped individuals. Loki 
also outputs the average IBD sharing at 2.5 cM intervals, but it uses LD-pruned data and does 
not output per-SNP IBD estimates, making follow-up by fine-mapping impossible.  
Using 2.5 cM intervals is also biologically and statistically meaningful: while the probability 
of IBD sharing decreases exponentially with the number of meioses, the length of shared 
segments only decreases linearly, so if a segment is shared IBD between distant relatives, this 
segment tends to be large [126]. It has been shown that IBD segments spanning 3 cM or more 
can accurately be inferred and give rise to fewer false positives [39, 127]. Additionally, I show 
that GIBDLD can sometimes give rise to false positive estimates of IBD sharing at specific 
SNPs (Section 4.3.1.3). Therefore, we have higher confidence that pairs who have high 
average regional IBD sharing (which is a result of high IBD sharing throughout all markers in 
the 2.5 cM region) really do share that segment IBD, and averaging the IBD sharing across 
the 2.5 cM regions also reduces noise due to sporadically high IBD sharing that is not 
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consistent throughout the region and may be the result of false positive IBD sharing estimates 
(Figure 24). 
4.4.2 Linkage Analysis 
As presented in Chapter 7, the results obtained with pedigree-based linkage analysis do not 
correlate well with those obtained using the pedigree-free linkage analysis, RH or GWAS. In 
contrast, the pedigree-free linkage analysis results show higher correlation with the results of 
RH and GWAS, and some results indicate that this method is capable of identifying signals 
originating from common variants, as long as these have large effects on a trait. The presence 
Figure 24 - True vs sporadic regional IBD sharing 
Where there is true IBD sharing across a 2cM region, the average IBD in that region will be 
high, due to the IBDs being consistently high at all markers within that region (top). The low 
average regional IBD sharing reduces the effect of high IBD sharing values that are incorrectly 




of loci identified with pedigree-free linkage analysis that do not show a signal with either RH 
or GWAS, however, suggests that there may be some additional QTLs segregating in the 
general population that linkage analysis is better suited to discovering. 
4.4.3 Pedigree-based Linkage Analysis 
With pedigree-based linkage analysis using IBD coefficients calculated by Loki, 16 regions 
have LOD scores exceeding 3.41, which is the suggestive significance threshold that is not 
corrected for the number of traits analysed. All but 4 of these regions exceed this LOD 
threshold in the pedigree-based linkage analysis that uses IBD coefficients calculated by 
IBDLD’s pedigree-based method (LD-RR), showing good agreement between the two 
methods of local IBD coefficient estimation. The hits that are missed are the refractive error 
(SER) hit on chromosome 22 in Shetland, the gamma-glutamyl transferase hit on chromosome 
10 in Vis, the central corneal thickness hit on chromosome 13 in Korčula and the alcohol 
consumption hit on chromosome 9 in Generation Scotland. Conversely, when a pedigree-
based linkage analysis is done using IBD coefficients calculated by IBDLD (the pedigree-
based, LD-RR method), a total of 158 loci pass the suggestive significance threshold, with 
over half of these originating in Generation Scotland, the cohort that has the highest power to 
detect linkage signals. This could be a consequence of the fact that IBD coefficients calculated 
by Loki were output at 2.5 cM intervals, while with IBDLD, they were output at 0.1 cM 
intervals, allowing the detection of smaller shared segments. With the Loki IBD coefficients, 
only a single region exceeds the significance threshold corrected for the number of traits 
analysed, while using the IBDLD IBD coefficients, 27 such regions are identified. Strangely, 
most of these originate in either Generation Scotland (the highest-powered cohort) or Vis (the 
lowest-powered cohort), with only a single hit originating in Orkney and Shetland, and no hits 
originating in Korčula. The reason for this is unclear and the hits in Vis should be treated with 
caution. 
With pedigree-based linkage analysis, the loci with LOD scores that exceed the trait-corrected 
multiple testing threshold generally explain a high proportion of the trait variance in Vis (25-
64%) while in Generation Scotland, they explain between 7 and 15% of the trait variance. This 
was expected, given the results of the power calculations that show that Vis is very under-
powered to detect a QTL effect unless it explains >40% of the trait variance, while Generation 
Scotland is powered to detect QTL effects explaining >8% of the trait variance. This, and the 
little overlap between pedigree-based and pedigree-free linkage analyses, casts some doubt on 
the “true positiveness” of the results. Some replication of signal across studies would lend 
more confidence in the regions implicated. Sequencing the regions flagged by these analyses, 
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or performing whole genome sequencing at the cohort level could help pinpoint the location 
of QTLs giving rise to these signals. Such sequencing efforts are currently being undertaken 
but were not completed before the due date of this thesis. 
In Generation Scotland, many regions across the genome show linkage to height. This is not 
unexpected, as height is the best-documented, highly-polygenic and highly heritable complex 
trait. It is interesting that the hits identified with linkage analysis are different to the ones 
identified by genome-wide association studies on the same cohort [62]. The peak on 
chromosome 7 is less than 500kb away from GWAS hits reported in the GWAS catalog [16] 
and the smaller peak on chromosome 15 is ~800kb away from a GWAS hit reported in the 
GWAS catalog, but in general, most loci identified with linkage analysis do not overlap with 
those identified by large-scale GWAS, despite the fact that over 180 loci have been found to 
associate with height [22]. This may suggest the presence of allelic heterogeneity with rare 
variants that are not tagged by common, genotyped markers and are not well-imputed, or 
variants segregating within some families, but not at the population level. 
In the case of the pedigree-based linkage results that were obtained using regional IBD 
coefficients calculated by IBDLD, it can often be seen that if the LOD score at the peak is 
high, the 2-LOD drop region around the peak encompasses only a single gene region. 
Generally, a clear relationship cannot be established between what is known about the function 
of these genes and the phenotype they appear to be linked to. However, below are some 
examples where such a functional relationship has been established experimentally, which 
lend some confidence to the accuracy of these results and encourages the functional follow-up 
of (some of) these hits.  
In Orkney, there is a strong hit on chromosome 2 for diastolic blood pressure (LOD 6.26). 
This signal is strongest within the YWHAQ (Tyrosine 3-Monooxygenase/Tryptophan 5-
Monooxygenase Activation Protein Theta) gene and studies have shown experimentally an 
interaction between this gene and blood pressure. YWHAQ is expressed in the heart and in 
neurons and has been shown to interact, and be co-expressed, with the ATP2B calcium 
regulator gene family, members of which have been found to associate with blood pressure in 
European and Asian individuals [143]. SNPs within this gene were associated with changes in 
heart rate following a 20-week endurance training regime [144] in a GWAS study of 483 
individuals belonging to 99 families. Methylation levels at the YWHAQ promoter have been 
shown to affect blood pressure in individuals with preeclampsia [145]. 
In Vis, the analysis of gamma-glutamyl transferase (GGT) levels yields a signal in the 
54,272,420-54,759,571 interval on chromosome 19. This is a gene-rich region that harbours a 
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cluster of leukocyte and killer cell immunoglobulin-like receptor genes, voltage-dependent 
calcium channel gene subunits and additionally, the NDUFA3 (NADH:Ubiquinone 
Oxidoreductase Subunit A3) gene. The NDUFA3 gene has been implicated in the progression 
of non-alcoholic fatty liver disease, which is often associated with metabolic syndrome [146]. 
GGT levels are used to assess liver function and can aid in the diagnosis of metabolic 
syndrome, as higher levels of GGT correlate with the prevalence of metabolic syndrome [147]. 
In Generation Scotland, the 20,610,914-27,344,662 interval on chromosome 9 is linked to 
educational attainment and its highest point falls within the ELAVL2 gene. A SNP in this 
region (rs1360382, at 23,379,721) has been identified by a GWAS of educational attainment 
performed on 106,000 individuals [148]. The ELAVL2 gene encodes a neuron-specific RNA 
binding protein that is highly expressed in the brain and its down-regulation led to a change in 
the expression and splicing of genes related to autism spectrum disorders, such as RBFOX1 
and FMRP, as well as genes involved in neurodevelopment and synaptic function [149]. It has 
also been shown to interact with transcripts linked to Alzheimer’s disease, affecting their 
splicing [150]. 
Within the same cohort and the same trait, there was also a peak on chromosome 12, in the 
63,048,066-66,422,374 interval. The gene at the apex of this peak, PPM1H, is highly 
expressed in brain and it contains a pseudogene (GAPDHP44) that contains SNPs that 
associate with late-onset Alzheimer’s disease [151]. Additionally, other linkage studies have 
also indicated that this region is linked to late-onset Alzheimer’s disease [152, 153].  
Also of interest is the sodium peak on chromosome 11 in GS. The SNX19 (sorting nexin 19) 
gene in this region affects insulin secretion and homeostasis by preventing insulin-containing 
vesicles in the pancreatic beta-cells [154]. There is evidence that increased insulin levels lead 
to sodium retention in healthy individuals [155], increasing sodium reabsorption by 
modulating the activity of sodium channels in the kidney [156].  
4.4.4 Pedigree-free Linkage Analysis 
From the results of the pedigree-free linkage analysis, it can be seen that in most cases, the 
LOD score of the region is lower than the LOD score of a single SNP within the region. This 
may indicate that IBD sharing at a specific position within that region is most strongly linked 
to a QTL, and the IBD sharing diminishes throughout the region, diluting this signal. 
Sometimes, however, the regional LOD score is higher than any of the LOD scores obtained 
from single SNPs within that region, indicating that such regions may harbour several causal 
loci as no IBD sharing at any one SNP explains as much variance as the average regional IBD 
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sharing. Some individuals in the population may carry one QTL, while a different subset may 
carry the other QTL, giving rise to allelic heterogeneity and the regional IBD sharing better 
represents this than the IBD sharing at any one SNP. 
In general, the amount of trait heritability explained by a GWS region in the pedigree-free 
linkage analysis, where all pairs of individuals are used, is more modest than the amount of 
heritability explained by the IBD sharing patterns between closely related individuals in GWS 
hits reported using the pedigree-based linkage analysis. Where the pedigree-free linkage 
analysis identifies regions that were also reported in GWAS (such as the SLC2A9 locus for 
uric acid and the ABO locus for von Willebrand factor), the proportion of heritability explained 
by these regions matches those quoted in the GWAS literature.  
In the Orkney pedigree-free linkage, the chromosome 16 peak for HDL cholesterol is adjacent 
to the CETP (cholesteryl ester transfer protein) gene which has been implicated by association 
in many HDL GWAS. CES1 (carboxylesterase1) and CES5A (carboxylesterase 5A) are within 
the region itself and have been shown to participate in cholesterol ester metabolism [157]. This 
peak also contains a cluster of metallothionein genes which have been implicated in preventing 
the development of obesity. Specifically, metallothionein-2 null mice that were fed a high-fat 
diet showed a greater increase in body weight and plasma cholesterol than null mice on a 
control diet, or mice without the knockout on a high-fat diet [158]. Interestingly, no variants 
within these two genes have been found to associate with HDL cholesterol in published 
GWAS. 
In Orkney, the chromosome 19 peak for systolic blood pressure falls into a cluster of zinc 
finger protein genes. Zinc finger proteins have previously been implicated in the modulation 
of blood pressure [159], and it has been shown that differential methylation of zinc finger 
genes is associated with changes in blood pressure due to drops in temperature [160]. One of 
the zinc finger genes in this region, ZNF667, is also known as ‘myocardial ischemic 
preconditioning upregulated ortholog 1’, and it is named after the same gene discovered in 
mice, where it is abundantly expressed in the heart and has been implicated in maintaining 
vascular homeostasis, and is upregulated during myocardial ischemia [161]. Several of the 
zinc finger proteins in this region are expressed in the nervous system, and are involved in 
neuronal processes, being implicated in amyotrophic lateral sclerosis and alternating 
hemiplegia of childhood (a neurological condition that causes temporary paralysis in all or 
parts of the body). Since blood pressure is regulated by the sympathetic nervous system, this 
locus presents an attractive candidate for follow-up studies. 
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The chromosome 11 peak for serum uric acid levels in Orkney lies 3.5 Mb away from the 
SLC22A12 gene, which is a urate anion exchanger [105]. The same region has been identified 
with a variance component linkage study on American Indians [162], and associations with 
SNPs in the SLC22A12 region have been reported in GWAS of African [163], Japanese [164] 
and European [114] individuals. This is also the site of the unusual signal detected with the 
HRC imputation GWAS in Orkney, where associations were detected with low-frequency 
SNPs in the 46-72 Mb region. Re-running the linkage analysis by fitting the genotype of 
rs370311822, the top GWAS SNP, as a covariate causes the trait heritability to drop from 0.41 
to 0.375 and the LOD score of this region also drops to 0.83. Interestingly, the SNP that has 
the overall highest LOD score in this region in the pedigree-free linkage analysis, rs7925914, 
has a p-value=0.99 in the HRC GWAS in Orkney, and the two SNPs are not in LD (R2=0, 
D’=0.35) in this cohort. Conditioning on this SNP has no effect on the pedigree-free linkage 
analysis results.  
Pedigree-free linkage analysis of serum uric acid levels in Orkney identifies the SLC2A9 
region that is also identified with GWAS and RH. SLC2A9 encodes a well-characterised 
transporter protein affecting serum uric acid levels [69], and common variants explaining 1.7-
5.3% of the trait variance have been described in trans-ethnic studies. Conditioning on the top 
GWAS SNP, rs11723439, causes the heritability to drop from 0.41 to 0.40 and the LOD score 
to drop from 4.63 to 2.92. This means that the common variant explains 2.5% of the trait 
heritability (1% of the trait variance) in Orkney, and, because it fails to account for the entire 
linkage peak signal, suggests that other independent QTL effects are also present in this region. 
Similarly, linkage analysis of von Willebrand factor identifies the ABO locus, which also 
yielded strong signals with GWAS and RH, and this is discussed in more detail in section 
7.1.4. Briefly, re-running the linkage analysis while conditioning on rs514659, the SNP with 
the most significant p-value in the GWAS, causes the heritability to drop from 0.62 to 0.51. 
This is in line with the results obtained from the simulation studies in Chapter 6, that show 
that a QTL needs to explain around 10% of the trait variance to be consistently detected with 
pedigree-free linkage analysis in Orkney. When conditioning on rs514659, the LOD score 
drops from 10.48 to 1.24, so this common SNP explains the majority of the pedigree-free 
linkage signal. The interaction between ABO blood types and von Willebrand factor levels has 
been known for over 40 years [165] and this locus is consistently identified in von Willebrand 
factor GWAS [166] and linkage analyses [167], explaining around 30% of the heritability of 
this trait [1]. 
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4.4.4.1 Axial Length in Orkney 
In Orkney, the chromosome 8 peak in the pedigree-free linkage analysis of eye axial length 
contains 7 genes (Figure 25). In the axial length GWAS using imputed genotypes in Orkney, 
the SNP with the lowest p-value (-log10(p-value)=3.83) is rs79194994, located between 
CYP7A1 and SDCBP. The GWAS catalog reports several associations with refractive error 
and astigmatism, myopia and hyperopia, ocular disorders that arise because the eye is not the 
right length in relation to its refractive ability, in the region upstream of TOX (just outside the 
linkage region, also shown in Figure 25) [168–171], but no linkage signal is detected at this 
locus when analysing refractive error in Orkney. Despite the GWAS catalog hits being 
upstream of TOX, one of these studies [168], which is a large GWAS meta-analysis of eye 
traits from the CREAM consortium, proposes SDCBP (syndecan binding protein, syntenin-1) 
as the most likely candidate in this region, especially because associations are also detected 
with SNPs in CLSTN2 (calsyntenin-2) on chromosome 3, indicating a potential role for 
syntenins in eye morphology. SDCBP shows high expression in all eye tissues and 
microduplications in the 8q12-8q13 region have been described in individuals who had Duane 
retraction syndrome, a form of strabismus (cross eye) that is often associated with short eyes 
[172].  
The presence of a cluster where there is an increased amount of IBD sharing could help narrow 
down the location of the QTL contributing to the linkage signal in this region. IBD coefficients 
calculated at every SNP in this region by GIBDLD were used to assess this, and Figure 25 
shows a plot of the number of alleles shared IBD in this region between pairs of individuals in 
the dataset. The plot contains 3893 pairs that were selected based on two criteria. First, they 
had to share at least one allele IBD at 10% (17) of the SNPs within this region. Second, their 
phenotypes had to be similar, where “similar” is defined as: the phenotype differences between 
the two members of each pair are calculated and only those pairs are kept where this difference 
is within half of the first quartile of the distribution of these differences. Overlaid on this plot 
is the average IBD coefficient at each SNP, calculated by using all pairs in the data, as long as 
both members had the phenotype measured. These results show that this locus has two regions 
of increased IBD sharing separated by a region of decreased IBD sharing, suggesting that it is 
the combined signals contributed by both regions that lead to this signal, which would be 
missed with single-SNP GWAS. This pattern of IBD sharing is not enough to home in on the 
location of the QTL, however. 
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Haplotype analysis was then carried out in order to identify haplotypes that segregate with this 
trait in Orkney. Using the 1000 Genomes recombination map, this region was divided into 
haplotype regions based on recombination hotspots – specifically, points where the cM/Mb 
exceeded 20 were used as the region boundaries, yielding 10 haplotype blocks in this region 
(Figure 26). Next, every genotyped SNP in each haplotype region was extracted from the 
phased Orkney genotypes, and was used to construct the segregating haplotypes. For each 
unique haplotype, every individual was assigned values of 0, 1 or 2 to indicate whether they 
carried 1, 2 or no copies of this haplotype. The residuals of the normalised phenotype, adjusted 
Figure 25 - Axial length pedigree-free linkage region in Orkney 
The grey horizontal line indicates chromosome position, in Mbp. The region of the linkage peak 
is indicated by the thick blue vertical lines. Genes are shown as blue rectangles. The location of 
rs79194994, the SNP reaching the highest -log10(p-value) in the GWAS of axial length in Orkney 
is indicated by the thin vertical blue line. SNPs reported to associate with eye traits in the GWAS 
catalog are indicated by pink vertical lines. 
The plot on top shows the number of alleles shared IBD at each genotyped SNP in this region, 
between those pairs of individuals who share at least one allele IBD at 10% (17) of the SNPs in 
this region, and whose phenotypes are similar. Dark blue colour in this plot indicates that a pair 
shares no alleles IBD at a SNP, purple colour indicates that 1 allele at a SNP is shared IBD by a 
pair, while pink colour (seen very rarely here) indicates that 2 alleles are shared IBD. The average 
IBD coefficient at each SNP, across all pairs with the phenotype measured, is overlaid on this plot 




for covariates and genetic kinship, were regressed onto these haplotype counts using a simple 
linear model.  
A haplotype within the regions containing the start of the TOX gene showed the strongest 
association (logP=3.68, 11 instances of this haplotype in Orkney, all in heterozygotes, though 
the phenotype was measured in only 5 of these). The haplotype analysis was also carried out 
in Shetland, as this is the cohort most similar to Orkney. While the haplotype identified in 
Orkney was not present in Shetland, a different haplotype in the same region yielded the 
strongest association (logP=3.93, 15 heterozygotes) out of all haplotypes across each region.  
Fitting this haplotype as a covariate in the linkage analysis caused the LOD score to drop from 
3.56 to 3.23, the heritability explained by the region to drop from 0.072 to 0.068 – indicating 
that this haplotype only explains a small proportion of the signal originating from this locus. 
Next, the expression of the 7 genes in this region was assessed using the Ocular Tissue 
Database [173], which provides gene expression values within 10 different tissues in the eye 
(Figure 27). SDCBP showed the highest levels of overall expression, followed by TOX, and 
the tissue-specific expression patterns of this genes revealed that while SDCBP is expressed 
ubiquitously throughout all eye tissues, TOX is predominantly expressed in the lens, which 
Figure 26 - Haplotypes flanked by recombination hotspots 
The cM positions of SNPs present in the 1000Genomes recombination map are plotted along 
the X axis. Each haplotype is delimited by a point where the cM/Mb recombination rate 
(plotted on the Y axis) exceeds 20. Haplotype start points are indicated with green lines, while 
their end points are indicated with red lines, and each haplotype regions is numbered 
sequentially. Genes in this region are shown with coloured horizontal lines, and the name of 




implies that TOX may have an effect on refractive error (as the lens is one of the refractive 
media in the eye), which is why hits upstream of it were detected in GWAS meta analyses of 
refractive error. 
Finally, the function of SDCBP and TOX was assessed. TOX (Thymocyte Selection Associated 
High Mobility Group Box) encodes a DNA-binding protein that plays a role T-cell 
development [174], but there are no studies of its function in relation to eye development. 
SDCBP encodes a syndecan binding protein and it is primarily localised to the membrane-
associated adherens junctions and focal adhesions, interacting with many transmembrane 
proteins. Functional enrichment of SDCBP and interacting genes shows an enrichment in 
cytoskeletal functions and ephrin receptor signalling, as well as axon guidance, 
phototransduction, retinoid metabolism, cell adhesion and extracellular matrix development. 
Ephrins affect neuronal, vascular and epithelial development and are especially involved in 
axon guidance [175]. Interestingly, neuronal functions are intimately linked with eye 
morphology. Axial length is not fixed, increasing until humans each adulthood, and decreasing 
Figure 27 - Gene expression in the Ocular Tissue Database 
This figure shows the expression levels of the 7 genes within the linkage region, normalised to 
account for the use of different arrays and expressed in PLIER (Probe Logarithmic Intensity 
Error) scores. On the left is an aggregate PLIER score for each gene, obtained by summing the 
PLIER scores reported for 10 different eye tissues. On the right, eye tissue-specific PLIER 




with old age, but it also shows circadian changes. The eye needs to adjust to this change in 
length in order to ensure that the images are focused on the focal plane of the retina and it is 
suggested that this happens through an active emmetropisation mechanism by altering the 
extracellular matrix composition of the sclera [176]. The fact that SDCBP and its interacting 
gene partners are enriched in functions pertaining to extracellular matrix development and cell 
adhesion is an encouraging sign that this gene could really effect axial length. 
4.4.5 Meta-analysis 
The results of the meta-analysis reveal regions where several cohorts contribute weak signals 
that would have gone unnoticed if the results were only analysed within each cohort separately. 
In some cases, these signals appear in cohorts that are geographically distant, suggesting the 
presence of common variants present in all these cohorts, or the presence of cohort-specific 
QTLs segregating in the same region.  
For example, Orkney, GS and Korčula all contribute to the educational attainment peak on 
chromosome 6. This peak is within the major histocompatibility complex (MHC) region and 
one case-control study fine-mapped a QTL in this region using individuals with extremely 
high intelligence in an attempt to identify QTLs influencing IQ, and while one variant passed 
their study-wide significance threshold, it failed to explain a large proportion of trait variance 
[177]. A large meta-analysis of GWAS of educational attainment using SNPs imputed to the 
1000 Genomes reference panel identified several associated common variants 3-10Mb away 
from this region [104]. The peak region contains three genes, MUC21, STFA2 and DPCR1, 
none of which have obvious links to cognitive functions or intelligence. 
Meta-analysis of fasting glucose levels identifies a peak at the 4q34.1 locus, with signals 
contributed by the Orkney, Shetland and Korčula studies. This locus has been linked to type 2 
diabetes with obesity in a study of Korean individuals, where the region was identified with 
whole-genome linkage analysis and this region was then fine-mapped with association 
analysis [178]. The 0.1 cM peak encompasses a single gene, HPGD (hydroxyprostaglandin 
Dehydrogenase 15-(NAD)). One study suppressed diabetes in mice with the help of Isaria 
sinclarii, a fungus cultured on silkworm, and studied the subsequent changes in gene 
expression [179]. Isaria sinclarii produces myriocin, which modulates the sphingosine-1-
phosphate receptor, and sphinghosine-1-phosphate is an upstream regulator of prostaglandin 
production [180]. The researchers found that the drop in glucose levels correlated with the 
drop in HPGD expression, suggesting a possible role for the HPGD gene product in regulating 
glucose levels.  
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Conversely, some signals are only present in cohorts from the same geographical region, 
suggesting the presence of region-specific QTLs that may be absent in geographically distant 
cohorts. 
For example, meta-analysis of HDL cholesterol levels reveals a region at the 18q21.33 locus. 
The three Scottish cohorts contribute to this signal (LOD = 0.38, 3.47 and 2.99 in Orkney, 
Shetland and GS, respectively), while it is absent in Vis and Korčula. The peak contains a 
single gene, VPS4B (vacuolar protein sorting 4 homolog B), but no functional associations 
between this gene and cholesterol are reported in the literature. 
The 15q21.3 peak is due to signals from GS and Shetland, and this locus contains the TCF12 
gene and part of the ZNF280D gene. TCF12 (Transcription Factor 12) is a transcription factor 
that is expressed in skeletal muscle and cardiac muscle and GWAS have identified associations 
between this gene and coronary artery disease (CAD). Its targets, identified with chromatin 
immunoprecipitation sequencing (ChIP-Seq) were enriched for growth-factor binding and 
matrix interaction functions, and TCF12 target genes are over-represented among genes 
associated with height. Short stature has repeatedly been linked to increased risk of CAD [181] 
with a Mendelian randomisation study establishing a causal link between height-affecting 
SNPs and CAD risk [182], hinting at a common pathway affecting both traits. 
Generally, the pedigree-free linkage meta-analysis results highlight regions that are primarily 
driven by the results obtained in one cohort, while a signal is either absent or very modest in 
the other cohort. Although limited to two cohorts only, this suggests the presence of cohort-
specific QTLs that are only segregating within Croatian or Scottish populations, but not both. 
One exception to this is the hit on chromosome 22 in gamma-glutamyl transferase levels. Both 
Orkney and Vis pedigree-free linkage results contribute roughly equally (but individually not 
significantly) to this peak. This region contains the GGT1 and GGT5 genes, giving support for 
this result to be a true positive as the genes are paralogs and give rise to gamma-glutamyl 
transferase enzymes. No SNPs (in the case of GWAS) or regions (in the case of RH) at this 
locus reach genome-wide significance in either cohort. However, GWAS using imputed 
genotypes in this region reveals an association with rs2330795 (MAF 36% in Orkney, 41% in 
Vis) that has a -log10(p-value) of 7.52 in both cohorts. Additionally, in Shetland, RH yields a 
sharp peak at this locus, further validating this region as a QTL for circulating GGT enzyme 
levels in a third cohort. 
The two regions that yield the strongest meta-analysis signals in the pedigree-free linkage 
analysis are the ABO region for von Willebrand factor and the SLC2A9 region for serum uric 
125 
 
acid levels, which are both well-characterised loci that affect these traits, having previously 
been identified by GWAS [69, 166]. The stronger signal in these regions is detected in Orkney, 
but some signal is also present in Vis, as shown in Table 16. 
An important consideration is the size of the regions used in meta-analysis. For pedigree-based 
linkage analysis, IBD sharing was output at every 0.1 cM interval along each chromosome. 
The per-cohort results can easily be aggregated for meta-analysis regardless of what SNPs are 
within these intervals. Problems may arise when several cohorts have high LOD scores in 
close, but non-overlapping regions.  
The educational attainment meta-analysis hit (in the region spanning 50-51.3 cM) on 
chromosome 6 exemplifies this: the 2-LOD drop region around the peak (at 50.8 cM) contains 
the HLA region. In GS, IBD sharing at a 50.4 cM in this region yielded a LOD score of 5.61 
but no signal was detected in the other cohorts. However, at 50.8 cM, the GS LOD score is 
smaller but not insignificant (3.85), and Orkney and Korčula also have LOD scores above 1 
here, which is why this is detected in the meta-analysis (Figure 28, left panel). Another 
scenario, however, could be that there are three distinct, non-overlapping peaks within a 2 cM 
region. If results are aggregated at every 0.1 cM, this region would be missed in the meta-
analysis. If, however, the maximum LOD score is selected out of all regions within a larger 
interval (for example, every 2 cM along each chromosome), then this region would result in a 
meta-analysis signal that all analysed cohorts contribute to (Figure 28, right panel). This would 
come at the expense of resolution, as these regions would necessarily be larger and may span 
several genes. 
Figure 28 - Challenges with defining meta-analysis regions 
LOD scores, obtained at every 0.1 cM position within 2 cM interval, are plotted for each cohort.  
Right panel: Region that yielded a peak for educational attainment on chromosome 6. The meta-
analysis peak is indicated by the green rectangle while the peak in GS is indicated by the blue 
rectangle. 




Chapter 5 Regional Heritability 
5.1 Introduction 
Yang et al. [18] proposed a method to address the missing heritability problem that arose when 
it was found that the genome-wide significant loci from GWAS only explained a small amount 
of trait heritability [17] and implemented it in a program called GCTA. They demonstrated 
that most of the heritability is “hidden” rather than missing, because collectively, genotyped 
variants do explain a large proportion of trait heritability, but the effect sizes of individual 
variants are often too small to be detected by GWAS. Regional heritability (RH) mapping [45] 
was developed following on from this rationale – if one can calculate the total proportion of 
trait variance captured by all genotyped SNPs across the genome, then the genome could be 
partitioned into smaller regions, and the variance captured by all genotyped SNPs within each 
region can also be calculated. 
Using simulated data, Riggio and Pong-Wong showed that RH mapping outperformed 
association and linkage analyses in terms of power to detect a QTL, as it identified more true 
QTLs than these other methods [183]. RH mapping has been used to identify a novel 
relationship between major depressive disorder and a transcription factor binding site within 
the TOX2 gene, in GS [184]. Variants within this locus modulate the expression of TOX2 and 
RP1-269M15.3, a long non-coding RNA, in the brain. A comparison of GWAS and RH 
mapping of blood lipid traits (LDL cholesterol, HDL cholesterol, triglycerides and total 
cholesterol) in Vis, Korčula and a metropolitan cohort from the city of Split had revealed that 
RH can identify additional significant signals compared to GWAS performed in the same 
cohorts [48], all corresponding to loci reported in large lipid GWAS meta-analyses ([97, 185]). 
The same work also showed that a locus that was flagged by GWAS in our cohorts, but not 
the large GWAS meta-analysis, did not yield a significant test statistic with RH, indicating 
that RH may be less sensitive to false positive signals. 
Within this chapter, I use RH mapping to systematically analyse the quantitative traits listed 
in Section 2.2, in each cohort separately, followed by a meta-analysis. In order to enable the 
meta-analysis, I use a modified version of RH mapping that is based on ‘haplotype’ blocks 
defined by cohort-independent recombination maps, rather than regions defined by a sliding 
window consisting of a fixed number of SNPs. This has the twofold benefit of reducing LD 
block complexity within each region and ensuring that regions are comparable between 




Regional heritability analyses were carried out using the program REACTA [186] and its 
successor, DISSECT [187], developed by the same team at the University of Edinburgh. 
These programs are based on the statistical principles employed by GCTA [18] but extend its 
functionality by implementing and automating regional analysis. 
5.2.1 Linear mixed models 
These programs use linear mixed models (LMMs) to compute the trait variance explained by 
all, or a subset of, genotyped SNPs, using the restricted maximum likelihood (REML) 
method. As was the case for variance component linkage analysis, presented in section 4.2.3, 
the regional heritability approach, as described in [45], adjusts the LMM equation presented 
in section 3.2.2 to account for both whole-genome and regional effects: 
𝑦 = 𝑋𝛽 + 𝑍𝑢 + 𝑊𝑣 + 𝑒 
where Z and W are the design matrices for random effects, u is the whole-genome additive 
effect with variance 𝑣𝑎𝑟(𝑢) = 𝐺𝜎𝑢
2, v is the regional additive effect with variance 𝑣𝑎𝑟(𝑣) =
𝑄𝜎𝑣
2, e is the residual effect with variance 𝑣𝑎𝑟(𝑒) = 𝐼𝜎𝑒
2. Matrices G, Q and I are the whole-
genome GRM, regional GRM and the identity matrix. The phenotypic variance 𝜎𝑝




2 and the whole genome heritability ℎ𝑢











In RH analyses, as shown above, two random effects are fitted: a whole-genome GRM 
(calculated using all the available genotyped SNPs) to account for background relatedness 
and polygenic effect, and a regional GRM (calculated using a subset of adjacent SNPs) that 
accounts for local effects. These GRMs are calculated as described in section 3.2.1, using 
either all autosomal SNPs across the genome in the case of whole-genome GRMs, or a 
subset of SNPs in the case of the regional GRM. 
The LMM described in [45] is the same that is used by DISSECT, but there is one difference 
in the whole-genome GRM used: while only one whole-genome GRM is computed for each 
cohort, the regional GRM is subtracted from the whole-genome GRM prior to each regional 
analysis. This ensures that a regional effect is not “counted twice”, which might reduce the 
likelihood of detecting a regional effect.  
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5.2.2 Defining a Region 
The genome can be broken down into regions consisting of arbitrary combinations of SNPs, 
such as regions containing all SNPs within a gene, or regions flanked by recombination 
hotspots. The original implementation of RH mapping in REACTA uses sliding windows of 
n SNPs, sliding the window m SNPs forward after each analysis. While this keeps the number 
of SNPs in each region constant, the number of resulting windows depends on the number of 
genotyped SNPs available.  
In order to keep the window positions consistent across different cohorts, regardless of the 
number of genotyped SNPs available in a cohort, I created 0.3 cM windows spanning the 
whole genome. This gave rise to 12101 non-overlapping windows, some of which may contain 
no SNPs in some cohorts. This definition of a window enables the meta-analysis of results, as 
the regions will be located at the same positions regardless of cohort. Windows of this size 
were chosen in order to ensure that most regions have >1 SNPs in all cohorts. Figure 29 shows 
the distribution of the number of SNPs allocated to each region, within each cohort. 
REACTA only implements on-the-fly GRM calculations if the sliding window approach 
described above is used, so is not particularly well-suited for analysing arbitrarily-defined 
regions. This means that for each region, the regional GRM has to be pre-calculated and stored, 
the whole-genome GRM has to be adjusted by the regional GRM with the help of external 
programs, then the regional and adjusted whole-genome GRMs have to be read into REACTA 
to perform the analysis, which adds significant time and storage overheads.  
In contrast, DISSECT implements a grouping approach where an input file may assign 
genotyped SNP to one (or more) groups (a SNP may also be assigned to no group). The whole-
genome GRM and whole-genome genotype files are read into the program once, and then, for 
each group, the regional GRM is calculated using all its constituent SNPs on-the-fly, 
subtracted from the whole-genome GRM and the REML is performed on the full and reduced 
models, outputting the variances, heritabilities and logLikelihoods attributed to these models, 
as well as the LRT and its associated p-value. Within this thesis, I have initially used REACTA 






5.3.1 Regional Heritability Results by Cohort 
RH analyses have been performed in DISSECT for each trait available in each cohort. The 
genome was partitioned into 0.3 cM segments, and all SNPs falling into each segment were 
used to calculate the regional GRM. In total, 97 hits yielded RH test statistics that exceed the 
suggestive significance threshold (-log10(0.05/12101)=5.38), and Table 17 lists the 70 hits that 
exceed the genome-wide significance threshold that is adjusted for the number of traits 
analysed in each cohort. The hits that exceed the suggestive but not the genome-wide 
suggestive threshold are presented in Supplementary Table 6. The majority (49) of the GWS 
hits originate in GS, which has the largest sample size out of all the cohorts analysed.  
All of the hits reported in Table 17, and most of the hits reported in Supplementary Table 6, 
replicate the findings of GWAS reported in the GWAS catalog [16] or within this thesis, and 
Figure 29 - Distribution of the number of SNPs in 0.3 cM regions across the 
genome 
The X axis shows the number of SNPs in each 0.3 cM region across the autosomal genome, 





persist in the meta-analysis. 18 of the per-cohort hits are not found in the meta-analysis, either 
because the trait was only available in one cohort, or because the result is no longer significant 
in the meta-analysis, these are indicated with asterisks in the table and they all contain genes 
for which associations have been reported in the GWAS catalog. 
The body fat percentage phenotype was only available in GS, so this trait was not meta-
analysed, but the region identified in GS corresponds to the well-known FTO locus, which 
was shown to associate with BMI and obesity for the first time in 2007, in several independent 
studies [188–190]. The same locus has a strong signal in RH analyses of BMI in GS, and some 
signal is also present in Vis and Korčula, but not Orkney and Shetland. 
Table 17 - Regional heritability results that exceeded the GWS threshold in 
individual cohorts 
The RH -log10(p-value) of each region is displayed in the logP column. The chromosome and 
start and end positions of each region (in Mbp) are provided. Additionally, the start of each 
0.3 cM region is also indicated in cM. The total trait heritability (h2) and heritability explained 
by the region (h2reg), are shown, as well as the chromosome band (Band) where the region is 
located. Rows with asterisks (*) indicate hits that are not present in the RH meta-analysis. 
GWAS in the literature have reported associations between the relevant trait and a SNP within 
every region reported here. 






HDL 16 72.9 56.95-57.04 13.32 0.53 0.051 q13 
LDL 19 70.5 45.34-45.43 7.77 0.32 0.051 q13.32 
Uric acid1 4 23.4 9.91-10.54 21.01 0.44 0.057 p16.1 
Uric acid2 4 23.4 9.91-10.54 20.53 0.43 0.057 p16.1 
vWF 9 166.2 136.13-136.37 32.81 0.66 0.275 q34.2 
Vis 
vWF 9 166.2 136.13-136.37 22.65 0.51 0.134 q34.2 
Shetland 
Central Corneal 
Thickness 16 127.5 88.24-88.38 10.75 0.8 0.017 q24.2 
CRP 1 175.2 159.53-159.76 6.85 0.29 0.025 q23.2 
GGT 22 22.8 24.98-25.14 8.22 0.38 0.029 q11.23 
Glucose 11 99.9 92.63-92.8 9.45 0.3 0.03 q14.3 
Glucose_nodiab 11 99.9 92.63-92.8 10.95 0.29 0.033 q14.3 
HDL 16 72.9 56.95-57.04 15.34 0.44 0.031 q13 
LDL 19 70.5 45.34-45.43 11.86 0.13 0.038 q13.32 
Total Cholesterol 19 70.5 45.34-45.43 7.29 0.16 0.025 q13.32 
Triglycerides 11 126 116.55-117.1 7.19 0.31 0.026 q23.3 
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Uric acid1 4 23.4 9.91-10.54 18.49 0.46 0.037 p16.1 
Uric acid2 4 23.4 9.91-10.54 19.80 0.46 0.042 p16.1 
Korčula 
HDL 16 72.9 56.95-57.04 13.24 0.42 0.044 q13 
Heart Rate* 2 246.3 228.29-228.52 7.60 0.15 0.033 q36.3 
Uric acid1 4 23.4 9.91-10.54 16.11 0.35 0.029 p16.1 
Uric acid2 4 23.4 9.91-10.54 15.92 0.32 0.032 p16.1 
GS 
BMI 16 64.5 53.77-53.85 16.18 0.47 0.002 q12.2 
Body fat* 16 64.5 53.77-53.85 12.08 0.44 0.001 q12.2 
Creatinine* 5 200.1 176.78-176.96 7.45 0.44 0.002 q35.3 
Forced Vital 
Capacity* 6 20.4 7.68-7.92 6.83 0.35 0.004 p24.3 
Glucose 2 185.4 169.65-169.82 71.38 0.22 0.019 
q24.3-
q31.1 
Glucose* 3 179.7 170.38-170.77 8.73 0.23 0.004 q26.2 
Glucose 7 69.3 43.89-44.27 24.01 0.24 0.013 p13 
Glucose 8 133.2 118.18-118.3 8.20 0.23 0.004 q24.11 
Glucose_nodiab 2 185.4 169.65-169.82 77.85 0.25 0.023 
q24.3-
q31.1 
Glucose_nodiab* 3 179.7 170.38-170.77 8.17 0.26 0.005 q26.2 
Glucose_nodiab 7 69.3 43.89-44.27 28.90 0.27 0.015 p13 
Glucose_nodiab 8 133.2 118.18-118.3 9.54 0.26 0.004 q24.11 
Glucose_nodiab* 13 20.7 28.45-28.59 7.75 0.26 0.003 q12.2 
HDL 8 47.1 19.71-19.94 28.38 0.5 0.012 p21.3 
HDL 9 124.2 107.63-107.68 11.11 0.5 0.006 q31.1 
HDL* 11 126 116.55-117.1 8.86 0.5 0.008 q23.3 
HDL 15 78.3 58.63-58.71 26.02 0.5 0.005 q21.3 
HDL 16 72.9 56.95-57.04 165.85 0.5 0.042 q12.2-q13 
HDL 19 70.5 45.34-45.43 12.08 0.5 0.006 q13.32 
Heart Rate 14 11.7 23.76-23.98 10.31 0.25 0.005 q11.2 
Height* 1 150.6 118.84-119.31 6.99 0.82 0.002 p12 
Height* 1 33.9 17.19-17.5 6.89 0.82 0.002 p36.13 
Height 2 83.1 55.9-56.24 10.35 0.82 0.003 p16.1 
Height 3 153.6 141.01-141.34 13.73 0.82 0.002 q23 
Height 4 153.6 145.2-146.17 8.17 0.82 0.004 q31.21 
Height* 4 33.6 17.74-18.27 7.42 0.82 0.001 
p15.32-
p15.31 
Height 5 51 32.7-32.89 8.09 0.82 0.006 p13.3 
Height 6 151.5 142.63-143.06 11.11 0.82 0.002 
q24.1-
q24.2 
Height* 6 49.2 25.69-26.67 9.16 0.82 0.006 p22.2 
Height* 6 54.3 34.04-34.24 7.99 0.82 0.003 p21.31 
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Height* 6 132.6 126.44-127.53 7.53 0.82 0.002 
q22.32-
q22.33 
Height 7 108.3 92.06-92.49 6.92 0.82 0.001 q21.2 
Height* 12 79.2 66.3-66.42 7.31 0.82 0.001 q14.3 
Height 15 115.2 89.37-89.45 9.44 0.82 0.004 q26.1 
Height 18 42.9 20.68-21.07 10.68 0.82 0.002 q11.2 
Height 20 53.7 32.9-34.72 19.41 0.82 0.007 
q11.22-
q11.23 
Total Cholesterol 1 138.6 109.73-110.12 14.48 0.27 0.005 p13.3 
Total Cholesterol 1 80.7 55.47-55.51 12.20 0.27 0.005 p32.3 
Total 
Cholesterol* 1 92.1 62.83-63.38 8.02 0.27 0.001 p31.3 
Total Cholesterol 2 42 21.25-21.54 16.43 0.27 0.003 p24.1 
Total Cholesterol 2 68.4 43.91-44.1 9.39 0.28 0.008 p21 
Total Cholesterol 5 85.8 74.24-74.95 8.25 0.27 0.002 q13.3 
Total 
Cholesterol* 8 24.9 9.1-9.2 6.71 0.27 0.003 p23.1 
Total Cholesterol 9 124.2 107.63-107.68 6.99 0.27 0.003 q31.1 
Total 
Cholesterol* 16 87.3 72.1-72.93 7.25 0.27 0.004 
q22.2-
q22.3 
Total Cholesterol 19 70.5 45.34-45.43 90.24 0.32 0.083 
q13.31-
q13.32 
Total Cholesterol 19 31.8 11.01-11.28 25.92 0.28 0.017 p13.2 
Urea 3 206.7 187.63-187.8 11.89 0.22 0.005 q27.3 
Urea 18 63 43.13-43.3 6.96 0.22 0.004 q12.3 
5.3.2 Meta-analysis Results 
Meta-analysis was conducted by applying Fisher’s combined test, as described in section 4.2.7, 
to the RH results obtained in each cohort. Regions with meta -log10(Pmeta) > 5.38 are considered 
suggestively significant, while regions with meta -log10(Pmeta) > 6.89 are considered genome-
wide significant (GWS), taking into account the number of traits analysed. 
After meta-analysis, 45 regions yield GWS meta-analysis results, and these are presented in 
Table 18. In total, 69 regions pass the suggestive significance threshold, and the suggestively 
significant results are presented in Supplementary Table 7. Most of the meta-analysis hits are 
predominantly led by strong signals originating in GS, and published GWAS [16] have 




Table 18 - RH meta-analysis results that pass the GWS threshold 
The meta-analysis -log10(p-value) is indicated (logP column) for each peak. These peaks represent 0.3 cM regions that start at the cM position indicated 
(cM column). The start and end positions of these regions are also shown in Mbp, as is the chromosome band (Band) where these regions can be found. 
The per-cohort -log10(p-values) at the peak region are shown (O = Orkney, S=Shetland, G=GS, V=Vis, K=Korčula). The final column shows the genes 
in each region (or on the same chromosome band) that have been implicated in GWAS of the corresponding trait reported in the literature. 
Trait 
Chr cM Mbp logP Band O S G V K GWAS 
BMI 16 64.5 53.77-53.85 17.79 q12.2 0.38 0.30 16.18 1.54 4.96 FTO 
Central Corneal 
Thickness 16 127.5 88.24-88.38 14.73 q24.2 0.61 10.75 NA 2.32 5.22 ZNF469 
CRP 1 175.2 159.53-159.76 14.96 q23.2 5.38 6.85 NA 5.68 NA CRP 
GGT 22 22.8 24.98-25.14 8.64 q11.23 0.36 8.22 NA 2.61 NA GGT1 
Glucose 2 185.4 169.65-169.82 70.27 q24.3-q31.1 3.69 1.45 71.38 0.67 0.73 G6PC2 
Glucose 7 69.3 43.89-44.27 23.52 p13 0.30 3.45 24.01 0.30 1.43 GCK 
Glucose 11 99.9 92.63-92.8 14.29 q14.3 2.92 9.45 2.82 1.87 2.51 MTNR1B 
Glucose 8 133.2 118.18-118.3 9.26 q24.11 0.42 4.75 8.20 0.30 0.30 SLC30A8 
Glucose 3 179.7 170.38-170.77 7.19 q26.2 0.30 0.32 8.73 0.45 1.78 SLC2A2 
Glucose_nodiab 2 185.4 169.65-169.82 79.83 q24.3-q31.1 3.91 2.37 77.85 0.96 2.60 G6PC2 
Glucose_nodiab 7 69.3 43.89-44.27 31.93 p13 0.69 4.38 28.90 1.16 3.23 GCK 
Glucose_nodiab 11 99.9 92.63-92.8 13.71 q14.3 2.79 10.95 1.41 0.63 3.13 MNTR1B 
Glucose_nodiab 8 133.2 118.18-118.3 10.47 q24.11 0.42 4.67 9.54 0.30 0.40 SLC30A8 
HDL 16 72.9 56.95-57.04 201.08 q12.2-q13 13.32 15.34 165.85 2.70 13.24 FTO 
HDL 15 78.3 58.63-58.71 32.15 q21.3 4.20 2.74 26.02 3.17 2.44 LIPC 
HDL 8 47.1 19.71-19.94 30.61 p21.3 0.90 2.03 28.38 0.34 5.32 LPL 




Chr cM Mbp logP Band O S G V K GWAS 
HDL 19 70.5 45.34-45.43 8.93 q13.32 0.30 0.30 12.08 0.49 0.42 APOE 
HDL 18 68.7 46.56-47.18 8.18 q21.1 0.30 4.27 6.07 0.76 1.33 LIPG 
Heart Rate 14 11.7 23.76-23.98 9.41 q11.2 NA 1.11 10.31 NA 0.61 MYH6 
Height 20 53.7 32.9-34.72 19.37 q11.21-q11.23 0.93 2.46 19.41 0.89 1.37 GDF5 
Height 3 153.6 141.01-141.34 15.36 q23 0.30 5.23 13.73 NA 0.30 ZBTB38 
Height 15 115.2 89.37-89.45 9.32 q26.1 2.38 0.30 9.44 NA 0.89 ACAN 
Height 4 153.6 145.2-146.17 9.12 q31.21 0.55 2.06 8.17 1.21 1.82 HHIP 
Height 6 151.5 142.63-143.06 9.12 q24.1-q24.2 1.06 0.30 11.11 NA 0.32 GPR126 
Height 18 42.9 20.68-21.07 9.01 q11.2 0.70 0.30 10.68 0.71 1.30 CABLES1 
Height 2 83.1 55.9-56.24 8.56 p16.1 0.30 1.21 10.35 NA 0.30 EFEMP1 
Height 7 3.9 2.69-2.92 7.79 p22.3-p22.2 3.74 1.68 5.33 1.15 0.37 GNA12, AMZ1 
Height 7 108.3 92.06-92.49 7.38 q21.2 0.95 2.16 6.92 1.24 0.53 CDK6 
Height 5 51 32.7-32.89 6.95 p13.3 0.30 1.31 8.09 0.46 1.13 NPR3 
LDL 19 70.5 45.34-45.43 19.97 q13.32 7.77 11.86 NA 1.00 3.84 APOE 
Total Cholesterol 19 70.5 45.34-45.43 94.92 q13.31-q13.32 3.51 7.29 90.24 0.87 1.12 APOC1, APOE 
Total Cholesterol 19 31.8 11.01-11.28 24.91 p13.2 1.22 0.30 25.92 2.37 1.16 LDLR 
Total Cholesterol 2 42 21.25-21.54 12.94 p24.1 0.66 0.35 16.43 0.30 0.34 APOB 
Total Cholesterol 1 138.6 109.73-110.12 12.72 p13.3 0.96 1.67 14.48 0.34 0.37 
SORT1, 
CELSR2 
Total Cholesterol 5 85.8 74.24-74.95 9.24 q13.3 0.93 1.81 8.25 1.85 1.09 HMGCR 
Total Cholesterol 1 80.7 55.47-55.51 8.76 p32.3 0.30 0.30 12.20 0.30 0.30 PCSK9 
Total Cholesterol 2 68.4 43.91-44.1 8.64 p21 0.71 0.56 9.39 0.59 2.01 
ABCG8, 
ABCG5 




Chr cM Mbp logP Band O S G V K GWAS 





Urea 3 206.7 187.63-187.8 11.28 q27.3 0.99 0.41 11.89 1.88 NA LPP, BCL6 
Urea 18 63 43.13-43.3 7.24 q12.3 2.42 1.01 6.96 0.30 NA 
SLC14A1, 
SLC14A2 
Uric acid1 4 23.4 9.91-10.54 55.92 p16.1 21.01 18.49 NA 5.99 16.11 SLC2A9 
Uric acid2 4 23.4 9.91-10.54 56.1 p16.1 20.53 19.80 NA 5.55 15.92 SLC2A9 






Every peak that is GWS in the RH meta-analysis contains SNPs that associated with the 
relevant trait in the GWAS literature. The benefit of RH over GWAS is that here, these effects 
are detected in a sample size of 23000 European individuals, while some of the GWAS hits 
reported in the GWAS catalog [16] required over 100000 individuals to be detected. This could 
either be because of the lower multiple testing penalty applied with RH mapping, or it could 
also be due the presence of multiple independent signals in a region. If the RH signal 
disappears when conditioning on the top GWAS SNP, this would be evidence for the presence 
of a single causal variant in the region, while if some signal remains, this could suggest the 
presence of multiple independent signals. In section 7.1.4, both scenarios are demonstrated to 
occur in adjacent regions at the ABO locus. Some of the GWS and suggestively significant 
meta-analysis hits are discussed in more detail below, and illustrate the ability of RH to 
identify ‘true positive’ hits using sample sizes that are smaller than those used in large GWAS 
meta-analyses. 
Meta-analysis of gamma-glutamyl transferase levels flags the GGT1 gene locus as GWS. This 
locus was identified with the pedigree-free linkage meta-analysis and also yields a GWS signal 
in Shetland RH analysis. In the RH meta-analysis, Vis contributes a weak signal (Vis 
logP=2.61) (note, GS does not have this phenotype measured). It is interesting that this locus 
has a strong signal in Shetland while a signal is completely absent in Orkney. 
The GWS peak on chromosome 3 for urea levels falls into an intergenic region. A GWAS 
meta-analysis of blood urea nitrogen (BUN) levels in east Asian populations reports a hit in 
the same intergenic region [191]. The flanking genes (BCL6 and LPP) have not been 
implicated in kidney function. In contrast, the peak on chromosome 18 for the same trait 
contains the SLC14A1 and SLC14A2 genes, both of which produce urea transporter proteins. 
This locus is also flagged by the same study, but no studies of European individuals have 
linked it to this trait before. 
The suggestively significant heart rate signal on chromosome 2 originates in Korčula, with 
neither GS nor Shetland contributing signal. A heart rate GWAS has identified a signal in the 
COL4A3 gene 155kb away [192], but the RH region only contains the AGFG1 and C2orf83 
genes, neither of which have functions associated with heart rate. This does not preclude that 
they may have regulatory functions that affect heart rate, however. 
The suggestively significant signal on chromosome 5 for serum creatinine levels contains the 
SLC34A1 gene, with GS contributing most strongly to the signal (GS logP=7.45). This signal 
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is also identified in the GS GWAS using genotyped SNPs, while a GWAS meta-analysis of 5 
European population isolates, including Orkney and Vis, failed to identify this signal [193], as 
did a larger meta-analysis of ~24000 European individuals [194]. This locus has, however, 
been associated with chronic kidney disease and glomerular filtration rate of creatinine in a 
meta-analysis of 67000 individuals [195] as well as a meta-analysis of 133000 individuals 
[196].  
Some of the genes implicated in this meta-analysis encode proteins whose functions can 
clearly be linked to the measured trait with which they associate. For example, SLC2A9 is a 
urate transporter, SLC14A1 and SLC14A2 are urea transporters, SLC2A2 is a glucose 
transporter, the apolipoproteins and lipases are involved in the regulation of cholesterols, 
glucokinase mediates glucose uptake while glucose-6-phosphatase is involved in glucose 
homeostasis, GGT1 and CRP produce the proteins that are detected in GGT tests and CRP test, 
respectively, the calcium-sensing receptor encoded by CASR is responsible for calcium 
homeostasis, ZNF469 regulates the organisation of collagen fibres in the cornea, MYH6 
produces cardiac muscle myosins and aggrecan is a component of cartilage that withstands 
compression. Such results lend confidence to the validity of the signals detected with RH 
mapping. 
One possible concern with using RH is that the effect of a QTL may be ‘diluted’ by the effects 
of other SNPs included in the same region. Nagamine et al.[45] show that this is not the case, 
because the magnitude of the regional effect does not change substantially in a region 
containing a QTL, regardless of whether 10, 20 or 100-SNP windows are used. This also 
means that there is no requirement to keep the number of SNPs in each region constant, which 
is reassuring because within this thesis, the genome was divided into 0.3 cM regions, and SNPs 
were allocated to each region based on their cM position. Because each cohort has a different 
number of genotyped SNPs, this results in a different number of SNPs allocated to the same 
region in different cohorts. In Figure 30, I show a comparison of the RH mapping results 
obtained from regions defined in 3 different ways: the first and second analyses both used the 
sliding window approach, with windows consisting of 100 or 50 SNPs, with a 50 or 25 SNPs 
overlap between regions, respectively. The third analysis corresponds to 0.3 cM windows that 
contain between 1 and 77 SNPs in each window, with 23 SNPs per window on average. It can 
be seen that the results of all three analyses are similar, corroborating the statement that the 
effect of a QTL is not substantially diluted by the number of SNPs in the window. 
Nagamine et al.[45] also demonstrate that the average GWAS test statistic obtained from all 
SNPs in a region harbouring a QTL is substantially worse than the RH test statistic. This is 
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why effects that are detected by GWAS are also detected by RH, but additional regions are 
also discovered with RH. In part, this is due to QTL effects originating from single SNPs with 
test statistics that fell below the multiple-testing significance threshold with GWAS – with 
RH, this threshold is lower, because the number of regions analysed is smaller than the number 
of genotyped SNPs. It may also be because of the presence of regions containing several QTLs 
with effects that would be too small to be detected with single-SNP GWAS. RH also provides 
an advantage here, as it accounts for the joint heritability explained by all SNPs within each 
region. Chapter 7 provides a systematic comparison of RH, GWAS and linkage analysis results 
obtained in each cohort, and demonstrates that RH detects all but two of the 56 GWS hits 
identified by GWAS but also identifies 26 additional hits that were missed by GWAS using 
genotyped SNPs only. 
 
Figure 30 - Regional heritability results obtained from regions defined in three 
different ways 
These three plots show the results on chromosome 4 of regional heritability mapping 
performed in Vis using serum uric acid as the phenotype. Chromosome positions are plotted 
along the x-axis in Mb, while the -log10(p-value) is plotted on the Y axis. The region definitions 




Chapter 6 Simulations 
The methods used within this thesis identify novel loci that have not been reported in the 
literature. These could be due to real signals that are specific to these cohorts, but they could 
also be false positives. Additionally, these analyses miss some known QTLs, either because 
they are underpowered to detect the QTL effect, or because the QTL does not segregate in 
these populations.  
To shed light on these issues, GWAS, linkage and RH analyses can be performed on simulated 
traits, where the true underlying QTL is known and its effect size can be specified prior to 
analysis. This enables the assessment of true positive as well as false positive rates and also 
enables the comparison of the power to detect QTLs with these methods. Traits over a range 
of heritabilities were generated using combinations of a stronger genetic effect originating 
from a “sentinel” SNP, a polygenic background consisting of 1000 SNPs that individually 
have a small effect on the simulated trait as well as residual environmental noise.  
While the canonical threshold for classical linkage analyses is a LOD score of 3.3 [74], there 
is no well-established threshold for variance component linkage methods. These simulations 
will also serve to establish a genome-wide significance threshold for variance component 
linkage analysis. 
6.1 Methods 
6.1.1 Phenotype Simulations 
The program DISSECT was used to simulate quantitative traits based on genotype data in 
Orkney. DISSECT simulates quantitative traits based on the additive effects of an arbitrary 
number of causal loci: 𝑦𝑖 = 𝑔𝑖 + 𝑒𝑖 where 𝑦𝑖 is the phenotype for individual i and consists of 
the genetic effect 𝑔𝑖 = ∑ 𝑤𝑖𝑘𝑢𝑘
𝑁
𝑘=1  and environmental noise 𝑒𝑖. 𝑒𝑖 is a random normally 
distributed variable with a mean of 0 and a variance determined by the total trait heritability 
and the variance of 𝑔𝑖. The absolute genetic effect of each SNP, 𝑤𝑖𝑘, is calculated using 
(𝑠𝑖𝑘−2𝑝𝑘)
√2𝑝𝑘 (1−𝑝𝑘)
, where 𝑠𝑖𝑘 is the number of copies of the reference allele at SNP k in individual i 
and 𝑝𝑘 is the frequency of this allele. This genetic effect is multiplied by 𝑢𝑘, which is the 
weight (effect size) assigned to that SNP. This effect size can be specified separately for each 
SNP in the data and can be set to 0, in which case that SNP does not contribute to the simulated 
phenotype. 
6.1.1.1 Initial Models 
The initial phenotype generation process is outlined in Figure 31, as described below: 
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39 sentinel SNPs were selected to have an effect on the phenotype, emphasizing SNPs with 
minor allele frequencies < 5%. A summary of these SNPs can be found in Table 19. When 
presenting summaries, these SNPs will be broken down into three groups – the low MAF 
group (MAF < 5%), the medium MAF group (10% > MAF > 5%) and the high MAF group 
(MAF > 10%).  
For each simulated phenotype, one of these SNPs was given an effect size that explained either 
4, 10 or 40% of the trait heritability. Environmental noise was added by varying the trait 
heritability, so traits with heritabilities ranging from 10% to 100% were generated. 
A polygenic background was generated using 1000 randomly selected SNPs (the same 1000 
SNPs were used in all simulations), each of these SNPs was assigned the same effect size, 
which was kept constant throughout all simulations. Individual components of the polygenic 
variance never had an effect greater than the sentinel SNP, with any one polygene explaining 
at most 0.096% of the trait heritability. 
 
 
Figure 31 - Phenotype simulation process 
Each phenotype is composed of the effects of three components – the sentinel SNP effect, the 
effects of 1000 polygenes and environmental noise. The effect size of the sentinel SNP was 
varied so it explained 40, 10 or 4% of the heritability. Maintaining this sentinel SNP 
effect:polygene effect ratio, environmental noise was added to vary the trait heritability 




6.1.1.2 Follow-up Modelling 
Following the results of the initial simulation analyses, a smaller follow-up was conducted to 
assess the gain in power obtained by using pedigree-free linkage analysis, using phenotypes 
that resemble the observed traits more closely. The reason the full-scale analysis described 
above was not conducted here was due to the long time required to perform pedigree-free 
linkage analysis. For this follow-up, the same overall phenotype simulation process was used, 
with the following modifications: The trait heritability was set to either 0.4 (the mean 
Table 19 - Summary of sentinel SNPs used in the simulation 
The minor allele frequencies (MAF) are shown for each SNP and the table is sorted by MAF. On 
the first set of 4 columns, SNPs with MAF < 5% are shown, while on the second set of 4 columns, 
SNPs with MAF > 5% are shown. The SNPs under the thick line in this set of columns have MAF 
> 10%. The columns labelled nAlt refer to the number of alternate alleles present in Orkney, while 
FamAlt indicates the highest number of alternate alleles carried in one family (here, family is 
defined by the social pedigree). 
rsID MAF nAlt FamAlt rsID MAF nAlt FamAlt 
Low MAF Medium MAF 
rs4977114 0.016 66 5 rs6750185 0.050 197 8 
rs9516949 0.018 71 11 rs7307400 0.054 211 8 
rs7914943 0.019 76 12 rs1341598 0.063 240 12 
rs2200674 0.020 77 6 rs12718123 0.067 259 13 
rs3784635 0.023 77 15 rs739999 0.071 270 10 
rs16865292 0.026 100 18 rs10494476 0.074 267 9 
rs4568351 0.026 101 6 rs867191 0.087 350 18 
rs17670378 0.027 105 8 rs2958431 0.089 345 13 
rs1673443 0.031 117 9 rs13029379 0.090 327 16 
rs6030760 0.038 146 4 rs3113176 0.092 363 14 
rs12610125 0.039 151 11 High MAF 
rs10144225 0.041 162 8 rs10938462 0.110 432 11 
rs4129315 0.043 170 5 rs6985783 0.116 451 16 
rs5749011 0.044 174 5 rs1014290 0.221 864 18 
rs12636173 0.045 177 5 rs2665739 0.273 1062 27 
rs4393596 0.045 178 5 rs6481838 0.349 1357 35 
rs1405040 0.047 184 5 rs657152 0.361 1408 30 
rs9659165 0.047 185 10 rs3764261 0.380 1397 34 
rs10499266 0.049 190 5 rs2291334 0.388 1531 30 
    rs1360738 0.404 1587 28 




heritability of traits analysed within this thesis is 0.37) or 0.7 (to represent a trait with high 
heritability). The sentinel SNP’s effect was set such that it explained either 4 or 10% of the 
overall trait variance, as shown in Table 20. Varying the trait heritability but keeping the 
proportion of total trait variance that the sentinel SNP explains constant means we can gain 




heritability due to 
sentinel SNP 
Proportion of total 
trait variance due 
to sentinel SNP 
0.4 0.1 0.04 
0.7 0.057 0.04 
0.4 0.25 0.1 
0.7 0.14 0.1 
 
6.1.2 Analysis Process 
The first simulated phenotypes were analysed using linkage analysis (using a pedigree, and 
IBD sharing as output by Loki) and GWAS, as described previously. The phenotypes in the 
follow-up simulation were additionally analysed by regional heritability (RH) and pedigree-
free linkage analysis. 
One aim of the simulation study was to see whether the sentinel SNP could be detected if it is 
not directly genotyped (to mimic the common situation where incomplete genotyping 
information is available). In the case of GWAS, all SNPs are analysed independently of each 
other, so after obtaining its association p-value, the sentinel SNP was removed from the 
summary statistics prior to downstream analysis of the results. In the case of RH, the sentinel 
SNP was removed from the genotype file prior to the analysis of the region it belonged to. As 
linkage analysis uses IBD sharing between pairs of individuals instead of genotype data, and 
because IBD segments extend over several SNPs, the sentinel SNPs were not removed when 
performing linkage analyses. 
6.2 Results 
6.2.1 Initial Model Analysis 
After performing linkage analysis and GWAS, I extracted the loci with the highest test statistic 
(LOD score or -log10(p-value)) from the chromosome that harbours the sentinel SNP. With 
GWAS, the test statistic of the sentinel SNP exceeded the genome-wide significance threshold 




50% of the time when this SNP explained 1.5% of the trait variance, and always exceeded the 
significance threshold as long as this SNP explained at least 3% of the trait variance. This is 
an indicator of the power of GWAS to detect a QTL effect in Orkney. After ascertaining this, 
the sentinel SNP was removed prior to downstream analysis to assess whether other SNPs 
were able to ‘tag’ this signal. I also extracted the loci with the highest test statistic from the 
rest of the genome in order to assess the prevalence and magnitude of false positives.  
Figure 32 shows whether the highest test statistic on the target chromosome exceeded the 
canonical genome-wide significance threshold (LOD 3.3 for linkage analysis, and -log10(p-
value)=7.3 for GWAS) in each of the 39 independent loci tested under each variation of the 
genetic architecture. This figure shows that in Orkney, pedigree-based linkage analysis is only 
reliably able to detect the signal originating from the sentinel SNP if this explains at least 30% 
of the trait variance, but detection is not dependent on the allele frequency of the sentinel SNP. 
In contrast, GWAS can detect the signal originating from a sentinel SNP that explains at least 
2% of the trait variance, even when the sentinel SNP itself is removed, as long as the sentinel 
SNP is common (MAF > 20%). With a few exceptions, when the sentinel SNP is rare (MAF 
< 5%), it needs to explain at least 12% of the trait variance for ‘tagging’ SNPs to yield GWS 
signals with GWAS.  
Table 21 and Table 22 show the summaries for the pedigree-based linkage analysis and 
GWAS, respectively. Within each set of 39 simulations, I have averaged the highest test 
statistic on the target chromosome, the highest test statistic in the rest of the genome as well 
as the number of non-target chromosomes that had test statistics exceeding the canonical 
genome-wide significance threshold. I have also calculated these averages within each SNP 
allele frequency class.  
In Table 21, the summary for pedigree-based linkage reinforces what could be observed in 
Figure 32 – that detecting the QTL with this method is largely independent of the allele 
frequency of the sentinel SNP, and it also shows that the magnitude of the LOD score depends 
on the proportion of trait variance explained by the sentinel SNP. Because the LOD scores 
shown in this table are averaged across all 39 sentinel SNPs, it appears that pedigree-based 
linkage analysis is well-powered to detect a signal as long as these explain at least 24% of the 
trait variance, even though when studied individually (as is shown in Figure 32), it can be seen 
that over half of the simulated QTLs do not yield signals exceeding a LOD of 3.3 when the 
sentinel SNP explains 24% of the trait variance. This apparent discrepancy is due to stronger 
signals originating from a few simulated traits rather than all simulated traits having a 
consistently detectable signal. Table 21 also shows that the occurrence and magnitude of false 
144 
 
positive hits with pedigree-based linkage analysis is positively correlated with the variance 
explained by the sentinel SNP. Allele frequency does not in general appear to be a factor in 
the prevalence of false positives, except in the most extreme example where the sentinel SNP 
explains 40% of the trait variance in a trait that is 100% heritable, where rarer sentinel SNPs 
tend to lead to more false positives.  
In Table 22, in addition to the magnitude of the association signal increasing as the proportion 
of trait variance explained by the sentinel SNP increases, a clear positive correlation can also 
be seen between the magnitudes of the association signals and the MAF of the sentinel SNP. 
As stated previously, the summaries presented in this table were generated after removing the 
sentinel SNP, which yielded GWS signals in all analyses as long as it explained at least 2% of 
the trait variance. Variants that tag the sentinel SNP yield GWS signals when the sentinel SNP 
is rare (MAF < 5%) and explains at least 8% of the trait variance. Variants tagging sentinel 
SNPs with intermediate allele frequencies (5% < MAF < 10%) yield GWS signals when the 
sentinel SNP explains at least 6% of the trait variance, while variants tagging common sentinel 
SNPs (MAF > 10%) yield GWS signals when the sentinel SNP explains at least 3% of the trait 




Figure 32 - Highest test statistic on the target chromosome for each simulated phenotype 
The loci with the highest test statistic have been extracted from the chromosome harbouring the sentinel SNP. In the case of GWAS, the sentinel SNP 
was removed prior to this step. If the highest test statistic on the target chromosome exceeded the canonical significance threshold (LOD > 3.3 for linkage 
analysis, -log10(p-value) > 7.3 for GWAS), its box is coloured green. The Y axis is sorted by the allele frequency of the lead SNP and the thicker horizontal 
bars indicate the limits for low (MAF < 5%), medium (10% > MAF > 5%) and high (MAF > 10%) minor allele frequencies. The top X axis shows the 





Table 21 - Summary of pedigree-based linkage analysis of simulated phenotypes 
The results of 39 simulated traits have been averaged and broken down by sentinel SNP allele frequency into Low, Medium and High MAF groups. The 
maximum LOD score on the chromosome containing the lead causal SNP (target chromosome, A) or the maximum LOD score in the rest of the genome 
(false positives, B) is shown. The average number of non-target chromosomes that had LOD scores exceeding 3.3 is also shown (C). In each case, more 
intense shading denotes a higher number, and values in bold and surrounded by a frame are LOD scores exceeding 3.3 (A and B) or non-zero values in the 






Table 22 - GWAS simulation summaries 
The results of 39 simulated traits have been averaged and broken down by sentinel SNP allele frequency into Low, Medium and High MAF groups. The 
maximum -log10(p-value) on the chromosome containing the lead causal SNP (target chromosome, A) or the maximum -log10(p-value) in the rest of the genome 
(false positives, B) is shown. The average number of non-target chromosomes that had -log10(p-values) exceeding 7.3 is also shown (C). In each case, more 
intense shading denotes a higher number, and values in bold and surrounded by a frame are -log10(p-values) exceeding 7.3 (A and B) or non-zero values in the 







6.2.2 Follow-up Analysis 
I performed linkage analysis (using IBD coefficient calculated by Loki in the case of pedigree-
based linkage analysis, or IBD coefficients calculated by GIBDLD in the case of pedigree-free 
linkage analysis), regional heritability (RH) analysis and GWAS on the follow-up simulated 
phenotypes. As described in section 6.2.1, I extracted the highest test statistic (LOD score or 
-log10(p-value)) from the chromosome that harbours the sentinel SNP. I also extracted the 
highest test statistic from the rest of the genome in order to assess the prevalence of false 
positives.  
Figure 33 shows whether the highest test statistic on the target chromosome in a simulation 
exceeded the canonical genome-wide significance threshold (LOD 3.3 for both linkage 
analyses, -log10(p-value)=7.3 for GWAS, -log10(p-value)=5.38 for RH).  
Figure 33 - Highest test statistic on the target chromosome for each simulated 
follow-up phenotype 
If the highest test statistic on the target chromosome exceeded the canonical significance 
threshold (LOD > 3.3 for linkage analysis, -log10(p-value) > 7.3 for GWAS, -log10(p-value) > 
5.3 for RH), its box is coloured green. The Y axis is sorted by the allele frequency of the lead 
SNP and the thicker horizontal bars indicate the limits for low (MAF < 5%), medium (10% > 
MAF > 5%) and high (MAF > 10%) minor allele frequencies. The top X axis shows the trait 
heritability while the bottom X axis shows the proportion of variance explained by the lead 




From this figure, it can be seen that pedigree-based linkage is the poorest performer as it is 
unable to detect most QTLs. This is not surprising given that the sentinel SNPs here only 
explain up to 10% of the trait variance, and I have shown with the help of the initial models 
that pedigree-based linkage does not have the power to detect QTLs with this magnitude of 
effect in Orkney. Pedigree-free linkage shows some gain in power compared to pedigree-based 
linkage, as it is able to detect about half of the loci harbouring the sentinel SNP when this SNP 
explains 10% of the trait variance. This depends slightly on the allele frequency of the sentinel 
SNPs as signals originating from common (MAF > 10%) sentinel SNPs are more reliably 
detected. When the sentinel SNP explains only 4% of the trait variance, neither linkage method 
is able to detect the loci harbouring these SNPs. GWAS perform worse than pedigree-free 
linkage when detecting associations with variants tagging low MAF sentinel SNPs, but 
performs better when detecting associations with variants tagging medium MAF sentinel 
SNPs. The two methods perform similarly when detecting signals originating from common 
sentinel SNPs that explain 10% of the trait variance, but GWAS can also detect associations 
with variants tagging common SNPs that explain 4% of the trait variance. RH performs best 
across the board, being able to most reliably pinpoint the region where a sentinel SNP was, 
even when this SNP was removed prior to the RH analysis. Out of the four methods compared 
here, RH also appears to have the highest power to detect loci harbouring sentinel SNPs that 
explain 4% of the trait variance. As was the case with GWAS, signal detection with RH 
appears to be dependent on the allele frequency of the sentinel SNP.  
I summarise these results in Table 23, where within each set of 39 simulations, I have averaged 
the highest test statistic on the target chromosome, the highest test statistic in the rest of the 
genome as well as the number of non-target chromosomes that had test statistics exceeding the 
canonical genome-wide significance threshold. I have also calculated these averages within 
each SNP allele frequency class. The results presented here show similar trends to what could 
be gleaned from Figure 33: the allele frequency of the sentinel SNP seems to affect detection 
rate with every method except pedigree-based linkage. In contrast, allele frequency does not 
have a strong effect on the prevalence of false positives in any of the methods tested here. 
GWAS and RH have a lower prevalence of false positives than the two linkage methods, with 




The simulation scenario presented here simplifies complex trait architecture for tractability, 
but highlights some of the features of the methods used within this thesis. 
Pedigree-based linkage analysis had very low power to detect the simulated SNP effect in the 
Orkney dataset used for the simulation, only being able to reliably detect the locus if the SNP 
explains over 30% of the total trait variance. Effect sizes of this magnitude are expected for 
Mendelian traits.  
As long as there is a segregating allele, its allele frequency does not appear to affect the 
detection accuracy with linkage analysis. This makes sense because linkage analysis records 
Table 23 - Follow-up simulation summaries 
The simulation results have been averaged by analysis type across all MAFs and also broken down by SNP 
allele frequency into Low, Medium and High MAF groups. The maximum test statistic (LOD score or -
log10(p-value)) on the chromosome containing the lead SNP (target chromosome, A) or the maximum test 
statistic in the rest of the genome (false positives, B) is shown. The average number of non-target 
chromosomes that had test statistics exceeding their respective significance thresholds is also shown (C). In 
each case, more intense shading denotes a higher number, and values in bold and surrounded by a frame 
exceed their respective significance thresholds (A and B) or are non-0 values in the case of C (might appear 
as 0.0 due to rounding). Note that since the significance thresholds between methods are different, the 




the segregation of large chunks of DNA carrying a QTL in individuals with similar trait values 
(linkage). In contrast, GWAS relies on linkage disequilibrium (LD) between markers such that 
if a causal variant is not in strong LD with any genotyped markers, it will go undetected. 
Indeed, these simulations show that if the actual casual variant is removed, the power of 
GWAS to detect it via other variants declines as the allele frequency of the causal variant 
diminishes. This is compounded by the fact that low allele frequency variants are poorly 
represented on genotyping arrays.  
Compared to the pedigree-based linkage analysis, there is a large gain in power when the 
pedigree-free linkage analysis is used, as it is can identify the causal locus when the sentinel 
SNP explains 10% of the total trait variance. It is acknowledged that this is still quite a large 
effect size originating from a single locus, however. This gain in power compared to pedigree-
based linkage originates from the ability to use individuals who share IBD the DNA segment 
carrying the sentinel SNP, but who are not recorded as related in the social pedigree. 
There is a higher incidence of false positives with linkage analysis than with GWAS and RH. 
This could be because of imperfect IBD estimation, or because of excess IBD sharing at other 
loci across the genome, since if two individuals share segments that are IBD around the 
sentinel SNP, they are also likely to share other IBD segments in their genome. The former 
cause may be improved with the use of denser genotyping in the future, while the latter is a 
more intrinsic problem that might be circumvented by obtaining a null distribution of IBD 
sharing probabilities in a cohort. 
While it is affected by allele frequency, RH appears to perform best across the board, detecting 
the highest number of true hits out of all the methods tested, and yielding the lowest false 
positive rates. This additional power over GWAS was also reported by Nagamine et al. [45] 
where RH results correlate with those obtained by GWAS but also uncover new loci, in 
simulated and real traits. 
Due to the significant time required to prepare files for, and perform, linkage analysis, GWAS 
appear to be a more straightforward means to carry out genetic analyses to detect single-SNP 
effects. Due to its lack of reliance on LD, linkage analyses may however hold an advantage 
when the allele frequency of a causal SNP is low and all genotypes are not available. Since 
only the Orkney dataset was used in these simulations, it cannot be ruled out that linkage 
analysis may have more power to detect a segregating QTL in a population with a larger 
sample size or a different relationship structure. Additionally, in theory, linkage analysis 
should be able to better detect loci harbouring several independent causal variants (allelic 
heterogeneity), but this more complicated scenario was not implemented in this set of 
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simulations. The ability of RH to detect such loci has been demonstrated in a simulation study 
by Uemoto et al. [46].  
6.4 Linkage Analysis Significance Threshold 
While the LOD score value corresponding to a 5% significance threshold is easily determined 
pointwise (due to the distribution of scores relating to a chi-squared distribution), that 
corresponding to a 5% significance threshold genome-wide is not obvious. In a seminal paper, 
Lander and Kruglyak set this threshold in human genetics to 3.3 for the classical parametric 
linkage studies used for Mendelian traits, and to between 3.3 and 3.8 (depending on the degree 
of relatedness of the affected individuals compared) for allele sharing methods, the popular 
methods used for complex trait analysis at the time [197]. Variance components linkage 
analyses in the literature often use 3.3 or 3.4 (e.g. [198]) in reference to this paper, but it seems 
to be arbitrary and values up to 3.8 may be just as appropriate.  
Lander and Kruglyak used the mathematical theory of large deviations to determine the 
genome-wide threshold, which allowed them to derive the number of regions that would 
exceed this threshold by chance based on a Poisson distribution. The mean of this Poisson 
distribution critically depends on the number of chromosomes, the genome length and a 
measure ρ of how rapidly the statistic fluctuates across the genome, which reflects the total 
crossing over rate between genotypes being compared (Box 1 in [197]). It is clear that this 
measure ρ varies depending on the degree of relatedness of the individuals compared in a pair, 
and is more easily calculated when only one type of relative is used to build the allele sharing 
statistics (as in the methods described by Lander and Kruglyak). Hence the genome-wide 
significant LOD threshold varies from 3.3 when grandparent-grandchild pairs are used in allele 
sharing methods to 3.8 when second cousins are used. This makes sense, because compared 
to closely related individuals, in more distant relatives, more cross-over have occurred so the 
regions assessed along the genome are more likely to be independent. As a consequence, there 
is a higher number of independent test performed, resulting in a higher multiple testing penalty. 
I would argue that the LOD score corresponding to the IBD sharing variance component used 
within this thesis follows the same principle, but it is difficult to derive a significance threshold 
using this calculation due to the presence of varying degrees of relatedness between, and within 
each population used here. For an upper limit of the score corresponding to a genome-wide 
significant threshold of 5%, a Bonferroni correction could be applied based on the number of 
regions being tested (as was done for the RH method). This is very conservative given the fact 
that the regions are not independent: the threshold calculated this way will be 0.05/33000 
(33000 SNPs at 0.1 cM intervals are tested in the pedigree-based linkage analysis), which 
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corresponds to a LOD score of 4.7. Therefore simulations, for every population under study, 
should ideally be carried out to estimate this threshold. Another way would be to assign 
random phenotype values drawn from a normal distribution to each genotyped individual, and 
perform linkage analysis many times to obtain a distribution of the LOD score statistics. 
The simulations I had performed in the Orkney study in order to evaluate the power of the 
different methods to detect a major QTL can be used to this end. Since the simulated 
phenotypes aimed to mimic a complex trait caused by one SNP of large effect and 1000 
polygenes of small effect, if the chromosome containing the sentinel SNP is excluded, the rest 
of the genome should provide an adequate approximation for the null hypothesis of no major 
SNP effects. The prevalence of false positives on these chromosomes can be assessed, and this 
can be used to calculate an empirical significance threshold. Therefore, I obtained the most 
extreme LOD score from the pedigree-free linkage analysis results (4×39=156 samples) after 
removing the chromosome containing the sentinel SNP. I ordered these values and isolated the 
highest 5% of scores. The lowest among these was the LOD score of 3.41. This value is in line 
with the LOD significance threshold used in most linkage studies, and it is used as the genome-





Chapter 7 Method Comparisons and Conclusions 
7.1 Method Comparisons 
The simulations discussed in Chapter 6 test the performance of the methods used throughout 
this thesis using simulated traits. The simulation only considered one type of scenario – a 
single segregating major causal variant and a polygenic background – while in reality, complex 
traits are the result of many combinations of genetic and environmental effects – with 
additional complexity added by dominance or epistatic effects, gene by gene interactions or 
gene by environment interactions. While in chapters 3-5 I applied different analytical methods 
to the same set of real data, the results from each kind of analysis were presented in isolation 
from the other methods. In this chapter, I aim to systematically compare the results obtained 
with GWAS, RH and linkage analysis in order to identify trends obtained by analysing real 
data. I also compare the relationship coefficients estimated using IBD and IBS-based methods 
in order to dissect the reason why loci flagged by linkage analysis are often not picked up by 
GWAS or RH, and vice versa. These trends can then be compared to the trends observed when 
simulated data were used.  
7.1.1 Genetic Relatedness Calculated using IBS or IBD methods 
The GRMs calculated by GCTA-based methods utilise identity-by-state between SNPs in pairs 
of individuals to estimate relationships. In contrast, the kinship matrices calculated by IBDLD 
utilise identity-by-descent. While all markers that are identical-by-descent are also identical-
by-state, the opposite is not true. Here, I use Orkney as an example to demonstrate that while 
on the whole-genome level, IBD and IBS-based relatedness is comparable, this does not hold 
at the regional level. 
I calculated whole-genome kinship coefficients between all pairs of individuals in Orkney 
using the GIBDLD (pedigree-free) method of IBDLD, as described in section 4.2.2, as well as 
the whole-genome GRMs using GCTA [199], as described in section 3.2.1. Figure 34 
compares these relationship coefficients and shows that both IBD and IBS-based methods 
result in similar whole-genome relatedness values. It also reveals that GIBDLD gives slightly 
higher estimates of genetic kinship than GCTA.  
Additionally, I calculated regional kinship coefficients and GRMs using the same 28 
genotyped SNPs in a 0.3 cM region around the SLC2A9 gene, and plotted them against each 
other in Figure 35. The regional kinship coefficient is the same as that which was also used in 







Figure 34 - IBS vs IBD-based whole-genome relatedness 
Genetic relatedness between all pairs of genotyped individuals in Orkney was estimated by 
IBD-based methods (using GIBDLD, IBDLD’s pedigree-free method, on the Y axis) and IBS-
based methods (using GCTA, on the X axis). All pairs (including self-pairs, in the top right 
corner) in are depicted. The red line depicts x=y. Note that here, 2Φ is used (that is, twice the 
kinship coefficient, which can range from 0 to 2, and takes on a value of 1 in self-pairs in the 





Several things are revealed by Figure 35: First, that some pairs of individuals share all of their 
alleles IBD across this region. As established from Figure 16, these individuals have very low 
genome-wide kinship-values. While these pairs have the highest amount of possible IBD 
sharing, they do not have the highest regional relatedness values according to the IBS-based 
regional relatedness matrix. Second, while at the whole-genome level, IBD and IBS-based 
relatedness yields similar values, this does not hold at the regional level. The IBS-based 
relatedness values are not constrained to the 0-2 interval as they take on negative values and 
values that are higher than 2. This is a consequence of the way the kinship is calculated, as the 
equation described in section 3.2.1 is only dependent on the frequency of the reference allele 
of a SNP, and the number of these alleles carried by the two individuals being compared. 
Across the genome, these SNP-wise relatedness values average out, but at the regional level 
Figure 35 - IBS vs IBD-based regional relatedness at the SLC2A9 locus 
The same 28 SNPs in the 0.3 cM region around the SLC2A9 gene were used to calculate both 
IBD (Y axis) and IBS-based (X axis) relatedness. For IBD-based kinship, the IBD sharing 
probabilities obtained at all 28 SNPs were averaged for each pair of individuals. On the right 
side, a diagrammatic representation shows the expected IBD values given a number of alleles 
shared IBD. Here, the unordered alleles of two individuals are shown as nodes and the lines 




they can yield very high or very low values. For example, using the allele frequencies of these 
28 SNPs in Orkney (6 of which have MAFs below 10%), if two individuals both carry two 
copies of the reference allele at each of these SNPs, their regional relatedness value will be 
11.32, while if one individual carries two copies of the reference allele while the other carries 
0 copies of the reference allele at each of these SNPs, their regional relatedness value is equal 
to -2, indicating a high level of genetic dissimilarity in this region. 
In IBS-based relatedness, calculations are done based on the allele frequency of each SNP, 
and LD between SNPs is often ignored. This means that each SNP is assumed to explain the 
same proportion of trait variance, so rarer SNPs will have larger effect sizes, and clusters of 
rare SNPs in high LD with each other can skew these estimates. In addition to leading to 
kinship coefficients that are different to those obtained with IBD-based methods, this can also 
cause trait heritabilities to be incorrectly estimated, and it is suggested to weight SNPs based 
on their allelic correlations to circumvent this [200]. The software LDAK was developed 
specifically to address this problem, and it weights SNPs based on local LD between SNPs 
before calculating trait heritabilities [201]. 
To summarise, when whole-genome level SNP information is used, the resulting GRM 
provides an unbiased estimate of the genome-wide kinship coefficient [202] that is comparable 
to the whole-genome kinship calculated using IBD-based methods such as IBDLD [120]. On 
the other hand, this method does not result in a good approximation of regional kinship 
coefficients as it only models identity-by-state, but not identity-by-descent. This is also 
apparent in the fact that regional GRM values are not constrained between the values of 0 and 
1, and can even take on negative values. By definition, kinship coefficients do not exist outside 
of this interval – a kinship coefficient of 0 means a pair of individuals is completely unrelated 
and shares no regions IBD, while a kinship coefficient of 1 means that all four alleles in this 
pair are identical-by-descent. This difference in the regional relationship-values is likely to be 




7.1.2 Overlap of Results Obtained with GWAS, Linkage Analysis and RH 
Within this section, regional results of two methods are compared at a time, broken down by 
cohort. Note that the definition of ‘region’ differs based on which two methods are being 
compared (Figure 36): the pedigree-free linkage analysis (Orkney and Vis only) has the largest 
regions (encompassing 2.5 cM), RH regions encompass 0.3 cM, regions used in the pedigree-
based linkage analysis encompass 0.1 cM, and GWAS results were obtained at each genotyped 
SNP. To make the results of different methods comparable, all results from the method using 
the coarser scale were retained and the regions defined by this method were used to subdivide 
the results of the method with the finer scale. The SNP or region with the highest -log10(p-
value) was selected from each subdivided region to represent the result of the finer scale 
method. It should be noted that here, only the GWAS results obtained using genotyped SNPs 
are used. 
Table 24 presents the number of independent loci detected with each method, as well as the 
number of overlapping loci across methods. This table is broken down by cohort and groups 
methods pairwise, indicating the number of GWS loci obtained with each method, the number 
of regions where both methods obtained GWS results, as well as the Pearson correlation 
coefficient between the results reported by the two methods. 
The plots presented in Figure 37 to Figure 42 depict the -log10(p-value) of every analysed 
region, in each trait, and are a graphical representation of the results shown in Table 24. The 
figures presented here were chosen as exemplars to illustrate the similarities and differences 
between results obtained with different methods, so figures are not presented for each pair of 
methods in each cohort. In these figures, points can fall into one of four different areas 
depending on whether the region reached GWS with both methods (white background), with 
one method (light grey background) or with neither method (dark grey background). The GWS 
threshold for a given method corresponds to the inside border of these areas. Pearson’s 
correlation coefficient between the results obtained with these methods is shown under each 
plot title. 
Figure 37 compares GWAS and RH results in the GS study and Figure 38 zooms in on these 
results to better show the results with -log10(p-values) of up to 15, emphasizing the hits that 
were GWS with RH only. Figure 39 compares GWAS and linkage analysis results in the 
Korčula study while Figure 40 compares pedigree-free linkage analysis and GWAS results in 
the Orkney study. Figure 41 compares RH results to the linkage analysis results in the Korčula 




In general, the results of RH and GWAS agree with each other well (mean correlation 0.7), 
and all GWS regions identified by GWAS are also identified with RH except in Vis (the 
smallest cohort), where 2 out of 3 GWS GWAS hits fall below the RH GWS threshold. These 
two hits correspond to the well-established SLC2A9 locus in serum uric acid levels [69], 
corrected (-log10(p-value)=5.54 in RH) or uncorrected for BMI and alcohol consumption (-
log10(p-value)=5.99 in RH).  
In contrast, RH identifies several regions that yield no GWS SNPs with GWAS performed on 
genotyped SNPs – 2 regions in Orkney, 3 in Shetland, 1 region in Korčula and 21 regions in 
GS. In most cases, this gain in power is due to the lower GWS threshold with RH – indeed, in 
all of these regions, the highest single-SNP -log10(p-value) obtained by GWAS always exceeds 
4. Therefore, there are no examples of regions where a RH signal is present in the complete 
absence of a GWAS signal, but these signals would not normally be flagged in the course of a 
standard GWAS. Additionally, RH may be better suited to capturing additional variance 
contributed by several causal alleles at a locus, as has been demonstrated in a simulation study 
[46]. 
The results of pedigree-based linkage analysis do not correlate well with those obtained with 
GWAS and RH. This is not unexpected, since here, only the effects of variants segregating 
within families can be detected and these effects might not generalise to the whole population. 
This observation also works the other way around – variants with relatively large effects on 
traits such as HDL, glucose or serum uric acid concentration yield strong signals with RH and 
GWAS but signals at these loci are generally absent in linkage results. This is likely due to 
these variants segregating on many haplotypes that are not necessarily IBD, so no one 
haplotype segregates strongly enough within families for linkage analysis to detect it. 
Linkage signals also tend to be quite broad, spanning a large region, which is a consequence 
of large stretches of IBD sharing. This is why, in some cohorts, apparently many linkage 
signals are identified but these signals are not independent of each other, similar to large 
‘towers’ observed in GWAS Manhattan plots, where many SNPs that in LD with each other 
and the causal variant all pick up the signal. For the purposes of the summary presented in 
Table 24, such signals have been collapsed into one region. 
The pedigree-free linkage analysis aims to increase the power to detect a QTL with linkage 
analysis by looking at IBD sharing between all pairs of individuals in the data, not just pairs 
that are within the same family according to a social pedigree. Its results are mildly correlated 
with pedigree-based linkage analysis, as well as with GWAS and RH results (average 
correlation coefficients calculated from Orkney and Vis, 0.14, 0.20, 0.27, respectively), 
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indicating that it can detect effects segregating within close families and effects segregating at 
the cohort level (due to the increased power provided by IBD segments shared by distantly-
related individuals). Despite this correlation, with the exception of the ABO locus, which is 
GWS in GWAS, RH and pedigree-free linkage of von Willebrand Factor levels in Orkney, 
there is no overlap between the GWS results obtained with linkage analysis (pedigree-based 
and pedigree-free) and either GWAS or RH. 
Table 24 - Summary of GWS hits obtained with different methods 
These tables are broken down by cohort and show pairwise comparison of GWS hits obtained 
with GWAS performed on genotyped SNPs, RH, pedigree-based linkage analysis and 
pedigree-free linkage analysis (NoPed, Orkney and Vis only), as well as indicating the number 
of overlapping regions (where both methods obtained a GWS test statistic). The number of 
traits that were analysed in each cohort is indicated. Pearson’s correlation coefficient is shown 
(Corr column) and it was calculated by comparing the test statistics yielded by the two methods 
in corresponding regions within the same trait, across all traits and regions. 








RH - GWAS 4 6 - - 4 0.71 
Linkage - GWAS 4 - 1 - 0 0.03 
RH - Linkage - 6 1 - 0 0.04 
NoPed - GWAS 4 - - 1 1 0.21 
NoPed - Linkage - - 1 1 0 0.15 
NoPed - RH - 6 - 1 1 0.26 
       









RH - GWAS 3 1 - - 1 0.69 
Linkage - GWAS 3 - 9 - 0 0.03 
RH - Linkage - 1 9 - 0 0.04 
NoPed - GWAS 3 - - 0 0 0.18 
NoPed - Linkage - - 9 0 0 0.13 
NoPed - RH - 1 - 0 0 0.28 
 
      






Overlap Corr  
RH - GWAS 3 4 - 3 0.72  
Linkage - GWAS 3 - 1 0 0.01  
RH - Linkage - 4 1 0 0.03  
 
      










Overlap Corr  
RH - GWAS 38 59 - 48 0.71  
Linkage - GWAS 38 - 15 0 0.02  
RH - Linkage - 59 15 0 0.02  
 
      






Overlap Corr  
RH - GWAS 8 11 - 8 0.66  
Linkage - GWAS 8 - 1 0 0.02  
RH - Linkage - 11 1 0 0.03  
 
Figure 36 - Region definitions used when comparing results of different 
methods 
When discussing individual methods, all results are used (first row). When methods are 
compared, region boundaries are defined by the method with the coarser scale (dashed lines). 
Within each region, only the most significant result obtained with the finer scale method is 




Figure 37 - GWAS vs RH in GS 
For RH, the -log10(p-value) of each region is plotted. For GWAS, the SNP with the highest -log10(p-value) within each RH region is plotted. Traits are 
ordered based on the highest -log10(p-value) in each trait. Trait numbers are assigned to points that exceeded the GWS threshold in one (light grey 




Figure 38 - GWAS vs RH results in GS, zoomed 
This image zooms in on Figure 37, having removed all results with -log10(p-value) > 15. Traits are ordered based on the highest -log10(p-value) in each 
trait. Trait numbers are assigned to points that exceeded the GWS threshold in one (light grey background) or both analyses (white background). Points 





Figure 39 - GWAS vs Linkage analysis results in Korčula 
For linkage analysis, the -log10(p-value) of each region is plotted. For GWAS, the SNP with the highest -log10(p-value) within each linkage region is 
plotted. Traits are ordered based on the highest -log10(p-value) in each trait. Trait numbers are assigned to points that exceeded the GWS threshold in 




Figure 40 - GWAS vs Pedigree-free linkage analysis in Orkney 
For linkage analysis, the -log10(p-value) of each region is plotted. For GWAS, the SNP with the highest -log10(p-value) within each linkage region is 
plotted. Traits are ordered based on the highest -log10(p-value) in each trait. Trait numbers are assigned to points that exceeded the GWS threshold in 




Figure 41 - RH vs Linkage analysis results in Korčula 
For linkage analysis, the -log10(p-value) of each region is plotted. For RH, the region with the highest -log10(p-value) within each linkage region is plotted. Traits 
are ordered based on the highest -log10(p-value) in each trait. Trait numbers are assigned to points that exceeded the GWS threshold in one (light grey background) 




Figure 42 - RH vs Pedigree-free linkage analysis in Orkney 
For linkage analysis, the -log10(p-value) of each region is plotted. For RH, the region with the highest -log10(p-value) within each linkage region is 
plotted. Traits are ordered based on the highest -log10(p-value) in each trait. Trait numbers are assigned to points that exceeded the GWS threshold in 




7.1.3 Trait Heritabilities 
The narrow-sense heritability (that is, the heritability attributable to additive genetic effects) 
was calculated for each trait (after applying normalisation and adjusting for covariates), within 
each cohort. To calculate heritabilities, three different genome-wide relationship matrices were 
used, to reflect those used in pedigree-based linkage analysis, GWAS/RH (which use genetic 
relationship matrices estimated using the same method) and pedigree-free linkage analysis:  
1. Kinship coefficients estimated from relationships indicated in the social pedigree. This 
kinship matrix is not based on marker genotype information and depends purely on the 
relationships recorded in the social pedigree, giving the average expected kinship-value 
for each type of relationship (e.g. full siblings will always have a 0.5 kinship coefficient 
regardless of the actual proportion of their genomes they share IBD). This social pedigree-
based heritability was calculated by the polygenic command within SOLAR [203]. 
2. A genetic relationship matrix (GRM) calculated from the genotype data using the ibs() 
function in the GenABEL R package [72]. This GRM is based on SNPs that are identical 
by state between pairs of individuals and is described in more detail in section 3.2.1. The 
heritability was calculated using the polygenic() function in GenABEL. This function uses 
maximum likelihood to estimate the variance explained by the SNPs, as described in [18]. 
3. In Orkney and Vis, an IBD-based kinship matrix was calculated from the genotype data 
using the GIBDLD program within IBDLD3 (described in section 4.2.2). Briefly, genetic 
kinship was calculated between every pair in the data (regardless of their relationship in 
the social pedigree), and it is based on DNA segments that are identical by descent between 
pairs of individuals, taking the linkage disequilibrium (LD) between markers into account. 
The heritability was calculated by the polygenic command within SOLAR after overriding 
the pedigree-based kinship coefficients with this IBD-based kinship matrix. 
Figure 43 shows the social pedigree and GRM-based heritability estimates for each trait, 
within each cohort. Generally, the social pedigree-based heritabilities are slightly higher than 
the ones obtained by using the genetic data only. This could be caused by non-additive genetic 
effects (such as dominance, epistasis or gene-gene interactions) segregating within families 
[204]. Additionally, as discussed in section 4.3.1.1, the social pedigree-based kinship matrix 
fails to account for many relationships (mostly between distantly related individuals). This 
might cause biases in heritability estimates because it only considers closer relatives, who not 
only share genetic, but also environmental effects, which will cause their phenotypes to be 
more similar than can be explained by their shared genotypes alone. In Orkney and Vis, 
genotype-based IBD sharing matrices were calculated by GIBDLD in addition to the social 
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pedigree to estimate heritability. The heritabilities estimated with these matrices are generally 
lower than the heritability estimated based on the social pedigree and often more in line with 
the GRM-based heritability estimates (Figure 44). The fact that these values are still not 
identical is attributable to the differences in how the GRMs are calculated (either using identity 
by state (discussed in Section 3.2.1) or identity by descent (discussed in Section 4.2.2)). 
Overall, however, in Orkney and Vis, the heritabilities estimated using the three methods 
described here are broadly similar, as indicated by the overlapping error bars in Figure 44 
Figure 43 - Trait heritabilities estimated from genetic or pedigree data 
This figure shows the heritability of each trait, as estimated from genetic kinship (calculated by 
GenABEL, dark blue columns) or using social pedigrees only (no genetic data, using SOLAR, 
light blue columns). These are grouped by cohort (indicated on the bottom of the plot, Ork – 
Orkney, She – Shetland, Kor – Korčula, GS – Generation Scotland). Note that this figure is 











Figure 44 - Trait heritabilities estimated from pedigree or genetic data (using 
either marker identity by state or identity by descent) 
This figure shows the heritability of each trait, as estimated using kinship matrices obtained 
from social pedigrees only (no genetic data, using SOLAR, light blue columns) or using 
GRMs generated from genetic data (dark blue columns - based on identity by state 
(GenABEL), red columns - based on identity by descent (GIBDLD)). These are grouped by 
cohort (indicated on the bottom of the plot, Ork – Orkney). Note that this figure is continued 





7.1.4 ABO Locus 
The ABO locus contains common variants that strongly associate with von Willebrand Factor 
(vWF) plasma levels, explaining a large proportion of the heritability in this trait. vWF 
expresses ABO antigens, and polymorphisms within the ABO gene cause the ABO enzyme to 
attach either N-acetyl glucosamine (A allele) or galactose (B allele) to a precursor antigen, 
while the O allele results in a non-functional ABO enzyme that leads to an unmodified antigen 
[205]. Individuals with the O blood group have the highest rates of vWF clearance, individuals 
with the B blood group have higher vWF levels compared to individuals with the A blood 
group, while individuals with AB blood groups have the highest vWF levels, which suggests 
that several polymorphisms at the ABO gene may act in concert to affect vWF levels [206]. 
This locus was selected to evaluate the ability of GWAS (using genotyped or imputed SNPs), 
RH and pedigree-free linkage analysis to identify major signals originating from common 
variants, as well as to assess the presence of other independent, potentially rare QTLs of strong 
effect segregating in this region. A schematic of this region, and a summary of results, is 




In Orkney, GWAS, RH and pedigree-free linkage analysis all yield strong signals at this locus: 
LOD=10.48 with pedigree-free linkage analysis, -log10(p-value)=32.8 with RH, and -log10(p-
value)=25.1 with GWAS using genotyped SNPs only, at rs657152 (MAF=37%)). The imputed 
SNP yielding the strongest signal (-log10(p-value)=35.19 at rs514659, MAF=34%) is in perfect 
LD with rs657152, the genotyped SNP that yielded the strongest GWAS signal in this region. 
This imputed SNP is also in perfect LD with rs687289, the SNP that tagged the O serotype in 
a vWF GWAS [167]. This RH region contains one splice variant (ABO-201, 937bp) of the 
ABO gene that has a short final exon.  
The adjacent RH region contains a part of the ABO gene that is only present in a second splice 
variant (ABO-001, 6341bp) but not the first one (Figure 45), and the RH test statistic in this 
region far exceeds the GWS threshold (-log10(p-value) = 17.14) while no genotyped SNPs in 
this region reach this threshold with GWAS (highest -log10(p-value)=5.04 at rs7036324, 
MAF=10%). This may indicate the presence of causal variants at this locus that are poorly 
captured by genotyped SNPs. Indeed, the GWAS using imputed SNPs reveals a SNP that 
Figure 45 - RH and GWAS results at the ABO locus 
Two splice variants of the ABO gene are depicted. Retained exons are indicated by purple rectangles 
while introns are indicated by purple lines. The direction of gene transcription is shown. The grey 
dashed line indicates the border between the two RH regions. RH results and test statistics for the most 
significant SNPs in the GWAS using genotyped (called GWAS on the plot), or imputed SNPs (called 
Imputed GWAS on the plot) are shown for each region, and the rsIDs and MAFs of these SNPs are 
indicated, as are their LD statistics. At the bottom, the pedigree-free linkage, RH and imputed GWAS 




reaches -log10(p-value)=17.12 in this region (at rs8176759, MAF=11%), and this SNP is not 
in LD with rs7036324 (R2=0.003, D’=0.628). This demonstrates the ability of RH to detect a 
signal originating from a SNP that is not genotyped. 
When the analyses are re-run by conditioning on the genotype of the imputed SNP that yielded 
the strongest signal at the ABO locus, rs514659, the pedigree-free linkage signal is mostly lost 
(LOD=1.24), indicating that this one variant captures most of the linkage signal. In this 
conditional analysis, the imputed GWAS still highlights hits with -log10(p-value)=10 in both 
regions (at rs8176704 in the primary region and at rs34039247 in the secondary region, these 
SNPs are in complete LD with each other and have MAF=6%), indicating that the initial strong 
GWAS signal was masking a secondary signal originating from these variants. The RH signal 
is lost in the primary region, but in the secondary region a signal remains with -log10(p-
value)=6.41, which suggests that the source of the secondary signal may lie within this region. 
The imputed SNP yielding the most significant p-value in this region in the conditional GWAS 
analysis, rs34039247, is in perfect LD with rs8176704, a SNP that tags the A serotype in the 
same vWF GWAS mentioned above [167].  
Because the pedigree-free linkage analysis region covers the entire locus discussed here, it 
may be detecting the joint effects of these variants that independently modulate vWF levels. 
In contrast, the fact that the ‘O’ and ‘A’ variants lie in two adjacent RH regions might be the 
reason why they appear as two separate signals in the RH analysis, while the effect of the 
strongest (‘O’) SNP masks the effect of the secondary (‘A’) SNP in the imputed GWAS. 
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Chapter 8 Discussion 
Within this thesis, I used five family-based datasets to conduct genetic analysis of 45 
medically-relevant human complex traits with three distinct statistical methodologies. The aim 
of this thesis was to provide a systematic assessment of the strengths and weaknesses of 
GWAS, variance component linkage analysis and regional heritability mapping to detect QTLs 
under a wide range of genetic architectures; as a consequence of these analyses, novel 
candidate loci contributing to complex trait variation were also uncovered. 
The results presented here reaffirm that human complex traits vary in terms of their underlying 
genetic architecture. For example, the highly polygenic nature of height, well known from 
published analyses, is also demonstrated here because in the Generation Scotland study as well 
as in meta-analyses, all three statistical methods reveal many loci, individually of small effect, 
influencing this trait. In contrast, some blood biochemistry traits such as the serum levels of 
cholesterol, von Willebrand Factor or uric acid are influenced by a combination of a few loci 
of large effect and many additional loci with individually small effects. These findings make 
it clear that the genetics of complex trait variation cannot be described with any one model 
(such as the common disease-common variant [6], common disease-rare variant [9] or 
infinitesimal [11] models described in the Introduction), because complex traits are often the 
consequence of a combination of large and small effects originating from common as well as 
rare variants [10]. 
My results were consistent with GWAS, RH and linkage analysis being capable of uncovering 
different types of genetic signals. While both GWAS and RH were able to detect signals 
originating from a single causal variant, as evidenced by the fact that all but a few hits 
discovered with GWAS also appear in the results of RH, 27 additional hits are detected with 
RH only. This method might therefore be better powered to detect regions where several 
independent causal SNPs are present, which may not be detected with single-SNP GWAS. 
Additionally, most of the loci identified with RH but not GWAS in the cohorts studied here 
have also been reported in published GWAS meta-analyses, but their detection required 
sample sizes much larger than the ones used within this thesis. This is a clear advantage of 
using RH in cohorts where complex traits that are not widely measured are available (for 
example phenotypes that are costly to measure or require specialist equipment to quantify). 
In contrast, pedigree-based linkage analyses often do not detect the loci identified with GWAS 
or RH, even when these harbour QTLs that have large effects on a trait. This is likely a 
consequence of the limited power of pedigree-based linkage analysis, as the simulation studies 
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presented within this thesis suggest that pedigree-based linkage analysis can detect the same 
loci found with GWAS or RH, but only if the effects of a QTL are sufficiently large. Instead, 
relying on the assessment of genomic segments that are shared IBD, both pedigree-based and 
pedigree-free linkage analyses reveal loci that are not detected with GWAS and RH. Such loci 
could be false positives, but they could also harbour rare causal variants that segregate on 
specific haplotypes. The simulation studies I performed demonstrated that pedigree-free 
linkage analysis can sometimes detect signals originating from low frequency (MAF < 5%) 
variants even when these are missed with GWAS, suggesting that some of the loci flagged 
when analysing ‘real’ phenotypes might be true positives. 
The fact that linkage analysis results often depend on the family structures (and therefore 
genetic segregation patterns) present in a study means that while they may reveal novel loci 
that have not been discovered with GWAS, these loci could be hard (or impossible) to replicate 
in other cohorts. Indeed, in the literature, novel linkage peaks explaining a large proportion of 
the trait variance in a specific cohort often lack replication or functional follow-up that would 
lend more confidence to their validity. For example, in one study [167], linkage analysis of 
von Willebrand factor levels has resulted in a peak with a LOD score of 2.9 on chromosome 
9 at the ABO locus, and this peak explains 24.5% of the trait variance and was also detected 
with GWAS in the same study as well as with linkage analysis and GWAS within this thesis. 
However, this study also reports a linkage peak with a higher LOD score of 5.3 on 
chromosome 2, which explains 19.2% of the trait variance, but this signal is not present in 
their GWAS and also not present in the GWAS or linkage analysis results reported in this 
thesis. In the same study, the authors also fail to identify haplotypes in this region that have a 
strong effect on the trait. While they flag two 1 Mb loci by looking at differences in SNP LD 
structure, these loci do not harbour any genes that play an obvious role in vWF biology. This 
emphasizes the difficulty in following up regions identified by linkage analysis but it may also 
indicate the possibility that this may be a false positive hit.  
The advantage of isolate populations over cosmopolitan populations for linkage analysis is 
evidenced by the fact that, according to the power calculations performed using SOLAR, 
Orkney and Generation Scotland appear to have the same power to detect a QTL with 
pedigree-based linkage analysis, despite the tenfold smaller sample size in Orkney. This is a 
consequence of the more complex family structure and a higher number of individuals in 
families in Orkney. However, when analysing real phenotypes instead of quantitative traits 
simulated using a single QTL, more loci are identified with pedigree-based linkage in 
Generation Scotland than in Orkney, with the caveat that these could again be due to false 
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positives. This discrepancy may be due to the fact that simulation studies are often unable to 
account for latent factors that drive complex trait variation so they may provide results that do 
not hold up when the same method is applied in a ‘real’ scenario. Similarly, in the simulation 
studies I performed, phenotypes simulated using DISSECT were not an accurate 
representation of complex traits as they simulated a single major QTL on a polygenic 
background, and did not take account of the fact that environmental variance is not distributed 
randomly within families. This means that they may not be entirely suitable for comparing the 
performance of the same statistical methods in different populations due to their inability to 
capture some factors such as cohort-specific environment effects that may lead to cohort-
specific trait variation. Nonetheless, such simulation studies still provide useful guidance for 
interpreting the results obtained when analysing ‘real’ data. 
By setting up the pedigree-free linkage analysis pipeline, I have attempted to provide a boost 
to the power to detect a QTL compared to pedigree-based linkage analysis by extending 
linkage analysis to include distantly-related individuals who are not recorded in a social 
pedigree but who may still share some segments IBD. This should lead to an increase in power 
particularly in population isolates, due to these having a higher number of relatives and an 
overall increase in IBD sharing. Interestingly, pedigree-free linkage analysis reveals genetic 
effects segregating at the population level that have been detected with GWAS but remained 
undetected with pedigree-based linkage analysis, which is likely due to a gain in power as a 
larger number of related individuals are used. In theory, linkage analysis can be a useful tool 
for identifying regions harbouring QTLs missed by single-SNP GWAS, as it can detect the 
combination of effects of several independent alleles at the same locus or allelic heterogeneity 
with multiple rare variants. Detecting such loci would be a boon for prioritising regions 
influencing traits in the age of whole-genome sequencing. However, I acknowledge that 
linkage analysis overall is not very powerful for studying the genetic basis of complex traits 
in the cohorts that I have studied here. The power of discovery could be boosted by using 
larger studies that have a higher number of related individuals. More critically, the use of 
denser genotyping data (or in the near future, the use of whole genome sequencing) might 
allow for more accurate estimation of IBD sharing. The inaccurate estimation of IBD sharing 
may have been a source of false positives in the studies presented here and the accurate 
determination of segments shared IBD might have been hindered by the fact that fairly sparse 
genotype data were used, which is a consequence of the use in the same cohort of multiple 
genotyping platforms that have a limited amount of overlapping SNPs. Another consideration 
is that pedigree-free linkage analysis is very time-consuming to run even with the pipeline that 
I have created, because of current software limitations. The two rate-limiting steps are the 
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conversion of the IBD coefficient files output by IBDLD to SOLAR format (which could 
easily be circumvented by IBDLD outputting files directly to this format, and its developers 
have communicated to me that this is something they are already considering), and the linkage 
analysis step in SOLAR, which is unable to perform the analysis when provided with pairwise 
IBD sharing between more than 2000 individuals. Instead, the variance component analysis 
could be performed using DISSECT, the program that was used to conduct RH mapping within 
this thesis, as it can handle a large number of pairwise relationships, but it is not currently 
optimised for performing analysis sequentially on many externally-computed matrices. 
Within this study, traits that have been extensively studied with GWAS were used as positive 
controls, and it is reassuring that I find many loci that replicate published findings obtained 
from large GWAS meta-analyses. These positive controls also lend confidence to the validity 
of novel loci I identify. Currently, most large GWAS meta-analyses report the results of 
GWAS performed on genotypes imputed to the 1000 genomes reference panel [90] and many 
hits reported within this thesis replicate these findings. However, low frequency (MAF in the 
range of 0.5-5%) variant detection with GWAS has been improved with the help of the HRC 
imputation panel which allows many such variants to be inferred with a high degree of 
confidence, and several novel associations with low frequency variants are identified within 
this thesis, particularly in Generation Scotland as well as the GWAS meta-analysis. It will be 
interesting to see whether these associations will replicate in independent GWAS performed 
using genotypes imputed to the HRC panel.  
One such dataset is the UK Biobank [207], which consists of genotype and phenotype data for 
500,000 participants, who also have had their genotypes imputed to the HRC panel [208]. Due 
to its sheer size alone, this resource will lead to the discovery of many associations with rare 
variants, as compared to smaller studies, there will be more instances of a rare variant with the 
same allele frequency within UK Biobank. One exception to this is if a specific rare variant is 
enriched within a population isolate due to drift or founder effect for example, in which case 
there could be a higher number of minor alleles carried by a smaller number of individuals. In 
addition to its size, another advantage of UK Biobank is the fact that phenotypes were 
measured the same way across all UK Biobank participants, and consistent genotyping and 
imputation protocols were used. This should eliminate a lot of noise that would normally be 
present in a meta-analysis combining the results of many different cohorts. As a consequence, 
GWAS performed using the UK Biobank data should have an additional boost in power 
compared to a meta-analysis using the same number of samples. UK Biobank will therefore 
act as the primary point of reference for replicating the findings of other complex trait mapping 
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studies. For this purpose, an atlas of genetic associations in UK Biobank has already been 
created, where GWAS results of over 700 traits are reported [209]. While the searchable 
database provided by this study is still in its infancy, it (or related tools such as the Global 
Biobank Engine (http://gbe.stanford.edu/)) will eventually provide simple means of 
assessing whether a signal detected in a study was also present when analysing the same trait 
in UK Biobank using GWAS.  
A resource of this magnitude provides clear advantages for performing GWAS, especially of 
well-studied, easily measurable phenotypes. However, one advantage of the smaller cohorts 
used in this study is that, compared to  the UK Biobank dataset which sampled individuals 
aged 40-69, our populations are richer in ‘vertical’ family relationships. The 29-yeasr age 
range results in an underrepresentation of multi-generational family relationships in UK 
biobank, so studies that make use of, or explicitly model, this kind of relationship will benefit 
from using cohorts sampled with this in mind. Indeed, in the UK biobank, there are only 1066 
trios (two parents and an offspring), 172 families with 5 or more 2nd degree or close relatives 
and no instances of three-generation families [208]. In contrast, in the Orkney cohort for 
example, according to the ‘clipped’ pedigrees, there are 170 families with an average number 
of 11 genotyped individuals per family, while in Shetland, the clipped pedigrees show 273 
families with an average number of 8 people per family. These deep pedigrees are particularly 
advantageous for studying parent-of-origin effects or pedigree-associated genetic variation 
[210]. Whether they will be used in linkage analysis will depend on the future assessment and 
improvement of the pedigree-free linkage analysis methodology. In Orkney, whole-genome 
sequencing data will soon be available, which should allow for more in-depth follow-up of the 
novel regions identified within this cohort.  
My work has led to a publication presenting the results of the Generation Scotland GWAS 
using HRC imputed data, of which I am the lead author [62]. By curating the social pedigrees 
and genetic data in the Generation Scotland study, I also contributed to the work of others 
studying the genetics of Alzheimer’s disease [211], the genetic interactions between longevity 
and educational attainment [212], the genetic and environmental factors contributing to 
depression [184, 213], cardiometabolic and anthropometric trait variation [210] and regional 
differences in obesity-related phenotypes [214]. By performing genetic analyses in the 
Orkney, Vis and Korčula cohorts, I have contributed to a study assessing the genetic and 
environmental factors affecting retinal microvasculature [215] as well as a study that aimed to 
predict complex traits using a combination of SNPs obtained from meta-analysis results and 
machine learning prioritisation methods [216]. In addition to work that has already led to 
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publications, I am currently contributing to a project led by Prof. Ruth Jarrett at the University 
of Glasgow on integrated chromosomally inherited human herpesvirus 6. The pedigree-free 
linkage pipeline I created and IBD sharing estimation methods are being used to determine the 
sites of the human genome this virus has integrated into in different families in the Generation 
Scotland study. Finally, the same methods and pipelines that I have developed can readily be 
applied to other traits, particularly new phenotypes derived from biological samples such as 
metabolomics and proteomics that are becoming available in the isolates cohorts but are not 
currently feasible at scale in large cohorts such as the UK Biobank. 
This thesis contributes to the field of complex trait genetics by systematically comparing 
different statistical study designs, creating robust pipelines and identifying novel genetic loci 
that affect medically-relevant human traits, which can improve human trait prediction and 
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Supplementary Table 1 - Hits that exceed the suggestive but not the genome-wide significance threshold in cohort-specific 
GWAS following HRC imputation 
This table summarizes the hits that passed the suggestive significance threshold (logP>7.3) in the GWAS using imputed genotypes, providing their -
log10(p-value), effect size and its standard error (Beta and Beta_SE columns), the allele for which the effect size is reported (EA column) as well as the 
cohort and trait-specific frequency of this allele (EAF column). The nhits column indicates the number of SNPs within 500kb of the reported SNP that 
exceeded the cohort-specific GWS threshold in the GWAS using imputed genotypes. Within this 1Mb interval, the position and -log10 (p-value) of the 
SNP with the most significant test statistic in the GWAS using genotyped SNPs is shown (Pos_G and logP_G columns). The name of, and distance to, 
the gene closest to the reported SNP is indicated – the distance is 0 if the SNP lies within the gene itself. The final column indicates whether other GWAS 
have identified this hit before. The first value indicates whether any SNPs in the 1000 Genomes data that are in strong LD with the reported SNP (R2 and 
D’ > 0.8) have been identified with other GWAS, while the second value looks at all SNPs within 100kb of the reported SNP, regardless of LD. 
Trait 
Chr Pos rsID logP Beta Beta_SE EA EAF nhits Pos_G logP_G Gene Dist GWAS 
Orkney 
BMI 1 232053321 rs17821689 7.31 0.593 0.1087 G 0.0269 1 232477033 1.22 DISC1 0 0|0 
CRP 1 159665921 rs2808624 7.78 -0.216 0.0383 G 0.3703 5 159652939 7.45 CRP 16156 1|1 
CRP 6 33035969 rs3179779 7.37 -0.483 0.0883 G 0.0633 1 33026246 3.28 HLA-DPA1 0 0|0 
CRP 19 45411941 rs429358 7.85 -0.278 0.0489 C 0.1806 2 45395619 6.69 APOE 0 1|1 
Diastolic BP 7 5914756 rs146713555 8.44 6.451 1.0936 T 0.0217 3 6353371 2.05 OCM 5671 0|0 
Forced Vital Capacity 9 76961908 rs62550438 7.99 0.336 0.0587 T 0.0922 2 76786297 3.14 RORB 150342 0|0 
GGT 22 24996582 rs2330795 7.58 0.274 0.0492 A 0.3561 6 25368543 2.84 GGT1 0 1|1 
Total Cholesterol 19 45412079 rs7412 8.65 -0.373 0.0624 T 0.0764 2 45395619 4.31 APOE 0 1|1 
Triglycerides 11 116648917 rs964184 7.86 -0.143 0.0252 C 0.866 1 116621963 4.51 ZNF259 357 1|1 
Uric acid1 11 49346641 rs187788041 8.36 -0.971 0.1654 A 0.0103 9 49627833 0.92 FOLH1 116418 0|0 




Chr Pos rsID logP Beta Beta_SE EA EAF nhits Pos_G logP_G Gene Dist GWAS 
Uric acid1 11 59901327 rs181316004 8.11 -0.887 0.1536 C 0.0134 1 59824526 1.58 MS4A2 35386 0|0 
Uric acid1 11 71909897 rs117521416 7.78 -0.9 0.1595 A 0.0112 2 72107188 2.45 FOLR1 2529 0|0 
Uric acid2 11 46397253 rs147604011 7.48 -0.974 0.1762 G 0.0119 1 45975130 1.91 DGKZ 0 0|0 
Uric acid2 11 50720455 rs186997623 7.69 -0.902 0.1608 C 0.0136 1 50522307 0.34 LOC646813 340652 0|0 
Uric acid2 11 57989542 rs202065992 8.09 -0.885 0.1535 A 0.0193 1 58004159 1.58 OR10Q1 5810 0|0 
Uric acid2 11 59901327 rs181316004 7.44 -0.889 0.1613 C 0.0141 1 59738667 1.21 MS4A2 35386 0|0 
Uric acid2 11 67512382 rs144771122 8.31 -0.822 0.1404 T 0.0179 1 67423892 2.35 LOC645332 46854 0|0 
Uric acid2 11 71120029 rs117991852 8.02 -0.892 0.1554 T 0.0145 1 70819038 2.15 LOC339902 0 0|0 
Uric acid2 11 72900306 rs79750124 7.97 -0.835 0.1460 T 0.017 1 72414189 3.33 P2RY2 29036 0|0 
Waist 11 65356754 rs948578 7.55 0.186 0.0335 T 0.4952 1 65494987 3.68 EHBP1L1 0 0|0 
Vis 
Calcium 10 77964415 rs74584091 7.78 0.487 0.0863 T 0.1369 1 77675236 3.19 C10orf11 0 0|0 
GGT 14 103569748 rs72706640 7.56 0.329 0.0592 C 0.2337 1 103756099 2.23 EXOC3L4 0 1|1 
GGT 22 24996582 rs2330795 7.52 0.293 0.0529 A 0.4144 8 24991144 1.77 GGT1 0 1|1 
Glucose 20 22847511 rs978411 7.62 0.726 0.1302 C 0.0553 1 22372227 2.4 SSTR4 168544 0|0 
Glucose_nodiab 12 51504172 rs10876137 7.82 0.455 0.0804 T 0.1086 3 51479682 2.19 TFCP2 0 0|0 
GPT 11 76660793 rs56789915 8.3 0.276 0.0472 C 0.5814 35 76414893 8.1 ACER3 0 0|0 
Height 5 101606071 rs2600831 7.81 0.018 0.0031 A 0.3915 7 101688812 4.31 SLCO4C1 0 0|0 
LDL 19 45412079 rs7412 8.17 -0.505 0.0871 T 0.095 1 45879279 2.19 APOE 0 1|1 
Shetland 
Alcohol consumption 12 107068030 rs149828296 7.68 -0.583 0.1041 C 0.0259 1 106931703 2.66 RFX4 0 0|0 
BMI 21 22896160 rs233799 8.08 0.201 0.0349 A 0.6637 2 22896160 7.96 NCAM2 0 0|0 
Educational 
Attainment 1 105502253 rs74954432 7.57 3.541 0.6367 G 0.0099 1 105067105 2.18 LOC100129138 882559 0|0 




Chr Pos rsID logP Beta Beta_SE EA EAF nhits Pos_G logP_G Gene Dist GWAS 
GGT 22 24994708 rs2017188 8.47 0.204 0.0345 C 0.3369 15 24992266 7.09 GGT1 0 1|1 
HbA1c 6 162977834 rs116884606 7.59 0.487 0.0875 T 0.0401 2 163270143 3.55 PARK2 0 0|0 
Heart Rate 3 31330858 rs9859166 7.47 4.363 0.7904 T 0.0409 6 31329185 7.04 STT3B 243631 0|0 
Height 3 141082990 rs13100711 8.54 0.012 0.0020 T 0.3259 8 141074962 7.67 ZBTB38 0 0|1 
Height 13 29559059 rs147382386 7.89 0.054 0.0096 G 0.0107 1 29063969 2.64 MTUS2 39687 0|0 
Waist 19 17483973 rs79607374 8.7 -0.587 0.0978 A 0.0314 1 17000632 4.69 PLVAP 0 0|0 
Korčula 
Albumin 4 73515987 rs115058973 8.17 0.85 0.1467 A 0.0103 1 73618440 2.12 ADAMTS3 81470 0|0 
Albumin 6 8344289 rs149984974 7.51 0.655 0.1183 C 0.0184 1 7924658 2.8 SLC35B3 69010 0|0 
Albumin 15 49771796 rs12901446 7.48 -0.492 0.0890 T 0.0266 1 49562266 1.95 FGF7 0 0|0 
Central Corneal 
Thickness 16 88331515 rs9934580 7.31 0.285 0.0523 G 0.5972 1 88298124 6.63 ZNF469 162362 1|1 
fev1perfvc 9 78732604 rs114200252 8.18 0.357 0.0615 A 0.1044 1 78688079 1.98 PCSK5 0 0|0 
fev1perfvc 10 16711372 rs7092141 7.64 -0.272 0.0486 C 0.1104 1 16556710 1.82 RSU1 0 0|0 
fev1perfvc 12 94417315 rs12146740 8.35 -0.359 0.0612 A 0.0621 1 94374805 1.73 PLXNC1 125182 0|0 
fev1perfvc 14 68861465 rs7145422 8.47 -0.224 0.0379 T 0.7028 3 69203145 1.67 RAD51L1 0 0|0 
fev1perfvc 16 31023414 rs72800849 7.62 0.186 0.0333 A 0.4262 1 31289396 1.27 STX1B 1584 0|0 
Triglycerides 9 88921734 rs117621872 7.39 -0.236 0.0430 A 0.0319 1 89035754 1.43 ZCCHC6 0 0|0 
GS 
BMI 2 228006255 rs10498218 7.4 -0.942 0.1715 G 0.0012 1 228336315 2.43 COL4A4 0 0|0 
BMI 15 39654281 rs149913955 7.66 -0.463 0.0827 A 0.0059 2 39458415 2.36 C15orf54 107232 0|0 
BMI 16 17177110 rs571835655 8.18 -1.06 0.1827 A 0.0011 1 17065473 2.09 XYLT1 18516 0|0 
Body fat 1 192893075 rs10921288 7.98 1.466 0.2561 C 0.0237 7 192891048 7.8 UCHL5 88419 0|0 
Body fat 2 227660641 rs142101835 7.49 5.537 1.0020 G 0.0022 1 227521410 2.12 IRS1 0 0|0 




Chr Pos rsID logP Beta Beta_SE EA EAF nhits Pos_G logP_G Gene Dist GWAS 
Body fat 18 46837578 rs141793746 7.48 4.318 0.7815 T 0.0029 1 46554787 2.66 DYM 0 0|0 
Creatinine 1 234420503 rs573421908 7.87 0.726 0.1278 A 0.0027 1 234452980 3.12 SLC35F3 0 0|0 
Creatinine 4 9542350 rs62412107 7.73 0.152 0.0270 A 0.0653 2 9443894 1.93 MIR548I2 15437 0|0 
Educational 
Attainment 2 113518931 rs187728767 7.43 1.979 0.3595 A 0.0027 1 113807144 3.13 CKAP2L 0 0|0 
Educational 
Attainment 9 99112276 rs753676304 7.49 2.302 0.4163 G 0.002 1 99085363 2.68 SLC35D2 0 0|0 
Educational 
Attainment 12 54690428 rs150528113 7.44 2.279 0.4138 C 0.0022 1 54568590 3.99 NFE2 0 0|0 
FEV1 19 54243719 rs117764849 7.63 0.339 0.0607 C 0.0155 1 53939690 4.09 MIR517C 846 0|0 
Forced Vital Capacity 2 186162246 rs182694754 8.5 -0.598 0.1010 T 0.0041 15 185926550 1.94 ZNF804A 358031 0|0 
Forced Vital Capacity 9 19468530 rs7021552 7.32 -0.071 0.0130 T 0.308 1 19468530 7.26 ACER2 16029 0|0 
Glucose 10 3328318 rs533883198 7.41 0.683 0.1243 A 0.0026 1 3442533 2.77 PITRM1 113315 0|0 
Glucose 13 28499962 rs7981781 7.86 0.079 0.0139 A 0.2334 22 28491198 7.5 PDX1 0 1|1 
Glucose 21 44276432 rs370189685 8.14 -1.176 0.2033 C 0.0013 1 44711272 4.93 WDR4 0 0|0 
Glucose_nodiab 1 214150821 rs79687284 7.73 0.204 0.0363 C 0.0364 1 214173840 2.61 PROX1 11037 0|1 
Glucose_nodiab 2 27741105 rs780095 8.09 0.071 0.0123 G 0.5758 11 27741237 7.53 GCKR 0 1|1 
Glucose_nodiab 9 96182703 rs143399767 7.85 0.362 0.0638 C 0.0103 1 96682611 1.96 FAM120AOS 26077 0|0 
Glucose_nodiab 21 44276432 rs370189685 7.56 -1.15 0.2070 C 0.0013 1 44711272 3.29 WDR4 0 0|0 
HDL 1 8233270 rs149963466 7.5 0.868 0.1569 A 0.0016 1 8280517 2.19 ERRFI1 146876 0|0 
HDL 2 43255645 rs76183280 7.38 -0.498 0.0908 C 0.0048 1 43314843 2.33 ZFP36L2 193894 0|0 
HDL 8 9183596 rs4841132 7.97 0.109 0.0191 G 0.9079 4 9177732 6.14 LOC157273 0 1|1 
HDL 9 107661742 rs2740488 7.6 -0.069 0.0124 C 0.2743 3 107666513 7.53 ABCA1 0 1|1 
HDL 14 106824367 rs2338129 8.16 -0.653 0.1127 A 0.0038 1 106846077 2.18 NCRNA00226 79399 0|0 
HDL 18 47106028 rs149615216 8.5 0.302 0.0509 T 0.0121 5 47179516 5.41 LIPG 0 0|1 




Chr Pos rsID logP Beta Beta_SE EA EAF nhits Pos_G logP_G Gene Dist GWAS 
HDL 20 44538484 rs435306 7.54 -0.07 0.0127 T 0.7452 1 44545048 7.11 PLTP 0 0|1 
Heart Rate 1 6296238 rs9970334 7.36 0.697 0.1272 G 0.4474 1 6278414 3.79 ICMT 193 0|1 
Heart Rate 3 87751558 rs755291044 7.74 8.6 1.5280 A 0.0017 1 87910931 2.52 HTR1F 288288 0|0 
Heart Rate 8 4102424 rs145669495 7.7 7.665 1.3660 G 0.0022 1 3797879 2.39 CSMD1 0 0|0 
Heart Rate 8 62481520 rs142916219 7.66 5.971 1.0670 G 0.0038 1 62517963 2.34 ASPH 0 0|0 
Height 1 177404510 rs146949893 7.35 0.039 0.0071 C 0.0031 1 177129230 2.43 FAM5B 152951 0|0 
Height 1 182706092 rs558671668 7.6 0.027 0.0048 C 0.0062 1 182971816 2.78 NPL 52336 0|0 
Height 4 17994298 rs35362908 8.15 -0.008 0.0013 C 0.1005 1 17957354 6.44 LCORL 0 1|1 
Height 4 86496830 rs552283803 7.4 -0.053 0.0096 C 0.0016 1 86751384 2.81 AHRGAP24 0 0|0 
Height 5 32773275 rs72742734 7.44 0.008 0.0015 G 0.0538 1 32765457 4.69 NPR3 0 0|1 
Height 7 113267859 rs184469050 7.8 -0.022 0.0038 G 0.0088 1 113333114 2.96 PPP1R3A 249021 0|0 
Height 11 75282052 rs634552 7.64 -0.006 0.0010 G 0.8635 5 75276178 7.35 SERPINH1 0 1|1 
Height 12 4384844 rs76895963 7.46 0.012 0.0023 G 0.0285 1 4071901 2.02 CCND2 0 0|0 
Height 12 93956672 rs11614062 7.68 0.005 0.0009 T 0.1944 4 93962959 7.12 LOC144481 2730 0|1 
Sodium 5 175615619 rs144466366 7.5 0.84 0.1517 T 0.0017 1 175248342 1.85 LOC643201 0 0|0 
Sodium 9 93886686 rs140344432 8.55 0.98 0.1649 C 0.0015 1 94179978 3.01 LOC100129316 49271 0|0 
Sodium 14 103031952 rs118075232 8.44 -0.367 0.0622 A 0.0102 1 103244840 3.53 MIR4309 25888 0|0 
Sodium 16 69548788 rs7200764 8.12 -0.085 0.0147 C 0.8403 25 69559696 8.02 CYB5B 48620 0|0 
Total Cholesterol 6 160997118 rs74617384 8.52 0.121 0.0204 T 0.084 4 160882029 3.89 LPA 0 1|1 
Total Cholesterol 16 72108093 rs2000999 8.15 0.083 0.0143 A 0.1781 5 72059149 5.61 HPR 0 1|1 
Urea 1 155178782 rs760077 8.2 -0.064 0.0110 T 0.5758 3 155053719 5.74 MTX1 0 0|1 
Urea 5 40635920 rs112647987 7.51 -0.119 0.0215 T 0.0686 1 40681254 5.82 PTGER4 44110 0|0 
Urea 7 1270699 rs6950388 7.8 0.08 0.0141 A 0.8122 1 1274582 7.3 UNCX 1953 1|1 
Urea 7 151413194 rs10224210 8.24 0.073 0.0125 C 0.2798 8 151405818 6.74 PRKAG2 0 1|1 




Chr Pos rsID logP Beta Beta_SE EA EAF nhits Pos_G logP_G Gene Dist GWAS 
Waist Hip Ratio 9 105853716 rs149924309 7.43 0.693 0.1258 T 0.0023 1 105788456 2.47 CYLC2 72945 0|0 
Waist Hip Ratio 14 94762510 rs187209742 7.31 -0.721 0.1322 G 0.0024 1 94971978 2 SERPINA10 2913 0|0 
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Supplementary Table 2 - Hits that exceed the suggestive but not the genome-wide significance threshold in the GWAS meta-
analysis 
This table summarizes the hits that passed the suggestive significance threshold (logP=7.3) in the GWAS meta-analysis, providing their -log10(p-value), 
effect size (Beta) of the effect allele (EA) and its standard error (Beta_SE) as well as the direction of the effect in each cohort (O=Orkney, V=Vis, 
K=Korčula, S=Shetland, G=GS; - or + values indicate effect size direction, ? indicates that this SNP was not available in the cohort, x indicates that the 
trait was not analysed in the cohort). The nhits column indicates the number of SNPs within 500kb of the reported SNP that exceeded the GWS threshold 
in the meta-analysis. The name of, and distance to, the gene closest to the reported SNP is indicated – the distance is 0 if the SNP lies within the gene 
itself. The final column indicates whether other GWAS have identified this hit before. The first column indicates whether any SNPs in the 1000 Genomes 
data that are in strong LD with the reported SNP (R2 and D’ > 0.8) have been identified with other GWAS, while the second value looks at all SNPs 
within 100kb of the reported SNP, regardless of LD. 
Trait Chr Pos rsID MAF logP EA Beta BetaSE nhits n O V K S G Gene Dist GWAS 
Albumin 19 15756663 rs575873404 0.1425 7.31 C -0.2323 0.0426 1 2676 ? ? - ? x CYP4F3 0 0|0 
Axial length1 4 4718847 rs62290301 0.0309 7.79 T 0.417 0.0738 2 3566 + + ? + x LOC100507266 6182 0|0 
Axial length2 4 4718847 rs62290301 0.0303 7.41 T 0.4126 0.0751 1 3517 + + ? + x LOC100507266 6182 0|0 
BMI 2 651349 rs2867112 0.1639 8.6 T 0.0783 0.0131 149 27488 - + + + + TMEM18 16622 1|1 
BMI 4 45182527 rs10938397 0.4402 8.19 A -0.056 0.0096 5 27488 - - - - - GNPDA2 453914 1|1 
BMI 16 17177110 rs571835655 0.0011 7.61 A -1.06 0.1901 1 19900 ? ? ? ? - XYLT1 18516 0|0 
BMI 18 57896742 rs17175643 0.2511 7.54 T 0.0605 0.0109 6 27488 + + + + + MC4R 141820 1|1 
Central Corneal 
Thickness 13 41655900 rs78169557 0.1307 7.39 T 0.1983 0.0361 1 4416 + + + + x WBP4 0 0|0 
Cortisol 6 150495762 rs62440055 0.2371 7.36 T -0.1816 0.0332 1 2921 - - x x x PPP1R14C 0 0|0 
Creatinine 1 15914135 rs6679323 0.1459 7.58 A -0.0994 0.0179 1 23950 - - - - - AGMAT 2529 0|0 
Creatinine 16 20392332 rs77924615 0.1915 7.55 A -0.072 0.013 1 23950 - - - - - PDILT 0 0|1 
Creatinine 1 234420503 . 0.0027 7.44 A 0.7259 0.1318 1 16347 ? ? ? ? + SLC35F3 0 0|0 
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Trait Chr Pos rsID MAF logP EA Beta BetaSE nhits n O V K S G Gene Dist GWAS 
Creatinine 1 168754413 rs548873184 0.0011 7.4 A 1.06 0.193 1 16347 ? ? ? ? + DPT 89916 0|0 
CRP 1 66155515 rs4655584 0.3574 8.23 T 0.1465 0.0252 67 4970 + + x + x LEPR 52338 1|1 
Diastolic BP 15 76295311 rs187680191 0.0006 8.28 A -18.58 3.1825 1 19429 ? ? ? ? - NRG4 0 0|0 
Diastolic BP 3 136063325 . 0.0054 8.04 C 12.0257 2.0934 1 1933 + ? ? ? ? STAG1 0 0|0 
Diastolic BP 1 60787284 rs80303520 0.005 7.95 A 12.8615 2.2515 1 2090 ? ? ? + ? C1orf87 247841 0|0 
Diastolic BP 4 20875931 rs79488205 0.0841 7.59 A -0.917 0.1647 2 26948 - - - - - KCNIP4 0 0|0 
Diastolic BP 3 193362377 rs528908640 0.0005 7.49 T -14.67 2.6539 1 19429 ? ? ? ? - OPA1 0 0|0 
Diastolic BP 3 147599147 rs187240817 0.0053 7.38 T -13.04 2.3785 1 1933 - ? ? ? ? ZIC1 464640 0|0 
Diastolic BP 9 109802437 rs568998724 0.0006 7.32 A 13.49 2.472 1 19429 ? ? ? ? + ZNF462 177059 0|0 
FEV1 4 106828795 rs6823809 0.3102 7.38 T 0.0639 0.0116 1 22682 + - - + + NPNT 0 0|1 
fev1perfvc 4 145454964 rs1489762 0.4041 8.71 T -0.0607 0.0101 65 22682 - - - - - LOC646576 109102 1|1 
fev1perfvc 9 78732604 rs114200252 0.1044 8.04 A 0.3566 0.062 1 2397 ? ? + ? ? PCSK5 0 0|0 
Fibrinogen 4 155416635 rs78318334 0.0222 8.08 A -0.5253 0.0912 2 4007 - - x - x DCHS2 3704 0|1 
Forced Vital 
Capacity 6 7807702 rs1225986 0.1689 8.41 T 0.0819 0.0139 16 22717 + - + + + BMP6 0 0|1 
Forced Vital 
Capacity 2 185767897 rs146201345 0.004 7.99 A 0.5929 0.1035 1 15867 ? ? ? ? + ZNF804A 0 0|0 
GGT 14 103565080 rs36027406 0.2233 8.44 T -0.1926 0.0326 14 3075 - x x - x EXOC3L4 1399 1|1 
GGT 12 121424574 rs2393775 0.365 7.71 A 0.1549 0.0276 7 3075 + x x + x HNF1A 0 1|1 
Glucose 21 44276432 rs370189685 0.0013 7.94 C -1.176 0.206 1 16076 ? ? ? ? - WDR4 0 0|0 
Glucose 2 27730940 rs1260326 0.3856 7.42 T -0.0551 0.01 2 23631 - - + - - GCKR 0 1|1 
Glucose_nodiab 2 27741237 rs780094 0.3757 8.01 T -0.0599 0.0104 5 22080 - - - - - GCKR 0 1|1 
Glucose_nodiab 1 214150821 rs79687284 0.037 7.49 C 0.1705 0.0308 1 22080 + - + + + PROX1 11037 1|1 
Glucose_nodiab 9 7698812 rs149779116 0.0055 7.44 A -0.4663 0.0847 1 22080 ? ? - - - C9orf123 97677 0|0 
Glucose_nodiab 21 44276432 rs370189685 0.0013 7.39 C -1.15 0.2096 1 15141 ? ? ? ? - WDR4 0 0|0 
HDL 1 230307222 rs4846923 0.2909 8.57 T -0.0628 0.0106 10 26920 - - - - - GALNT2 0 0|1 
205 
 
Trait Chr Pos rsID MAF logP EA Beta BetaSE nhits n O V K S G Gene Dist GWAS 
HDL 6 127825034 rs150971345 0.0169 8.55 A 0.2502 0.0421 1 26920 + + + + + C6orf174 0 0|0 
HDL 2 21208211 rs7557067 0.2268 7.92 A -0.0643 0.0113 11 26920 - - - - - APOB 16088 1|1 
HDL 8 116610180 rs2737205 0.4354 7.75 T -0.0541 0.0096 6 26920 - - - - - TRPS1   0|1 
HDL 12 125353810 rs67053123 0.1346 7.52 A 0.0789 0.0142 2 26920 - + + + + SCARB1 5290 0|1 
Heart Rate 20 5376623 #N/A 0.0008 8.14 A 18.54 3.2045 1 19798 x x ? ? + PROKR2 94306 0|0 
Heart Rate 3 87751558 . 0.0017 7.42 A 8.6 1.5639 1 19798 x x ? ? + HTR1F 288288 0|0 
Heart Rate 8 62481520 rs142916219 0.0038 7.34 A -5.971 1.0921 1 19798 x x ? ? - ASPH 0 0|0 
Height 7 92237426 rs42032 0.2575 8.75 A 0.0041 0.0007 8 27555 + + + + + CDK6 0 0|1 
Height 6 19838447 rs147448400 0.0612 8.71 A 0.0078 0.0013 1 27555 + + + + + ID4 0 0|1 
Height 1 17309718 rs3754512 0.4738 8.63 T 0.0035 0.0006 11 27555 + + + + + MFAP2 1636 1|1 
Height 4 82296362 rs28814370 0.2986 8.53 T 0.0038 0.0006 38 27555 + + + + + RASGEF1B 51855 0|1 
Height 13 46341501 rs75061684 0.0006 8.15 A -0.1252 0.0216 1 19965 ? ? ? ? - SIAH3 12913 0|0 
Height 12 93972987 rs11107115 0.1984 8.12 A -0.0043 0.0007 19 27555 - - - - - SOCS2 3008 0|1 
Height 4 17994298 rs35362908 0.0981 8.06 T 0.0065 0.0011 5 27555 + + + + + LCORL 0 1|1 
Height 1 149892872 rs11205277 0.4281 7.96 A -0.0035 0.0006 2 27555 - - - - - SF3B4 2337 0|1 
Height 19 8670147 rs62621197 0.0391 7.72 T -0.0099 0.0018 1 27555 - - - - - ADAMTS10 0 0|1 
Height 10 130682872 . 0.001 7.62 T -0.0919 0.0165 1 19965 ? ? ? ? - MGMT 582576 0|0 
Height 2 232790491 rs11900720 0.1244 7.54 T -0.005 0.0009 2 27555 - - - - - NPPC 0 0|1 
Height 15 100692953 rs72755233 0.1271 7.49 A -0.0054 0.001 1 27555 - - + - - ADAMTS17 0 0|1 
Height 6 126851160 rs1490384 0.4985 7.4 T 0.0032 0.0006 1 27555 + - + - + CENPW 181405 1|1 
Insulin 19 8917703 rs188218737 0.0053 7.62 A 1.3849 0.2482 1 2089 ? ? x + x ZNF558 2677 0|0 
LDL 1 109821307 rs583104 0.2278 8.12 T 0.1161 0.0201 10 7663 + + + + x PSRC1 867 1|1 
LDL 5 74656539 rs12916 0.3932 7.31 T -0.0932 0.0171 1 7663 - - - - x HMGCR 0 1|1 
Spherical 
Equivalent 
Refraction 14 76779969 rs188808208 0.0092 7.83 C -1.1541 0.2038 1 1924 ? ? ? - x ESRRB 57719 0|0 
206 
 
Trait Chr Pos rsID MAF logP EA Beta BetaSE nhits n O V K S G Gene Dist GWAS 
Total 
Cholesterol 16 72108093 rs2000999 0.1816 8.45 A 0.0716 0.0121 6 26960 + + + - + HPR 0 1|1 
Total 
Cholesterol 2 179387808 rs186622371 0.0068 7.56 C 1.2565 0.2261 3 2007 + ? ? ? ? LOC100506866 0 0|0 
Triglycerides 5 83471386 rs143440237 0.0045 8.38 T 0.7517 0.1279 1 2674 ? ? + ? x EDIL3 0 0|0 
Triglycerides 2 27730940 rs1260326 0.4054 8.19 T 0.0501 0.0086 4 7698 + + + + x GCKR 0 1|1 
Urea 1 155722506 rs12134456 0.4122 7.58 C -0.0607 0.0109 1 23316 - - x - - GON4L 0 0|0 
Uric acid1 11 69924331 rs531520064 0.0074 8.71 A 1.2364 0.2061 1 2003 + ? ? ? x ANO1 77 0|0 
Uric acid1 11 73682274 rs539867601 0.0067 8.5 A -1.2073 0.2039 1 2003 - ? ? ? x DNAJB13 0 0|0 
Uric acid1 11 56102498 rs182906282 0.0091 8.25 T -1.017 0.1746 1 2003 - ? ? ? x OR8K3 16715 0|0 
Uric acid1 4 89039082 rs1481012 0.0923 7.93 A -0.1669 0.0293 9 7715 - - - - x ABCG2 0 1|1 
Uric acid1 11 46559649 rs148042064 0.0085 7.85 T -1.04 0.1833 1 2003 - ? ? ? x AMBRA1 0 0|0 
Uric acid1 5 72425458 rs13182742 0.2564 7.59 T 0.1142 0.0205 1 7715 + + + + x TMEM171 0 0|1 
Uric acid2 11 47081384 rs757626652 0.0089 7.76 A -1.1139 0.1976 1 1715 - ? ? ? x C11orf49 0 0|0 
Uric acid2 11 50740928 rs117993891 0.0083 7.71 A -1.1122 0.198 3 1715 - ? ? ? x LOC646813 361125 0|0 
Uric acid2 11 50751235 . 0.0083 7.71 A -1.1122 0.198 3 1715 - ? ? ? x OR4A5 660143 0|0 
Uric acid2 11 56102498 rs182906282 0.0087 7.66 T -1.0641 0.1901 1 1715 - ? ? ? x OR8K3 16715 0|0 
Uric acid2 11 57113738 . 0.0088 7.65 A -1.0909 0.1951 1 1715 - ? ? ? x P2RX3 0 0|0 
Uric acid2 11 71674670 rs183077143 0.0087 7.62 A 1.1201 0.2008 4 1715 + ? ? ? x RNF121 0 0|0 
Uric acid2 11 69924331 rs531520064 0.0074 7.57 A 1.2224 0.2198 1 1715 + ? ? ? x ANO1 77 0|0 
Uric acid2 11 44713083 rs536771513 0.0104 7.4 C -1.0594 0.1929 1 1715 - ? ? ? x TSPAN18 34932 0|0 
Uric acid2 11 73682274 rs539867601 0.0067 7.4 A -1.2069 0.2198 1 1715 - ? ? ? x DNAJB13 0 0|0 
Waist 15 100516472 rs11634977 0.3406 8.38 A 0.0585 0.01 29 27212 + + + + + ADAMTS17 0 0|0 




Supplementary Table 3 - Loci that exceed the suggestive but not the genome-wide significance threshold with pedigree-based 
linkage analysis, using IBD coefficients calculated by IBDLD 
The rsID of the SNP at which the highest LOD score was obtained is shown, as is the chromosome (Chr column) and position (Pos column) where this 
SNP is located. The start and end positions of the interval where LOD scores that are within a 2-LOD drop of the top hit are shown, in Megabases (2-
LOD drop column). The total trait heritability (h2) and heritability explained by the hit (h2QTL), as output by SOLAR, are shown. The ‘Gene’ and 
‘Gene_Dist’ columns indicate the gene nearest the top hit, as well as the distance to this gene from the top hit (this distance is 0 when the top hit is within 
the gene itself). 
Trait 




QTL 2-LOD drop Band Gene Gene_Dist 
Orkney 
BMI 16 rs8045775 58867855 3.4169 0.43 0.24 56.57-64.44 q12.2-q21 GOT2 99608 
Cortisol 3 rs1564760 47582724 4.1181 0.29 0.23 42.33-54.81 p22.1-p14.3 CSPG5 21002 
Cortisol 3 rs1910236 59434420 3.9671 0.31 0.26 56.79-60.09 p14.3-p14.2 FHIT 300614 
Educational 
Attainment 12 rs10847446 123160304 4.1442 0.48 0.27 120.27-126.01 q24.23-q24.32 HCAR2 25534 
Educational 
Attainment 15 rs7171078 29900518 3.6896 0.47 0.27 28.15-32.19 q13.1-q13.3 FAM189A1 37590 
FEV1 12 rs11609579 101843240 3.7871 0.4 0.29 96.75-103.54 q23.1-q23.2 SPIC 28093 
Forced Vital 
Capacity 12 rs4964460 106704974 3.9456 0.34 0.28 105.43-108.51 q23.3 TCP11L2 0 
Glucose 4 rs2191684 14392330 3.4498 0.33 0.24 6.9-18.94 p16.1-p15.31 LOC152742 250653 
Insulin 22 rs8135371 40757228 4.0937 0.31 0.26 37.93-42.87 q13.1-q13.2 ADSL 0 
tPA 7 rs10248098 111636575 3.7611 0.32 0.32 101.63-129.66 q22.1-q32.2 DOCK4 0 
Uric acid1 15 rs1608962 23750690 3.4771 0.4 0.23 20.16-25.73 q11.1-q12 MIR4508 56517 
Uric acid2 17 rs9897025 63860895 3.4816 0.4 0.27 60.98-67.22 q23.2-q24.3 CEP112 0 








QTL 2-LOD drop Band Gene Gene_Dist 
Vis 
Central Corneal 
Thickness 1 rs2494467 182283352 3.8436 0.79 0.71 179.55-185.43 q25.2-q25.3 GLUL 67485 
Central Corneal 
Thickness 2 rs1507705 25714916 4.2914 0.7 0.7 23.75-26.81 p24.1-p23.3 DTNB 0 
Central Corneal 
Thickness 4 rs980038 31669915 3.7106 0.83 0.54 28.87-35.65 p15.1 PCDH7 521491 
Lens Thickness 5 rs2052852 31993222 3.7721 0.66 0.63 31.64-32.01 p13.3 PDZD2 0 
Lens Thickness 13 rs9544368 36016609 3.569 0.53 0.53 32.89-39.48 q13.1-q13.3 NBEA 0 
Systolic BP 9 rs7038500 38553816 3.7598 0.53 0.28 38.51-38.56 p13.1 ANKRD18A 17543 
Shetland 
Axial length1 9 rs10970529 3189170 4.0379 0.81 0.26 2.57-3.88 p24.2 RFX3 35475 
Axial length2 9 rs10970529 3189170 4.019 0.82 0.25 2.5-3.88 p24.2 RFX3 35475 
BMI 8 rs4732980 29473431 3.4223 0.57 0.25 28.06-30.81 p21.1-p12 C8orf75 105343 
Pulse Pressure 1 rs6429360 242654482 3.6847 0.21 0.21 242.2-245.02 q43-q44 PLD5 0 
Creatinine 9 rs6475020 16275107 3.649 0.41 0.25 14.72-18.17 p22.3-p22.2 BNC2 134392 
Diastolic BP 1 rs318405 83014374 4.0586 0.28 0.25 81.49-84.03 p31.1 LPHN2 556266 
Diastolic BP 19 rs10417057 58177308 4.2744 0.28 0.26 56.9-58.84 q13.43 ZSCAN4 2993 
Diastolic BP 19 rs12709954 56716579 3.4142 0.26 0.26 54.85-58.91 q13.42-q13.43 ZSCAN5B 12157 
Educational 
Attainment 2 rs7572507 111490731 3.5059 0.33 0.31 109.74-111.98 q12.3-q13 ACOXL 0 
Glucose 2 rs2177250 176346170 3.9739 0.28 0.27 175.21-177.57 q31.1 ATP5G3 299679 
Glucose 4 rs17064578 178221198 4.5595 0.3 0.3 177.34-178.99 q34.2-q34.3 NEIL3 9791 
Glucose 4 rs13102637 173491064 4.5233 0.3 0.3 172.9-176.57 q34.1-q34.2 GALNTL6 0 
Glucose 4 rs4692709 170228549 3.6024 0.3 0.26 168.99-180.55 q32.3-q34.3 SH3RF1 36299 








QTL 2-LOD drop Band Gene Gene_Dist 
Glucose_nodiab 4 rs17064578 178221198 4.4017 0.28 0.28 177.39-178.79 q34.2-q34.3 NEIL3 9791 
Glucose_nodiab 4 rs4692709 170228549 3.5242 0.27 0.25 169.6-180.32 q32.3-q34.3 SH3RF1 36299 
HbA1c 1 rs3134613 40364803 3.8234 0.42 0.27 39.39-41.24 p34.3-p34.2 MYCL1 0 
HbA1c 2 rs10203413 3629178 3.4611 0.45 0.26 3.15-3.87 p25.3 RPS7 668 
HbA1c 8 rs1825074 106510518 3.9771 0.43 0.27 105.39-107.34 q22.3-q23.1 ZFPM2 0 
HbA1c 8 rs2443786 109028325 3.7722 0.43 0.27 108.7-110.1 q23.1 RSPO2 0 
HbA1c 8 rs10093934 77331219 3.4919 0.44 0.25 75.85-87.25 q21.11-q21.3 LOC100192378 191893 
HDL 18 rs8099543 61130942 3.7127 0.45 0.26 60.69-61.33 q21.33 SERPINB5 13200 
IntraOcular 
Pressure 19 rs7251022 49534958 3.9219 0.27 0.27 48.53-51.1 q13.33 SNAR-G2 0 
IntraOcular 
Pressure 19 rs3859451 51548531 3.7747 0.26 0.26 51.28-51.87 q13.33-q13.41 KLK12 10382 
IntraOcular 
Pressure 19 rs873286 47163774 3.509 0.26 0.26 46.54-52.05 q13.32-q13.41 DACT3 0 
Triglycerides 1 rs11121374 9396660 4.1537 0.33 0.24 8.19-11.02 p36.23-p36.22 SPSB1 0 
Waist 5 rs11749791 166806876 4.1131 0.52 0.26 165.94-167.38 q34 ODZ2 0 
Korčula 
Axial length1 6 rs4706308 88825342 3.5187 0.63 0.63 88.52-95.34 q15-q16.1 CNR1 24241 
Axial length2 6 rs6454673 88871049 3.4546 0.63 0.63 88.52-90.63 q15 CNR1 0 
Calcium 15 rs11071215 56072934 3.9449 0.46 0.25 49.03-57.74 q21.1-q21.3 PRTG 37756 
Calcium 15 rs6495130 33810168 3.7299 0.47 0.25 30.16-36.7 q13.1-q14 RYR3 0 
Educational 
Attainment 3 rs3937932 2459320 4.1637 0.54 0.32 1.3-3.1 p26.3-p26.2 CNTN4 0 
Fibrinogen 17 rs2535609 15856740 3.4982 0.61 0.29 14.51-20.84 p12-p11.2 ADORA2B 0 
Fibrinogen 20 rs2273534 56285540 3.6765 0.63 0.35 55.42-56.74 q13.31-q13.32 PMEPA1 0 








QTL 2-LOD drop Band Gene Gene_Dist 
HbA1c 6 rs7768422 110796405 4.0879 0.44 0.32 109.29-113.71 q21 SLC22A16 0 
Uric acid2 4 rs10025159 37575251 3.6789 0.37 0.26 35.81-38.37 p14 C4orf19 0 
Waist Hip Ratio 4 rs13114765 189390949 3.6316 0.44 0.27 187.54-190.72 q35.2 LOC401164 0 
GS 
Alcohol 
consumption 2 rs2037221 18559177 3.7288 0.29 0.1 18.26-19.18 p24.2 RDH14 176810 
Alcohol 
consumption 6 rs416622 32973281 3.4785 0.28 0.09 32.74-33.31 p21.32 HLA-DOA 0 
Alcohol 
consumption 7 rs11981366 37316506 4.472 0.29 0.11 36.53-37.87 p14.2-p14.1 ELMO1 0 
Alcohol 
consumption 7 rs727162 34874038 3.4667 0.29 0.1 32.86-35.49 p14.3-p14.2 NPSR1 0 
BMI 11 rs11603598 12064576 3.6082 0.55 0.09 11.36-12.15 p15.3 DKK3 33658 
Body fat 7 rs2191261 12950387 3.5695 0.53 0.09 11.77-14.18 p21.3-p21.2 ARL4A 219828 
Pulse Pressure 1 rs11240777 798959 4.0299 0.11 0.11 0.8-1.06 p36.33 FAM41C 4490 
Pulse Pressure 1 rs513287 170664237 3.7903 0.11 0.11 169.58-172.3 q24.2-q24.3 PRRX1 0 
Pulse Pressure 11 rs704664 44787201 3.8152 0.11 0.1 44.64-44.92 p11.2 TSPAN18 0 
Pulse Pressure 11 rs2186580 101524873 3.6579 0.11 0.09 101.4-102.33 q22.1-q22.2 TRPC6 70213 
Creatinine 1 rs10913949 180178695 3.6621 0.53 0.12 177.93-181.76 q25.2-q25.3 FLJ23867 8835 
Educational 
Attainment 6 rs2523949 29917591 5.6092 0.49 0.09 29.34-30.77 p22.1-p21.33 HLA-A 3929 
Educational 
Attainment 9 rs17262780 20304873 4.0182 0.51 0.12 18.75-27.84 p22.1-p21.2 MLLT3 40093 
Educational 
Attainment 9 rs3808745 17627988 3.4247 0.51 0.11 16.36-28 p22.3-p21.1 SH3GL2 0 
Educational 








QTL 2-LOD drop Band Gene Gene_Dist 
Educational 
Attainment 11 rs4936417 117903836 4.4071 0.5 0.11 117.82-118.02 q23.3 LOC100526771 0 
Educational 
Attainment 11 rs11022262 12260355 3.5824 0.5 0.09 12.17-12.28 p15.3 MICAL2 0 
Educational 
Attainment 11 rs1379170 113866551 3.4758 0.5 0.1 113.32-114.12 q23.2 HTR3A 5516 
Educational 
Attainment 11 rs666290 117476142 3.4307 0.5 0.09 116.55-118.9 q23.3 DSCAML1 0 
Educational 
Attainment 12 rs10877461 61258329 3.9672 0.51 0.11 58.52-66.66 q14.1-q14.3 FAM19A2 843710 
Educational 
Attainment 12 rs1458614 75487456 3.7045 0.51 0.12 73.35-77.29 q21.1-q21.2 KCNC2 0 
Educational 
Attainment 12 rs1921051 81700111 3.631 0.5 0.11 77.81-89.68 q21.2-q21.33 PPFIA2 0 
Educational 
Attainment 20 rs1033859 16076697 4.1988 0.5 0.12 15.69-16.72 p12.1 MACROD2 42855 
Forced Vital 
Capacity 9 rs1867283 87450766 4.5389 0.42 0.15 86.87-88.11 q21.32-q21.33 NTRK2 0 
Forced Vital 
Capacity 9 rs357642 80793672 4.4117 0.41 0.14 79.79-82.45 q21.2-q21.31 CEP78 57317 
Forced Vital 
Capacity 9 rs11139921 85748119 4.3688 0.42 0.14 84.01-86.76 q21.31-q21.32 RASEF 70075 
Forced Vital 
Capacity 9 rs6420275 79219334 4.0177 0.42 0.13 76.95-82.52 q21.13-q21.31 PRUNE2 6956 
Forced Vital 
Capacity 21 rs2823687 17624130 4.3307 0.41 0.14 15.37-21.44 q11.2-q21.1 C21orf34 0 
Glucose 22 rs3827409 46875743 3.976 0.25 0.13 45.29-47.79 q13.31 CELSR1 0 
Glucose_nodiab 12 rs1919450 119303805 3.5119 0.29 0.13 117.08-119.94 q24.22-q24.23 SRRM4 115493 








QTL 2-LOD drop Band Gene Gene_Dist 
HDL 5 rs10050614 82154979 3.5508 0.59 0.1 73.84-84.09 q13.3-q14.3 MIR3977 18935 
HDL 11 rs3924413 134404193 3.5489 0.58 0.09 133.76-134.75 q25 LOC283177 28637 
Height 1 rs182358 97463150 3.8635 0.92 0.07 96.4-97.73 p21.3 DPYD 80148 
Height 1 rs492220 94542569 3.456 0.92 0.07 90.31-98.72 p22.2-p21.3 ABCA4 0 
Height 2 rs4667393 150714840 4.0427 0.92 0.08 143.26-151.73 q22.2-q23.3 MMADHC 270509 
Height 2 rs7572208 35584461 3.4896 0.92 0.08 34.97-36.56 p22.3 LOC100288911 997429 
Height 5 rs7705193 41133587 3.9552 0.92 0.08 40.18-41.44 p13.1 C6 8747 
Height 7 rs2107945 68285442 3.8846 0.92 0.08 67.28-70.55 q11.22 AUTS2 778461 
Height 7 rs2909668 131300258 3.8741 0.92 0.08 128.55-137.97 q32.1-q33 PODXL 58881 
Height 7 rs1534131 45523448 3.6936 0.92 0.08 43.48-52.76 p13-p12.1 ADCY1 90675 
Height 8 rs7459445 119683126 3.4781 0.92 0.07 118.47-120.08 q24.11-q24.12 NCRNA00252 0 
Height 10 rs11001471 77453942 4.242 0.92 0.08 76.81-80.03 q22.2-q22.3 C10orf11 88575 
Height 10 rs10822936 68649352 3.7031 0.92 0.08 68.08-73.34 q21.3-q22.1 CTNNA3 0 
Height 10 rs7090884 63962026 3.6903 0.92 0.07 63.46-67.76 q21.2-q21.3 RTKN2 0 
Height 11 rs10897109 60518182 4.5188 0.92 0.09 60.11-61.26 q12.2 MS4A15 6156 
Height 11 rs7130134 45719881 3.9585 0.92 0.07 45.5-46.33 p11.2 CHST1 32708 
Height 11 rs10835931 32515997 3.6427 0.92 0.06 32.13-32.6 p13 WT1-AS 54376 
Height 11 rs2902421 45016421 3.597 0.92 0.08 44.29-45.22 p11.2 LOC221122 16842 
Height 11 rs680999 79799533 3.4828 0.92 0.06 79.05-80.37 q14.1 ODZ4 647837 
Height 12 rs2258342 48690363 3.5106 0.92 0.07 43.06-49.92 q12-q13.12 H1FNT 32398 
Height 13 rs2329177 81725976 3.8325 0.92 0.08 76.6-83.83 q22.2-q31.1 SPRY2 810889 
Height 13 rs4622388 94428051 3.5256 0.92 0.08 88.19-94.9 q31.2-q31.3 GPC6 0 
Height 15 rs8024133 61130639 3.6337 0.92 0.08 60.02-61.58 q22.2 RORA 0 
Height 17 rs9891296 58275994 4.5367 0.92 0.09 54.98-60.54 q22-q23.2 USP32 0 








QTL 2-LOD drop Band Gene Gene_Dist 
Sodium 2 rs6545786 60403018 3.6665 0.26 0.1 59.79-62.02 p16.1-p15 MIR4432 211477 
Sodium 7 rs7811904 143425361 3.6296 0.26 0.11 141.57-144.64 q34-q35 FAM115C 0 
Sodium 11 rs10791302 133521772 4.3264 0.25 0.11 133.22-133.76 q25 OPCML 119368 
Sodium 11 rs11221452 128607061 3.4208 0.26 0.1 127.9-128.8 q24.3 FLI1 0 
Sodium 21 rs81481 42771362 3.5041 0.26 0.1 41.31-43.88 q22.2-q22.3 MX2 0 
Total 
Cholesterol 1 rs6604877 78289045 3.624 0.3 0.1 72.99-79.25 p31.1 FAM73A 0 
Total 
Cholesterol 1 rs11206690 56407227 3.4669 0.3 0.1 48.98-57.27 p33-p32.2 PPAP2B 553190 
Total 
Cholesterol 6 rs10946765 25361055 4.5571 0.3 0.11 24.51-26.33 p22.3-p22.2 LRRC16A 0 
Total 
Cholesterol 6 rs9381214 42693959 3.9993 0.3 0.12 42.28-44.47 p21.1 ATP6V0CP3 1353 
Total 
Cholesterol 6 rs927657 45164355 3.6764 0.3 0.11 44.5-46.02 p21.1 SUPT3H 0 
Total 
Cholesterol 6 rs12215142 65509089 3.5148 0.3 0.1 53.35-67.05 p12.1-q12 EYS 0 
Total 
Cholesterol 11 rs512932 121973541 3.777 0.3 0.1 121.77-122.59 q24.1 MIR100HG 0 
Total 
Cholesterol 13 rs10459371 41307789 3.6759 0.3 0.11 40.71-43.28 q14.11 MRPS31 0 
Total 
Cholesterol 13 rs7325834 33852798 3.5909 0.3 0.11 32.89-34.72 q13.1-q13.2 STARD13 0 
Waist 8 rs6999082 65807063 4.0009 0.42 0.1 62-66.32 q12.2-q13.1 CYP7B1 95714 
Waist 8 rs11996294 67114738 3.6286 0.42 0.09 62-69.69 q12.2-q13.2 LOC100505659 5183 
Waist 8 rs6985810 73429848 3.4568 0.41 0.09 73.07-74.27 q13.3-q21.11 KCNB2 19776 
Waist Hip Ratio 1 rs4920295 18438239 4.0873 0.28 0.11 17.53-19.04 p36.13 IGSF21 0 
Waist Hip Ratio 11 rs2062208 83696133 3.5213 0.27 0.08 83.58-84.22 q14.1 DLG2 0 
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Supplementary Table 4 - Meta-analysis results that exceed the suggestive but not genome-wide significance threshold in 
pedigree-based linkage analysis 
The meta-analysis -log10(p-value) is indicated (logP column) for each peak. These peaks represent a 0.1 cM interval that starts at the cM position indicated 
(cM column). The start and end positions of the region surrounding these peaks where the meta-analysis test statistic continuously exceeded the suggestive 
significance threshold (logP>4.43) is indicated in cM (Reg_cM) and Mbp (Reg_Mbp), as is the chromosome band where these regions can be found. The 
per-cohort LOD scores in the 0.1 cM peak region are indicated in the last columns (O = Orkney, S=Shetland, G=Generation Scotland, V=Vis, K=Korčula).  
Trait Chr cM logP Band Reg_cM Reg_Mbp O S G V K 
Axial length1 2 138.8 4.67 q14.1 138.7-139 118-118.41 0.37 1.95 NA 1.78 0.47 
Axial length1 2 138.3 4.60 q14.1 138.2-138.5 117.45-117.82 0.48 2.35 NA 1.22 0.45 
Axial length2 2 138.8 4.52 q14.1 138.7-138.9 118-118.37 0.39 1.86 NA 1.83 0.36 
BMI 11 21.8 5.50 p15.3 21.7-21.9 11.15-11.25 0 0.27 5.74 0.16 0.22 
Central Corneal Thickness 4 52 5.87 p15.1 51.5-53.3 31.16-32.59 0 0.95 NA 3.68 1.49 
Central Corneal Thickness 3 184.7 5.77 q26.31 183.4-185.2 172.32-173.16 1.21 0.09 NA 2.14 2.35 
Central Corneal Thickness 4 50.3 5.40 p15.1 49.7-50.7 29.13-30.2 0 0.66 NA 2.63 2.34 
Central Corneal Thickness 12 156.8 4.91 q24.32 156.7-156.9 127.88-127.92 0 0.52 NA 5.09 0 
Central Corneal Thickness 12 157.8 4.83 q24.32 157.4-157.9 128.05-128.16 0 0.4 NA 5.15 0 
Central Corneal Thickness 4 55.4 4.82 p15.1 55.3-55.6 35.15-35.33 0 1.07 NA 2.69 1.22 
Central Corneal Thickness 4 62.1 4.80 p14 61.8-62.6 40.02-40.4 0 0.45 NA 3.12 1.45 
Central Corneal Thickness 7 92.1 4.66 q11.23 91.7-92.5 75.24-75.59 0.57 0.68 NA 1.38 1.86 
Central Corneal Thickness 4 63.1 4.64 p14 62.9-63.5 40.47-40.61 0 0.9 NA 2.95 0.96 
Central Corneal Thickness 4 68 4.62 p12 67.9-68.3 45.02-46.12 0 0.49 NA 1.47 2.87 
Central Corneal Thickness 1 197.5 4.58 q25.2 197.4-197.6 176.44-176.71 0 0 NA 5.08 0.24 
Central Corneal Thickness 4 62.7 4.43 p14 61.7-63.6 39.75-40.66 0 0.93 NA 2.59 1.05 
Cortisol 17 78.2 4.75 q22 78.1-78.4 53.3-53.35 2.46 NA NA 1.62 NA 
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Trait Chr cM logP Band Reg_cM Reg_Mbp O S G V K 
Creatinine 6 172.2 5.49 q25.3 171.2-172.5 156.13-156.87 0.07 1.36 2.56 1.57 0.24 
Creatinine 9 41.8 5.14 p21.3 41.4-42.2 20.18-20.49 1.33 3.23 0.2 0 0.87 
Creatinine 4 203.7 4.74 q35.1 203.6-204.5 184.54-184.76 0.28 1.93 1.83 0.69 0.19 
Creatinine 6 170.3 4.50 q25.2-q25.3 170.2-170.4 155.49-155.53 0.25 1.25 1.91 1.21 0.07 
Creatinine 6 124.5 4.48 q22.1 124.3-124.6 117.57-117.63 1.27 0.68 2.02 0.27 0.35 
Diastolic BP 2 22.7 4.74 p25.1 22.3-23.3 10.09-10.5 6.23 0.01 0 0 0 
Diastolic BP 2 20.9 4.71 p25.1 20.5-21.4 9.35-9.91 6.26 0 0 0 0 
Educational Attainment 9 46.7 5.22 p21.3 46.5-47.2 23.68-24.72 0 0 6.14 -0.06 0.4 
Educational Attainment 11 54.1 5.18 p13 53.9-54.2 35.21-35.4 0 2.18 2.71 0.06 0.8 
Educational Attainment 11 128.8 4.97 q23.3 128.7-128.9 118.13-118.39 0.18 0.62 4.58 0.1 0.1 
Educational Attainment 2 79.1 4.71 p16.3 78.9-79.3 51.24-51.84 0.45 0.21 1.61 -0.11 2.93 
Educational Attainment 6 49.9 4.68 p22.1-p21.33 49.8-51.4 28.26-31.43 0.93 0.03 3.5 0.03 0.7 
Educational Attainment 12 149.7 4.66 q24.31 149.3-150 125.09-125.34 3.2 1.13 0.55 -0.01 0.24 
Educational Attainment 11 128.3 4.64 q23.3 128.2-128.4 117.9-117.98 0.02 0.97 4.41 0.03 0.02 
Educational Attainment 9 47.8 4.59 p21.3 47.5-47.9 24.83-25 0 0 5.73 -0.06 0.16 
Educational Attainment 12 147 4.57 q24.31 146.8-147.5 123.15-123.93 4.1 0.29 0.4 0.02 0.29 
Educational Attainment 9 47.3 4.56 p21.3 46.4-48 23.65-25.03 0 0 5.41 0 0.36 
Educational Attainment 12 146.7 4.52 q24.31 146.6-147.6 122.67-124.01 4.01 0.33 0.46 0.01 0.25 
FEV1 1 267.5 4.65 q43 267.3-267.8 236.68-236.81 0.13 1.18 2.72 0.76 0.13 
Fibrinogen 3 46.6 4.59 p24.2 46.5-46.9 25.46-25.51 1.1 0.16 NA 1.27 1.97 
Forced Vital Capacity 9 101.8 5.36 q21.33 101.7-102.9 87.23-87.81 0.54 0.97 4.36 0.07 0.02 
Forced Vital Capacity 9 92 5.10 q21.2 91.6-92.2 79.46-79.64 0.52 0.21 3.77 0.32 0.6 
Forced Vital Capacity 9 90.5 5.07 q21.13 90.1-90.9 78.81-79.15 0.38 0 3.81 0.87 0.53 
Forced Vital Capacity 9 89.1 4.90 q21.13 88.9-89.2 78.47-78.55 0.08 0 3.33 1.46 0.59 
Forced Vital Capacity 9 91.1 4.79 q21.13-q21.2 90-91.2 78.79-79.23 0.25 0.01 4.02 0.47 0.55 
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Trait Chr cM logP Band Reg_cM Reg_Mbp O S G V K 
Forced Vital Capacity 9 89.6 4.66 q21.13 89.4-89.7 78.64-78.67 0.16 0 2.95 1.28 0.72 
GGT 1 208.8 5.84 q31.1 208.7-208.9 188.77-189.38 0.01 0 NA 6.31 NA 
GGT 19 96.6 5.44 q13.42 96.5-97.4 54.93-55.2 0.6 0 NA 4.97 NA 
GGT 19 95.5 4.54 q13.42 95.4-95.7 54.74-54.81 0.51 0.06 NA 3.9 NA 
Glucose 12 145.2 4.47 q24.31 145.1-145.3 120.91-121.1 0.33 1.16 2.26 0 1.06 
Glucose 2 195.5 4.43 q31.1 195.4-195.6 176.64-176.77 0 3.78 0.18 0 1.26 
Glucose_nodiab 10 57.4 4.97 p11.23 56.9-58 30.01-30.42 0.46 0.48 0.02 0.04 4.65 
Glucose_nodiab 10 55.6 4.82 p12.1 55.3-56 29.32-29.6 1.2 1.21 0.02 0 2.95 
Glucose_nodiab 4 185.3 4.74 q34.1 184.8-185.6 175.28-175.72 1.2 4.41 0 0 0.05 
Glucose_nodiab 10 55 4.66 p12.1 54.8-55.2 29.13-29.32 1.31 1.39 0 0 2.58 
Glucose_nodiab 20 42.1 4.63 p12.1 41.8-42.3 17.61-17.83 0 1.66 0 2.35 1.23 
Glucose_nodiab 20 42.8 4.54 p12.1-p11.23 42.6-42.9 17.87-18.02 0 1.58 0 2.56 1.01 
Glucose_nodiab 2 172.8 4.50 q23.3 172.7-172.9 153.47-153.92 0.01 3.21 0.24 1.03 0.4 
Glucose_nodiab 4 182.3 4.50 q34.1 182.2-182.5 173.22-173.8 0.5 3.93 0 0.82 0 
Glucose_nodiab 20 41.6 4.48 p12.1 41.5-41.7 17.49-17.54 0 1.63 0 2.36 1.09 
HbA1c 8 106.2 4.91 q21.13-q21.2 106-106.4 84.54-85.1 0.89 4.36 NA 0.03 0.03 
HbA1c 1 67.8 4.74 p34.2 67.5-67.9 40.29-40.76 1.01 3.75 NA 0 0.29 
HbA1c 8 101.6 4.72 q21.11-q21.12 101.5-101.7 78.02-78.63 0.01 4.92 NA 0.39 0 
HbA1c 8 105.6 4.63 q21.13 105.3-105.7 83.43-83.99 0.46 4.4 NA 0.16 0.01 
HbA1c 2 6.2 4.61 p25.3 6.1-6.3 3.5-3.65 0 3.46 NA 0 1.67 
HbA1c 20 45.3 4.54 p11.23 45.1-45.4 19.61-19.71 2.99 2.05 NA 0 0 
HbA1c 1 68 4.48 p34.2 67.4-68.1 40.25-40.81 1.13 3.21 NA 0 0.37 
HbA1c 20 45.7 4.46 p11.23 45.6-45.8 19.81-19.88 2.81 2.02 NA 0.02 0 
HDL 16 71.5 5.46 q12.2 70.2-72.3 55.72-56.6 1.2 1.74 0.76 0.03 1.99 
HDL 11 160.1 4.66 q25 159.9-160.2 134.26-134.35 0.05 0.51 4.98 0.03 0 
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Trait Chr cM logP Band Reg_cM Reg_Mbp O S G V K 
Height 10 96.2 5.83 q22.1 95.6-97.3 72.23-73.05 0 0.84 5 0 0.88 
Height 17 86 5.76 q22-q23.2 84.9-87.8 56.18-60.2 1.9 0.01 4.54 0 0.19 
Height 5 61.2 5.54 p13.1 61-61.5 40.36-41.3 0.28 2.26 3.64 0.07 0 
Height 2 167.8 5.46 q22.3 167.5-168.2 147.25-148.37 1.23 0 5.14 0.11 0 
Height 13 79.4 5.39 q31.1 79.1-80.8 79.81-82.05 0.51 0 3.71 0.98 0.68 
Height 15 75.8 5.20 q21.3 75.7-76.3 56.79-57.64 0 2.8 3.41 0 0 
Height 17 83.8 5.11 q22 82.3-84 55.28-55.8 1.59 0 4.38 0 0.09 
Height 15 86.5 5.08 q22.2-q22.31 86.1-87.7 62.86-64.14 0.16 0.32 4.63 0 0.67 
Height 2 78.1 4.84 p16.3 77.9-78.2 50.14-50.56 0.09 1.39 2.31 0 1.51 
Height 7 73 4.82 p12.3 72.7-73.3 47.13-47.43 0 0.94 5.01 0 0 
Height 15 77.1 4.82 q21.3 76.9-77.4 57.77-58.04 0.03 2.55 3.16 0 0 
Height 10 94.5 4.70 q22.1 94.4-94.7 71.64-71.68 0 0.01 5.08 0 0.72 
Height 15 88.1 4.68 q22.31 87.8-88.2 64.19-65.1 0.19 0.05 4.03 0 1.1 
Height 7 77.1 4.67 p12.1 76.7-77.5 50.63-51.45 0 0.67 4.97 0.04 0 
Height 13 81.3 4.67 q31.1 81.2-81.5 82.58-82.95 0.55 0.3 3.61 0.31 0.23 
Height 1 241.5 4.65 q41 241.4-241.8 217.58-218.1 0.6 2.32 1.48 0.17 0.27 
Height 2 170 4.64 q23.2-q23.3 169.7-170.2 150.48-151.03 1.24 0 4.04 0.19 0 
Height 6 174.6 4.62 q25.3 174.5-174.7 158.35-158.49 1.26 2.62 1.37 0 0 
Height 2 168.4 4.62 q22.3-q23.1 168.3-168.6 148.54-149.21 1.15 0 4.23 0.11 0 
Height 17 99.9 4.56 q24.3 99.8-100 69.39-69.5 3.15 0 1.84 0 0.3 
Height 2 165.5 4.55 q22.3 165.3-165.6 144.14-144.51 0.87 0 3.97 0.47 0 
Height 2 166.8 4.54 q22.3 166.7-167 145.82-146.11 0.76 0 4.66 0.07 0 
Height 7 80.6 4.53 p11.2 80.5-80.7 54.75-54.93 0.09 2.22 2.7 0 0.14 
Height 2 168.8 4.53 q22.3-q23.1 167.4-168.9 146.94-149.64 1.53 0 3.66 0.15 0 
Height 15 90.8 4.49 q22.32 90.6-90.9 67.22-67.28 0.19 0 4.25 0.28 0.41 
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Trait Chr cM logP Band Reg_cM Reg_Mbp O S G V K 
Height 11 4.3 4.49 p15.5 4.2-4.4 1.8-1.86 0.84 0 3.28 -0.01 1.03 
Height 17 99.5 4.48 q24.3 99.4-99.6 69.19-69.24 3.27 0 1.59 0 0.34 
Height 2 169 4.48 q22.3-q23.2 167.3-169.1 146.66-149.93 1.63 0 3.45 0.17 0 
Height 7 77.9 4.47 p12.1 77.8-78 51.68-51.82 0 0.64 4.78 0.04 0 
Height 15 91.2 4.47 q22.33 91.1-91.3 67.41-67.47 0.16 0 3.9 0.47 0.5 
Height 17 82.2 4.46 q22 82.1-84.1 55.18-55.84 1.91 0 3.17 0 0.13 
Insulin 22 50 4.83 q13.1-q13.2 49.6-50.2 40.26-42.53 4.03 0.04 NA 0.71 NA 
IntraOcular Pressure 19 83.9 4.58 q13.41 83.8-84.1 51.53-51.57 0.3 3.77 NA NA NA 
Pulse Pressure 3 83.1 4.98 p14.2 82.9-83.3 62.44-62.59 0.19 2.7 2.26 0 0.36 
Systolic BP 3 188.9 5.15 q26.31 188.5-189.4 175.05-175.51 0.27 0 4.02 1.49 0.07 
Systolic BP 3 195.4 4.92 q26.33 195.1-195.5 180.04-181.24 0.27 0 2.55 2.63 0.08 
Systolic BP 3 187.5 4.80 q26.31 187.3-188.3 174.68-175.02 0.08 0 3.56 1.75 0.11 
Systolic BP 3 190.1 4.56 q26.32 190-190.2 176.03-176.27 0.14 0 2.95 2.06 0.06 
Systolic BP 3 190.4 4.49 q26.32 190.3-190.5 176.27-176.41 0.17 0 2.42 2.39 0.09 
Triglycerides 1 22.1 4.62 p36.22 21.8-22.2 10.88-10.99 1.42 3.13 NA 0 0.31 
Triglycerides 1 24 4.58 p36.22 23.9-24.1 11.82-11.99 0.97 2.56 NA 0 1.2 
Triglycerides 1 23.4 4.52 p36.22 23.1-23.5 11.63-11.75 1 2.38 NA 0 1.27 
Urea 9 63.7 5.60 p13.2-p13.1 63.6-64.3 38.25-38.44 0.07 0 0.12 6.18 NA 
Urea 21 27.3 5.01 q21.3 26.5-27.7 28.63-29.12 3.25 1.87 0.21 0 NA 
Urea 21 29 4.71 q21.3 28.8-29.2 29.95-30.84 2.89 2.2 0.03 0 NA 
Urea 21 28.7 4.49 q21.3 28.6-29.3 29.77-30.85 2.96 1.7 0.13 0 NA 




Supplementary Table 5 - Meta-analysis results that exceed the suggestive but not the genome-wide significance threshold in 
pedigree-based linkage analysis, with cohorts grouped by geographical location 
The meta-analysis -log10(p-value) is indicated (logP column) for each peak. These peaks represent a 0.1 cM interval that starts at the cM position indicated 
(cM column). The start and end positions of the region surrounding these peaks where the meta-analysis test statistic continuously exceeded the suggestive 
significance threshold (logP>4.43) is indicated in cM (Reg_cM) and Mbp (Reg_Mbp), as is the chromosome band where these regions can be found. The 
per-cohort LOD scores in the 0.1 cM peak region are indicated in the last columns (O = Orkney, S=Shetland, G=Generation Scotland, V=Vis, K=Korčula). 
Trait - Croatia Chr cM logP Band Reg_cM Reg_Mbp V K   
Central Corneal 
Thickness 1 197.5 5.78 q25.2 197.4-197.6 176.44-176.71 5.08 0.24   
Central Corneal 
Thickness 1 203 4.59 q25.3 202.8-203.3 182.04-182.39 3.84 0.25   
Central Corneal 
Thickness 2 46.1 4.51 p23.3 46-46.2 25.6-25.9 4.29 0   
Central Corneal 
Thickness 3 184.7 5.18 q26.31 183.9-185.2 172.59-173.16 2.14 2.35   
Central Corneal 
Thickness 4 52.3 5.84 p15.1 51.5-54.9 31.16-34.36 3.63 1.55   
Central Corneal 
Thickness 4 50.3 5.66 p15.1 49.4-51.2 28.94-30.7 2.63 2.34   
Central Corneal 
Thickness 4 62.1 5.24 p14 61.2-62.7 39.02-40.43 3.12 1.45   
Central Corneal 
Thickness 4 68.6 5.09 p13-p12 66.8-69 43.07-47.57 1.67 2.74   
Central Corneal 
Thickness 4 70 4.83 q12 69.9-70.2 53.88-54.55 1.94 2.22   
Central Corneal 
Thickness 4 55.4 4.56 p15.1 55.3-55.6 35.15-35.33 2.69 1.22   
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Trait - Croatia Chr cM logP Band Reg_cM Reg_Mbp V K   
Central Corneal 
Thickness 4 63.1 4.55 p14 62.9-63.2 40.47-40.57 2.95 0.96   
Central Corneal 
Thickness 4 69.7 4.55 q12 69.5-69.8 53.27-53.88 1.9 1.97   
Central Corneal 
Thickness 12 157.8 5.34 q24.32 157.4-157.9 128.05-128.16 5.15 0   
Central Corneal 
Thickness 12 156.8 5.29 q24.32 156.7-156.9 127.88-127.92 5.09 0   
Educational Attainment 3 4.9 4.58 p26.3 4.7-5 2.43-2.53 0.05 4.16   
Glucose 20 11.2 4.67 p13 10.9-11.6 3.08-3.68 1.25 2.76   
Glucose_nodiab 10 57.4 5.02 p11.23 56.9-58.2 30.01-30.65 0.04 4.65   
Glucose_nodiab 10 58.4 4.44 p11.23 58.3-58.5 30.66-30.69 0.18 3.8   
Systolic BP 9 64.6 4.68 p13.1 64.4-64.7 38.51-38.57 3.76 0.38   
Uric acid1 20 32.5 4.96 p12.2-p12.1 32.1-32.9 12.01-12.63 3.22 1.1   
Uric acid1 20 31.9 4.50 p12.2 31.8-32 11.78-12 3.15 0.74   
 
Trait - Scotland Chr cM logP Band Reg_cM Reg_Mbp O S G 
BMI 11 21.8 5.77 p15.3 21.6-21.9 11.12-11.25 0 0.27 5.74 
BMI 16 76.2 4.92 q21 75.8-76.9 58.01-58.95 3.21 0 1.69 
Pulse Pressure 1 281.9 5.07 q43 281-282 242.28-242.77 0.01 3.59 1.4 
Pulse Pressure 3 83.1 5.40 p14.2 82.8-83.4 62.41-62.6 0.19 2.7 2.26 
Pulse Pressure 11 110.1 4.72 q22.1 110-110.3 101.4-101.9 0.8 0.11 3.66 
Creatinine 9 41.8 5.01 p21.3 41.4-42.2 20.18-20.49 1.33 3.23 0.2 
Diastolic BP 2 22.7 5.77 p25.1 19.2-23.6 8.64-10.57 6.23 0.01 0 
Diastolic BP 2 239.4 4.47 q36.1 239.3-239.5 222.86-222.98 0.38 2.11 1.63 
Diastolic BP 2 24.4 4.45 p25.1 24.3-24.5 10.87-10.96 4.88 0 0 
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Trait - Scotland Chr cM logP Band Reg_cM Reg_Mbp O S G 
Diastolic BP 2 24.7 4.45 p25.1 24.6-24.9 10.98-11.01 4.87 0 0 
Educational Attainment 6 50.8 5.17 p21.33 50.7-50.9 30.77-30.99 1.32 0 3.85 
Educational Attainment 9 46.9 5.61 p21.3 46.3-48.1 23.64-25.04 0 0 6.14 
Educational Attainment 9 49.9 4.73 p21.2 49.7-50.3 25.89-25.96 0 0 5.18 
Educational Attainment 11 128.8 5.48 q23.3 128.7-128.9 118.13-118.39 0.18 0.62 4.58 
Educational Attainment 11 128.3 5.41 q23.3 128.1-128.5 117.82-118.02 0.02 0.97 4.41 
Educational Attainment 11 54.1 4.92 p13 53.9-54.2 35.21-35.4 0 2.18 2.71 
Educational Attainment 12 149.7 5.20 q24.31 148.3-150.9 124.73-125.77 3.2 1.13 0.55 
Educational Attainment 12 76.3 5.06 q14.2 76-76.6 63.24-63.64 0 0 5.54 
Educational Attainment 12 146.7 4.97 q24.31 146.3-148 122.2-124.63 4.01 0.33 0.46 
Educational Attainment 12 77.6 4.59 q14.2 77.4-77.7 64.43-64.91 0 0 5.03 
Educational Attainment 12 148.1 4.49 q24.31 146.2-148.2 121.82-124.72 3.32 0.38 0.54 
Educational Attainment 15 99.9 4.53 q24.1 99.8-100.1 74.45-74.55 0.19 2.29 1.77 
Educational Attainment 20 39.2 5.24 p12.1 39.1-39.5 16.06-16.22 0.74 0.16 4.2 
FEV1 5 89.4 4.54 q13.3 89.3-89.5 76.54-76.72 0.55 2.22 1.4 
FEV1 10 169.5 4.51 q26.2 169.4-169.6 130.07-130.21 0 2.35 2.1 
fev1perfvc 10 0 4.60 p15.3 0-0.1 0.07-0.37 0.45 0.86 2.98 
Forced Vital Capacity 9 93.2 4.97 q21.2 92.9-93.5 80.22-81.07 0.64 0 4.41 
Forced Vital Capacity 9 92 4.67 q21.2 91.8-92.2 79.5-79.64 0.52 0.21 3.77 
Forced Vital Capacity 9 103.9 4.66 q21.33 103.7-104 88.36-88.87 0.47 0.68 3.24 
Forced Vital Capacity 9 99.4 4.58 q21.32 99.3-99.5 85.59-85.8 0.26 0.02 4.37 
Forced Vital Capacity 9 105.4 4.52 q21.33 105.3-105.6 89.6-89.95 1.13 0.15 3.01 
Forced Vital Capacity 12 126.1 4.87 q23.3 125.9-126.2 106.66-107.27 3.8 0 1.08 
Glucose 4 185 5.37 q34.1 183.4-185.7 174.68-175.79 1.06 4.36 0 
Glucose 4 182.7 4.92 q34.1 182.2-182.8 173.22-174.29 0.59 4.42 0 
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Trait - Scotland Chr cM logP Band Reg_cM Reg_Mbp O S G 
Glucose 4 183 4.66 q34.1 182.1-185.8 173.01-175.87 0.69 4.03 0 
Glucose 20 77.3 4.51 q13.2 77.2-77.4 50.01-50.08 0.8 2.69 0.67 
Glucose_nodiab 4 185.3 5.55 q34.1 183.5-185.9 174.74-175.96 1.2 4.41 0 
Glucose_nodiab 4 183 4.57 q34.1 182.8-183.1 174.29-174.48 0.86 3.73 0 
Glucose_nodiab 4 183.2 4.50 q34.1 182.7-183.4 174.06-174.68 0.87 3.64 0 
Glucose_nodiab 4 186 4.45 q34.1-q34.2 182.6-186.3 173.95-176.38 0.98 3.47 0 
HDL 11 160.1 5.53 q25 159.6-160.3 134.2-134.35 0.05 0.51 4.98 
HDL 11 159.3 4.72 q25 159.2-159.4 133.9-133.93 0.03 0.16 4.64 
HDL 18 92.2 4.81 q22.1 92.1-92.5 64.95-65.29 0.08 2.14 2.39 
Height 1 241.5 4.77 q41 241.4-241.8 217.58-218.1 0.6 2.32 1.48 
Height 1 246.3 4.46 q41 246.2-246.4 222.59-222.74 0.61 1.86 1.61 
Height 1 246.3 4.46 q41 246.2-246.4 222.61-222.74 0.61 1.86 1.61 
Height 1 242.2 4.45 q41 242.1-242.3 218.3-218.39 0.48 1.44 2.16 
Height 2 169.9 5.25 q23.2-q23.3 169.4-170.5 150.19-151.27 1.24 0 4.04 
Height 2 165.5 4.80 q22.2-q22.3 165.1-165.7 144.06-144.63 0.87 0 3.97 
Height 2 193.5 4.51 q31.1 193.4-193.6 174.48-174.55 1.72 0 2.74 
Height 2 166.1 4.44 q22.3 166-166.2 144.94-145.22 0.85 0 3.6 
Height 5 63.6 4.74 q11.2 63.1-63.8 51.61-52.23 0.38 1.56 2.46 
Height 6 174.6 5.63 q25.3 172.8-175 157.05-158.96 1.26 2.62 1.37 
Height 6 172.6 4.59 q25.3 172.5-175.1 156.87-159.05 0.6 2.34 1.28 
Height 7 73 5.86 p12.3 72.4-73.6 46.8-47.57 0 0.94 5.01 
Height 7 77.1 5.52 p12.2-p12.1 76.6-78.5 50.42-52.21 0 0.67 4.97 
Height 7 80.6 5.19 p11.2 80.3-80.8 54.66-55.1 0.09 2.22 2.7 
Height 7 76 4.80 p12.2 75.4-76.3 49.29-50.25 0 0.63 4.24 
Height 7 73.7 4.64 p12.3 72.3-73.8 46.7-47.7 0 0.15 4.7 
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Trait - Scotland Chr cM logP Band Reg_cM Reg_Mbp O S G 
Height 10 96.2 5.73 q22.1 95.9-96.9 72.34-72.82 0 0.84 5 
Height 10 94.5 4.69 q22.1 94.4-94.7 71.64-71.68 0 0.01 5.08 
Height 10 112.9 4.58 q23.1 112.8-113 86.01-86.46 0 2.12 2.4 
Height 11 85.8 4.93 q14.1 85.7-86 78.35-78.48 0.32 1.14 3.19 
Height 11 67.5 4.69 q12.1 67.4-67.6 57.35-58.31 0.23 0 4.64 
Height 11 6.4 4.44 p15.5 6.3-6.5 2.55-2.6 1.14 0 3.28 
Height 13 80.6 4.83 q31.1 80.5-80.8 81.68-82.05 0.31 0.5 3.83 
Height 13 81.3 4.67 q31.1 81.2-81.5 82.58-82.95 0.55 0.3 3.61 
Height 15 87 5.37 q22.2 86.1-87.5 62.86-63.69 0.05 0.18 5.24 
Height 15 89.8 5.36 q22.31 89.1-90.2 66.36-67.02 0.17 0.04 5.29 
Height 15 88.9 4.51 q22.31 88.8-89 65.69-66.33 0.14 0.2 4.13 
Height 17 83.8 5.92 q22-q23.2 81.7-88.2 55.09-60.78 1.59 0 4.38 
Height 17 99.9 5.01 q24.3 99.4-100.2 69.19-69.54 3.15 0 1.84 
Height 17 101.4 4.91 q24.3 101-101.8 70.18-70.41 2.64 0 2.24 
Height 17 100.4 4.63 q24.3 99.3-100.9 69.08-70.16 3.11 0 1.44 
Height 17 90.1 4.56 q24.1 89.9-90.3 62.78-63.08 1.65 0.07 2.63 
Height 17 90.1 4.56 q24.1 89.9-90.3 62.79-63.08 1.65 0.07 2.63 
Height 17 90.1 4.56 q24.1 89.9-90.3 62.81-63.08 1.65 0.07 2.63 
Height 17 90.1 4.56 q24.1 89.9-90.3 62.82-63.08 1.65 0.07 2.63 
Height 17 90.1 4.56 q24.1 89.9-90.3 62.84-63.08 1.65 0.07 2.63 
Height 17 90.1 4.56 q24.1 89.9-90.3 62.86-63.08 1.65 0.07 2.63 
Height 17 90.1 4.56 q24.1 89.9-90.3 62.86-63.08 1.65 0.07 2.63 
Height 17 89.1 4.53 q23.3 89-89.3 62.11-62.41 1.62 0 2.84 
Total Cholesterol 1 107.3 5.34 p31.1 107-107.5 77.69-78.7 0 1.73 3.62 
Total Cholesterol 1 104.4 4.61 p31.1 104.3-104.6 74.98-75.15 0 1 3.61 
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Trait - Scotland Chr cM logP Band Reg_cM Reg_Mbp O S G 
Total Cholesterol 6 81.1 5.88 p11.2-q12 80.7-81.3 58.15-64.61 0.39 0 5.7 
Total Cholesterol 6 48.8 5.10 p22.3-p22.2 48.5-49.1 25.14-25.6 0.47 0.05 4.56 
Total Cholesterol 6 66.6 4.52 p21.1 66.3-66.7 42.45-42.83 0.23 0.24 3.94 
Total Cholesterol 11 135.1 4.81 q24.1 134.8-135.2 121.77-122.03 0.99 0.01 3.78 
Total Cholesterol 11 137.5 4.62 q24.1 137.3-137.6 123.07-123.16 1.45 0.41 2.42 
Urea 21 27.3 5.56 q21.3 25.8-27.9 28.39-29.29 3.25 1.87 0.21 
Urea 21 29 5.24 q21.3 28.2-29.4 29.45-30.96 2.89 2.2 0.03 
Urea 21 28 4.51 q21.3 25.7-28.1 28.39-29.42 2.63 1.71 0.02 
Waist 5 178.4 4.58 q34 178.3-178.6 166.67-166.86 0.42 4.11 0.04 
 
Trait - Scottish Isles Chr cM logP Band Reg_cM Reg_Mbp O S   
Axial length1 9 9.3 4.65 p24.2 9.1-9.6 3.09-3.35 0.17 4.04   
Axial length2 9 9.3 4.77 p24.2 9-9.6 3.03-3.35 0.26 4.02   
Creatinine 9 41.8 5.22 p21.3 41.4-42.2 20.18-20.49 1.33 3.23   
Diastolic BP 2 26 4.59 p25.1 19.1-26.1 8.63-11.52 4.37 0   
Diastolic BP 19 105.7 4.50 q13.43 105.6-105.8 58.06-58.38 0 4.27   
Educational Attainment 12 149.7 4.97 q24.31 148.9-150.5 124.97-125.54 3.2 1.13   
Educational Attainment 12 146.9 4.90 q24.31 146.3-147.5 122.2-123.93 4.14 0.27   
Educational Attainment 12 148.7 4.46 q24.31 148.4-148.8 124.76-124.95 3.1 0.74   
Glucose 4 189.9 5.01 q34.3 189.2-190.2 177.98-178.3 0.07 4.56   
Glucose 4 190.4 4.62 q34.3 189.1-190.5 177.97-178.35 0.08 4.15   
Glucose 4 179.7 4.57 q32.3-q33 179.5-179.8 169.99-170.53 0.42 3.6   
Glucose_nodiab 4 189.9 4.83 q34.3 189.7-190.2 178.15-178.3 0.06 4.4   
Glucose_nodiab 4 179.7 4.51 q32.3-q33 179.5-179.8 169.99-170.53 0.44 3.52   
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Trait - Scottish Isles Chr cM logP Band Reg_cM Reg_Mbp O S   
HbA1c 1 67.8 5.38 p34.2 67.5-68.3 40.29-40.93 1.01 3.75   
HbA1c 8 101.6 5.19 q21.11-q21.12 101.2-101.7 77.7-78.63 0.01 4.92   
HbA1c 20 45.3 5.73 p11.23 44.2-46.3 19-19.95 2.99 2.05   
HbA1c 20 51.5 4.83 p11.21 51.1-51.6 24.49-25.18 3.24 0.96   
HDL 18 87.7 4.50 q21.33 87.5-87.8 61.05-61.18 0.28 3.71   
Height 6 174.6 4.53 q25.3 174.5-174.7 158.35-158.49 1.26 2.62   
Insulin 22 49.9 4.45 q13.1-q13.2 49.8-50 40.53-41.41 4.09 0.03   
IntraOcular Pressure 19 83.9 4.58 q13.41 83.8-84.1 51.53-51.57 0.3 3.77   
Triglycerides 1 22.1 5.22 p36.22 21.6-22.4 10.84-11.03 1.42 3.13   
Triglycerides 1 19.4 5.18 p36.23-p36.22 18.5-19.9 9.07-9.54 0.51 4.11   
Triglycerides 1 18.2 4.98 p36.23-p36.22 18-20 8.96-9.58 0.47 3.97   
Triglycerides 1 20.6 4.73 p36.22 20.1-20.7 9.69-10.23 0.95 3.15   
Urea 21 27.3 5.80 q21.3 25.7-29.4 28.39-30.96 3.25 1.87   
Uric acid1 13 116.3 4.48 q33.3 116.2-116.5 108.74-108.83 2.56 1.26   
Uric acid1 13 116.7 4.45 q33.3 116.6-116.8 108.92-108.93 2.61 1.19   
Uric acid1 17 92.2 4.66 q24.1-q24.2 91.9-92.3 64.2-64.57 2.61 1.38   




Supplementary Table 6 - Regional heritability results that exceeded the 
suggestive but not the genome-wide significance threshold in individual 
cohorts 
The RH -log10(p-value) of each region is displayed in the logP column. The chromosome and 
start and end positions of each region (in Mbp) are provided. Additionally, the start of each 
0.3 cM region is also indicated in cM. The total trait heritability (h2) and heritability explained 
by the region (h2reg), are shown, as well as the chromosome band (Band) where the region is 
located. 






Albumin 5 15 5.83-5.97 5.47 0.28 0.019 p15.32 
CRP 19 70.5 45.34-45.43 6.25 0.3 0.022 q13.32 
Vis 
CRP 1 175.2 159.53-159.76 5.68 0.54 0.075 q23.2 
GPT 11 84.3 76.51-76.75 5.59 0.19 0.031 q13.5 
Uric acid1 4 23.4 9.91-10.54 5.99 0.31 0.033 p16.1 
Uric acid2 4 23.4 9.91-10.54 5.55 0.31 0.032 p16.1 
GS 
BMI 2 0.6 0.47-0.68 6.14 0.47 0.002 p25.3 
BMI 13 27 31.16-31.38 5.93 0.47 0.002 q12.3 
Body fat 12 67.8 53.64-54.24 5.70 0.44 0.001 q13.13 
Body fat 14 100.8 97.59-97.64 5.96 0.44 0.002 q32.2 
Creatinine 4 90.3 77.14-77.44 5.56 0.44 0.002 q21.1 
Forced Vital Capacity 9 39.9 19.45-19.47 5.56 0.34 0.001 p22.1 
Glucose 13 20.7 28.45-28.59 6.19 0.23 0.002 q12.2 
HDL 12 149.7 125.26-125.34 5.58 0.5 0.003 q24.31 
HDL 16 84.9 66.94-68.43 5.57 0.5 0.002 q22.1 
HDL 18 68.7 46.56-47.18 6.07 0.5 0.003 q21.1 
HDL 20 66.9 44.14-44.68 6.23 0.5 0.004 q13.12 
Heart Rate 20 55.8 36.74-36.9 5.70 0.25 0.002 q11.23 
Height 1 204.9 183.98-184.35 5.50 0.82 0.002 q25.3 
Height 2 253.2 232.79-233.32 5.89 0.82 0.002 q37.1 
Height 5 181.5 168.21-168.33 5.39 0.82 0.001 q34 
Height 6 92.1 80.92-81.77 6.01 0.82 0.003 q14.1 
Height 6 164.4 152.2-152.42 5.66 0.82 0.002 q25.1 
Height 10 106.8 81.06-81.18 6.61 0.82 0.002 q22.3 
Height 15 108.6 84.36-85.45 6.36 0.82 0.002 q25.2-q25.3 
Sodium 16 85.8 69.54-70.76 5.44 0.19 0.003 q22.1 
Urea 1 169.8 154.97-156.09 6.36 0.22 0.003 q21.3-q22 
Urea 18 63 43.13-43.3 6.96 0.22 0.004 q12.3 
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Supplementary Table 7 - RH meta-analysis results that pass the suggestive but not genome-wide significance threshold 
The meta-analysis -log10(p-value) is indicated (logP column) for each peak. These peaks represent 0.3 cM regions that start at the cM position indicated 
(cM column). The start and end positions of these regions are also shown in Mbp, as is the chromosome band (Band) where these regions can be found. 
The per-cohort -log10(p-values) at the peak region are shown (O = Orkney, S=Shetland, G=GS, V=Vis, K=Korčula). The final column shows the genes 
in each region (or on the same chromosome band) that have been implicated in GWAS of the corresponding trait reported in the literature. 
Trait Chr cM Mbp logP Band O S G V K GWAS 
Calcium 3 134.1 121.82-122.29 6.54 q13.33-q21.1 3.37 4.91 NA 0.30 1.31 CASR 
Creatinine 5 200.1 176.78-176.96 5.97 q35.2-q35.3 0.30 0.58 7.45 1.45 0.36 SLC34A1 
CRP 19 70.5 45.34-45.43 5.55 q13.32 6.25 1.25 NA 0.3 NA 
TOMM40, APOC2, APOE, APOC4, 
APOC1 
Glucose 13 20.7 28.45-28.59 5.58 q12.2 0.3 0.7 6.19 1.94 0.53 PDX1 
Glucose_nodiab 3 179.7 170.38-170.77 5.63 q26.2 0.36 0.33 8.17 0.3 0.58 SLC2A2 
Glucose_nodiab 13 20.7 28.45-28.59 5.43 q12.2 0.3 0.58 7.75 0.56 0.3 PDX1 
HDL 11 126 116.55-117.1 6.65 q23.3 0.30 0.64 8.86 0.84 0.31 APOA1,APOA5,APOA4,APOC3 
HDL 12 149.7 125.26-125.34 5.94 q24.31 0.76 1.96 5.58 1.34 0.46 SCARB1 
HDL 1 219.6 201.72-201.98 5.83 q32.1 1.32 2.19 3.1 0.77 2.59 NA 
Heart Rate 2 246.3 228.29-228.52 6.43 q36.3 NA 0.50 0.68 NA 7.60 COL4A3 
Heart Rate 20 55.8 36.74-36.9 5.56 q11.23 NA 1.79 5.7 NA 0.32 KIAA1755 
Height 6 49.2 25.69-26.67 6.84 p22.2 0.30 0.30 9.16 0.65 0.76 HIST cluster 
Height 12 79.2 66.3-66.42 6.73 q14.3 0.72 1.77 7.31 0.41 0.83 HMGA2 
Height 6 54.3 34.04-34.24 6.66 p21.31 0.36 1.03 7.99 NA 0.65 HMGA1 
Height 10 106.8 81.06-81.18 6.58 q22.3 1.55 0.30 6.61 1.76 0.65 ZMIZ1, PPIF 
Height 1 33.9 17.19-17.5 6.29 p36.13 0.30 1.45 6.89 0.39 1.49 MFAP2 
Height 15 108.6 84.36-85.45 5.95 q25.2-q25.3 1.83 0.49 6.36 0.53 0.90 ADAMTSL3 
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Trait Chr cM Mbp logP Band O S G V K GWAS 
Height 2 253.2 232.79-233.32 5.83 q37.1 2.13 0.3 5.89 0.74 0.91 DIS3L2, NPPC, ALPP 
Height 1 150.6 118.84-119.31 5.68 p12 0.42 1.19 6.99 NA 0.3 SPAG17, PHGDH 
Height 6 132.6 126.44-127.53 5.55 q22.31-q22.33 0.44 0.3 7.53 NA 0.48 CENPW 
Height 4 33.6 17.74-18.27 5.5 p15.32-p15.31 0.54 0.43 7.42 NA 0.3 FAM184B, NCAPG, LCORL 
Height 15 146.1 100.78-100.87 5.49 q26.3 0.3 1.17 5.01 2.78 0.3 IGF1R, ADAMTS17 
Total 
Cholesterol 1 92.1 62.83-63.38 5.77 p31.3 0.57 0.3 8.02 0.3 0.7 ANGPTL3, DOCK7 
Urea 1 169.8 154.97-156.09 5.9 q21.3-q22 0.3 0.79 6.36 1.7 NA MTX1, GBA 
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